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Autosomal dominant polycystic kidney disease (ADPKD) is one of the commonest
genetic diseases in man, affecting 1 in 1000 of the general population. It is
characterised by the progressive formation and enlargement ofmultiple cysts in the
kidney and other organs leading to deterioration in renal function and the
development of hypertension in middle life. End-stage renal disease is a common
outcome, leading to a need for dialysis or transplantation. In order to make a
significant impact on the understanding and treatment ofADPKD, it is necessary to
isolate the gene and determine its product and function.
Linkage was first demonstrated between the gene for ADPKD (PKD1) and the
D16S85 locus in chromosomal region 16pl3 in 1985, and this has since been
amply confirmed. Initial studies failed to show evidence of genetic heterogeneity,
but reports have subsequently appeared describing families that fail to show
linkage to the PKD1 region. A sample of 35 families with ADPKD from central
Scotland, previously typed with two markers from the PKD1 region [3'HVR
(D16S85), and CMM65 (D16S84)], were typed with three other markers, VK5
(D16S94), 26-6 (D16S125), and SM7 (D16S283). A multipoint analysis was carried
out in order to define the location of PKD1, and to look for evidence of genetic
heterogeneity. The results provided statistically significant evidence for the
presence of a second locus for ADPKD (PKD2). Two-point and multipoint lod scores
were calculated for families shown to be linked to chromosome 16p (designated
PKD1 families). Two-point linkage analysis gave highly significant lod scores for
each of the five chromosome 16 markers used, and multipoint analysis showed that
the most likely position of the PKD1 gene was between CMM65 (D16S84) and SM7
(D16S283). Haplotypes were drawn up for each family, and evidence for linkage
disequilibrium between PKD1 and VK5 (D16S94) was found. Eleven individuals
with interesting recombinants were identified, and these were analysed in detail
using a further set of 8 markers in collaboration with other workers. Nine of these
occur between the distally located 3'HVR (D16S85) and CMM65 (D16S84). However,
there is one recombinant with CMM65 (D16S84), and one with 26-6 (D16S125),
which localises PKD1 to between these markers.
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In order to obtain cloned DNA from this genetically defined region of
interest, spanning approximately 750 kb of DNA, yeast artificial chromosomes
(YACs) were isolated from available libraries. Two human YAC libraries and a mouse
YAC library were screened using polymerase chain reaction (PCR) amplification,
followed by probing, of pooled YAC DNA. Screening was performed using PCR
primers to the GGG1 (D16S259), 26-6 (D16S125), SM33p22, VK5 (D16S94), and
ATPL (ATPase-like vacuolar proton channel) loci. In this way, three YACs have been
identified: a 280 kb YAC containing the GGG1 locus, a 230 kb YAC containing both
the 26-6 and VK5 loci, and a 160 kb mouse YAC containing the ATPL locus.
The three YACs were characterised initially by pulsed field gel
electrophoresis (PFGE) purification, followed by digestion with a restriction
endonuclease and ligation to catch-linkers in order to amplify YAC fragments by
PCR. This amplified material was used to obtain a chromosomal localisation for the
YACs using fluorescence in-silu hybridisation. The GGG1 YAC was found to be
chimaeric and so was not characterised further. PFGE restriction maps were
produced for the 26-6/VK5 and ATPL YACs and attempts were made to isolate the
end clones. Clusters of CpG rich sites in the 26-6/VK5 YAC suggest the presence of
at least two expressed sequences in the cloned DNA.
Experiments were carried out in order to isolate expressed sequences from
the human 26-6/VK5 YAC using a YAC-cDNA hybrid selection technique. cDNA
libraries were PCR amplified using vector primers, the YAC was amplified using
biotinylated primers, and the two annealed at 65°C. YAC-cDNA hybrids were
selected by binding to streptavidin-coated magnetic beads, and taken through a
further round of selection. Enriched cDNA fractions were isolated and probed back
to the YAC and to a variety of control DNA samples. Several of the cDNA fractions
appeared to contain repetitive DNA sequences which made them difficult to
characterise. Further characterisation of these fractions is required in order to
definitively identify expressed sequences present in the YAC, which would therefore
be candidate genes for ADPKD.
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ABBREVIATIONS
ACE - angiotensin converting enzyme
ADPKD - autosomal dominant polycystic kidney disease
ARPKD - autosomal recessive polycystic kidney disease
ATPL - ATPase-like vacuolar protein
bp - base pairs
cAMP - cyclic AMP
cDNA - complementary DNA
cen - centromere
CEPH - Centre d'Etude du Polymorphisme Humain
DNA - deoxyribonucleic acid
dNTP - deoxynucleotide triphosphate
EDTA - ethylenediamine tetra-acetic acid
EGF - epidermal growth factor
GFR - glomerular filtration rate
IPTG - isopropylthio-fi-D-galactoside
kb - kilobase pairs (10® bp)
LMP - low melting point
Mb - Megabase pairs (10® bp)
mRNA - messenger RNA
p - short arm of the chromosome
PCR - polymerase chain reaction
PFGE - pulsed field gel electrophoresis
PGP - phosphoglycolate phosphatase
PKD - polycystic kidney disease
PKD1 - the ADPKD gene located on chromosome 16p
- ADPKD families demonstrating linkage to chromosome 16p
PKD2 - the ADPKD gene(s) located elsewhere in the genome
- ADPKD families which are unlinked to chromosome 16p
q - long arm of the chromosome
RFLP - restriction fragment length polymorphism
vi
RNA - ribonucleic acid
TBE - Tris borate EDTA
tel - telomere
tRNA - transfer RNA
0 - recombination fraction
X-gal - 5-bromo-4-chloro-3-indolyl-p-D-galactoside
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End-stage renal disease, leading either to long term renal replacement therapy with
dialysis or to renal transplantation, is a major financial burden on the health
service and an important cause of morbidity in the general population. In Europe,
the most common causes of end-stage renal disease are glomerulonephritis and
diabetes mellitus, closely followed by adult-onset polycystic kidney disease and
hypertension. This thesis is concerned with autosomal dominant polycystic kidney
disease, and the localisation of the gene responsible for the majority of cases of this
disease.
Adult-onset (autosomal dominant) polycystic kidney disease is one of the
most common genetic diseases in man, and is an important cause of chronic renal
failure. Since the biochemical defect responsible is unknown, "positional cloning"
techniques are being employed in an attempt to isolate the gene(s) involved.
Positional cloning describes the isolation of a disease gene on the basis of its
chromosomal location. Cytogenetic abnormalities in gene carriers are extremely
useful in determining the chromosomal location of a gene, especially when patients
with overlapping deletions are available. However, polycystic kidney disease has not
been associated with visible cytogenetic abnormalities. Under these circumstances,
linkage analysis is usually the first step in chromosomal localisation of a disease
gene. Genetic markers selected from throughout the genome are tested for co-
segregation with the disease, and highly polymorphic probes are used to maximise
the efficiency of the search. Once a gene has been localised to a particular
chromosomal region, high resolution genetic mapping can define the boundaries of
this region so that physical mapping techniques such as pulsed field gel
electrophoresis and cosmid and yeast artificial chromosome contig mapping can
then be employed. In order to clone the gene, various strategies are used such as
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searching for CpG islands, isolating cDNAs from the area of interest, and identifying
expressed sequences that are conserved across species. DNA from affected patients
and from controls is then screened to detect any mutations present. Disease-
causing mutations may be detected at more than one locus (genetic heterogeneity)
especially in patients from different populations.
If the processes involved in the pathophysiology of a disease have been
elucidated, a candidate gene approach can be taken in which a known gene, whose
function suggests that it may be involved in the disease process, is screened for
mutations in affected patients. This has so far not been possible in the case of
polycystic kidney disease. Where possible, a combination of linkage analysis
followed by a candidate gene approach may be most effective. This has been
demonstrated, for example, in the case of autosomal dominant retinitis pigmentosa
(ADRP), where some families show genetic linkage ofADRP to chromosome 3q, the
site of the rhodopsin gene, which led directly to the identification of rhodopsin
mutations (Dryja etal., 1990).
1.2 RENAL CYSTIC DISEASES
There are many causes of renal cysts, both inherited and acquired (Zerres et al.,
1984). The inherited causes are summarised in Table 1.1 and, of these, by far the
most common is autosomal dominant polycystic kidney disease (ADPKD) which will
be fully discussed in later sections. Other causes are autosomal recessive polycystic
kidney disease (ARPKD), medullary cystic kidney disease, and renal cystic disease
occurring as part of a recognised syndrome (e.g. trisomy 13, tuberous sclerosis, von
Hippel Lindau disease, and the rare autosomal recessive Meckel's and Jeune's
syndromes). A full list can be found in Zerres et al. (1984).
In ARPKD there are two phenotypes, which are distinguished by the age at
presentation and whether renal or hepatic manifestations predominate. Renal
disease predominates in patients presenting in the neonatal period or during
infancy. The most severely affected infants present with Potter's syndrome
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flattened facies), and die of respiratory failure soon after birth. Patients whose
disease develops in childhood or adolescence have predominantly hepatic problems
(e.g. hepatic cysts and fibrosis leading to portal hypertension and hypersplenism)
and less obvious kidney manifestations. Both types can usually be easily
distinguished from patients with ADPKD by their pattern of inheritance and the
high degree of liver involvement, although in very early onset ADPKD the presence
of renal cysts prenatally, or in infancy, can cause diagnostic confusion. There is
considerable overlap between the two phenotypes ofARPKD, and there may be veiy
variable expression within one family. As yet, the gene for ARPKD has not been
mapped.
There are various causes of acquired renal cystic disease, two ofwhich are
common and may potentially cause diagnostic difficulty in cases of ADPKD. Renal
cysts may occur at any age in the presence of uraemia. They develop as chronic
renal failure progresses, and are particularly common in dialysis-dependent
patients. In a study by Dunnill et al. (1977), 14 out of 30 patients on long term
intermittent maintenance haemodialysis had bilateral cystic disease, the main
complications ofwhich were haemorrhage and tumour formation. In these cases the
kidneys are usually shrunken, rather than enlarged as in ADPKD. Simple renal
cysts are common in later years and are found in healthy individuals. They do not
lead to progressive renal failure and, as discussed later, rarely lead to problems in
diagnosing ADPKD.
The best example of an environmental influence on cyst formation is seen in
the CFWwd mouse (Werder et al., 1984), discussed further in section 1.5.1.
Approximately 70% of these animals develop renal cysts, but this does not occur if
they are kept in a germ free environment. Renal cystic disease may also result from
chronic exposure to chemicals and drugs that are known to be cystogenic. These
include antioxidants such as diphenylamine. alloxan, streptozotocin, lithium
chloride and cis-platinum. All of these agents can produce bilateral uniform renal
cysts in otherwise normal kidneys (Gardner, 1988). Endogenous conditions, such
as obstruction to flow with resultant back pressure, can result in the development
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of renal cystic disease. Examples of this include the development of a unilateral
congenital multicystic-dysplastic kidney, which is a non-heritable form of renal
dysplasia, and the development of cystic kidneys following dialysis or
transplantation (Gardner, 1988).
1.3 AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)
This is the most common form of hereditary renal disease. There is progressive
expansion and an increasing number of renal cysts, which can arise from any part
of the nephron, leading to bilateral renal enlargement and, in a large proportion of
cases, irreversible renal failure. Much of the early information regarding polycystic
kidney disease came from a detailed study of the Danish population by Dalgaard
(1957). He found the lifetime risk of adult-onset polycystic kidney disease (PKD) to
be 1 per 1000 with marked variability in phenotype, although there was often a
striking similarity within families. The incidence of adult-onset PKD may be higher
than 1 in 1000, however, since autopsy studies have shown that there are likely to
be as many clinically silent cases as there are cases leading to symptomatic renal
impairment (Hatfield and Pfister, 1972). In Dalgaard's study of 284 patients
(Dalgaard, 1957), the mean age of onset of the disease was found to be 40.7 years
and the mean age of death 51.5 years, with the main cause of death being uraemia.
The inheritance ofADPKD is autosomal dominant with complete penetrance by the
age of 80 years. Dalgaard (1957) calculated the rate of new mutations to be 6.5 x
10-5 to 12 x 10"5 per gene per generation, which was of the same order of
magnitude as the highest rates found for other genetic diseases. However, prior to
the development of ultrasound scanning, relatively poor means of pre-symptomatic
diagnosis were available, and therefore some parents thought to be "unaffected"
may have been gene carriers. Using age at death as a marker for disease severity, no
significant evidence was found to support the presence of anticipation (i.e. an
increasing severity of phenotype in successive generations). More recently, the gene
responsible for the majority of cases of ADPKD has been localised to the short arm
of chromosome 16 (Reeders etal, 1985), and genetic locus heterogeneity has been
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demonstrated (Romeo et al., 1988; Kimberling et al, 1988). Approximately 86% of
families with ADPKD demonstrate linkage with 16p markers (PKD1 families) (Peters
and Sandkuijl, 1992), the remainder being unlinked to 16p (PKD2 families).
1.3.1 Pathology of ADPKD
The metanephros (permanent kidney) is derived from both mesoderm and ectoderm.
The nephron originates from the nephrogenic cord or metanephric blastema
(mesoderm). The collecting ducts, calyces, pelvis and ureters are derived from the
ureteric bud (ectoderm). During the 4th to 5th week of gestation the ureteric bud
arises from the mesonephric duct, and at about the 6th week, branches to form the
primitive pelvis and major calyces of the kidney. The nephrons are formed from the
ureteric bud and the metanephric blastema at 8 weeks. The blastema gives rise to
nephrogenic cells, which result in glomeruli and tubules, and stromatogenic cells
which become the interstitium. Nephrogenesis stops at birth and no new nephrons
can be produced later in life. In contrast, stromatogenesis continues to occur in
adult life.
The ureter enters the kidney at the hilum. dilates into the pelvis, and then
divides into the major and minor calyces. On cut surface, the kidney is made up of
a cortex and medulla. The medulla consists of renal pyramids, the apices of which
are called papillae, each related to a calyx. The functioning units of the kidney are
the nephrons (Figure 1.1). They consist of a glomerulus and a renal tubule, and
span the cortex and medulla. The glomerulus is a capillaiy network which is
invested in Bowman's capsule; the invaginated blind proximal end of the renal
tubule that has a visceral and a parietal layer. The glomerular filter is made up of
three layers; a thin layer of fenestrated capillary epithelial cells, the glomerular
basement membrane and the visceral epithelial cells of Bowman's capsule
(podocytes). The renal tubule consists of a proximal convoluted tubule, loop of
Henle, distal convoluted tubule and collecting duct. The collecting duct runs to the
tip of the renal papillae and opens into the calyces.
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Figure 1.1
Glomerular capsule Neck Proximal convoluted tubule
Figure 1.1 demonstrates the anatomy of a normal nephron, which consists of a
glomerulus, proximal convoluted tubule, loop of Henle, distal convoluted tubule
and collecting tubule. The nephron spans the cortex and medulla and empties into
the calyceal system. The blood supply to the nephron is also demonstrated.
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The structure of normal renal tubular epithelial cells varies considerably at
different levels of the nephron. Proximal tubular cells are highly developed cuboidal
cells with long microvilli, numerous mitochondria and extensive intercellular
interdigitations. A sodium (Na+) pump is located in the basal membrane. The
descending limb and the proximal part of the ascending limb of the loop of Henle
are lined by flat epithelium, and the distal part of the ascending limb is lined by
cuboidal cells. The distal tubule is lined by cuboidal cells that have fewer
mitochondria than those of the proximal tubule and do not possess brush borders.
In ADPKD there is diffuse involvement of the kidneys by cysts that are
usually spherical and unilocular, ranging from a few millimetres to several
centimetres in size. The kidneys usually retain a reniform shape, and the cysts are
distributed throughout the cortical and medullaiy regions. The pyramids are
difficult to identify, and the calyces and pelvis often greatly distorted. Most of the
cysts are filled with a clear fluid, but they may also be filled with haemorrhagic or
purulent material. The percentage of the nephrons undergoing cystic change is
estimated to be less than 1% (Birenboim et cd., 1987; Grantham et al.. 1987).
On light microscopy, normal renal tissue is found among the cysts although
it often shows the effects of compression by adjacent cysts. There may also be
secondary glomerular sclerosis, tubular atrophy and interstitial fibrosis. The cyst
epithelium is usually thin and undifferentiated in appearance. Focal hyperplasia of
the epithelial lining of the cysts has recently been shown to be a common finding
(Grantham et al, 1987), and this may be such as to cause formation of polyps
protruding into the cyst lumen. Electron microscopy shows that the cyst-lining
epithelial cells are usually devoid of apical microvilli, contain a small number of
organelles and lie on a basement membrane that varies inconsistently from normal
to thickened, or extensively laminated. Two types of epithelial lining cell can be
distinguished, depending on the composition of the cyst fluid. 'Proximal' epithelial
lining cells have smooth surfaces, indistinct cell margins, squamoid or low cuboidal
form and non-dilated intercellular channels. 'Distal' cyst epithelium has a
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cobblestone surface, distinct cell margins, taller cuboidal cells and prominently
dilated intercellular channels.
1.3.2 Radiology of ADPKD
The diagnosis of ADPKD depends on the finding of bilateral renal cysts. Ultrasound
scanning is now widely used as the most convenient and sensitive method of
screening. The ultrasonic appearance of a polycystic kidney is shown in Figure 1.2.
Since ADPKD shows age-dependent penetrance, the interpretation of negative
findings on ultrasound is also age-dependent, and genetic linkage analyses and risk
calculations require knowledge of the sensitivity and specificity of negative
screening results at a given age. Figures obtained by Bear et al. (1992) estimate the
probability of false negative diagnosis in PKD1 families to be 36% in the first
decade, 8% in the second and third decades and 0% thereafter. Other studies have
shown that a positive ultrasound diagnosis always correlates with the genotype,
and that all gene carriers more than 30 years old have ultrasound-detectable renal
cysts (Parfrey etal., 1990; Coto etal, 1992).
One of the main differential diagnoses is that ofmultiple simple renal cysts.
Simple cysts are multiple in 50% of cases and bilateral in 26%. They also show an
increasing frequency with age, being present in at least 27% of people over the age
of 50 years. Fortunately, the presence of simple cysts is exceptional under the age
of 30, and uncommon under the age of 40 (Tada et al., 1983), so that they rarely
present a problem in the diagnosis of ADPKD.
1.3.3 Clinical features of ADPKD
ADPKD is predominantly a renal disease, but there are many non-renal
manifestations. The penetrance of ADPKD is 100% by the age of 80 years (Dalgaard,
1957). Phenotypic heterogeneity in ADPKD is marked both within and between
families: variation exists in the age of onset, rate of loss of glomerular filtration rate
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abnormalities, and incidence of subarachnoid haemorrhage. The prognosis is also
highly variable.
The mean age of onset of symptoms is in the fourth decade, although a
minority of patients develop renal failure in the neonatal period. The most common
complications are the development of hypertension and renal failure. Overall, 36%
ofmales and 7% of females with ADPKD are asymptomatic and normotensive, but
in those under the age of 30 years this is higher, at 66% ofmales and 11% of
females. In women, the most frequent clinical manifestations are urinaiy tract
infection (present in 69%), and hypertension (present in 61%); in men, urinary tract
infection is present in 19% and hypertension in 42% (Milutinovic et al, 1984).
Other presenting symptoms are flank pain, haematuria, and nephrolithiasis.
Hypertension and symptoms such as haematuria and back pain, but not urinaiy
tract infection, correlate well with renal size on ultrasound (Milutinovic et al,
1984). There is no increase in the incidence of renal tumours in ADPKD patients
(Dalgaard, 1957). As in adults, cysts are detected in children by ultrasound
scanning. Gross haematuria, hypertension, and a palpable abdominal mass are
present in more than 90% of children with a positive ultrasound scan (Sedman et
al.. 1987).
Hypertension is common in patients with ADPKD, and usually predates the
onset of renal failure. Parfrey et al. (1990) found that hypertension was present in
22% of all ADPKD patients under the age of 20 years, 26% aged 20-39, 55% aged
40-59, and 75% over the age of 60. Hypertensive ADPKD patients manifest more
severe cystic involvement than normotensive patients, suggesting a relationship
between structural alteration and hypert ension prior to the onset of renal failure
(Gabow et al, 1987). It has been hypothesised that cystic involvement could lead to
local ischaemia and increased formation of renin-angiotensin. Support for this was
obtained by showing a significantly increased rise in plasma renin activity, in
response to angiotensin converting enzyme (ACE) inhibitors, in hypertensive
compared with normotensive ADPKD patients (Bell et al, 1988). Tubulo-cystic
epithelium has the potential to synthesise renin, and elevated levels are seen in
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both epithelial cells and cyst fluid (Torres et al, 1992). Thus it seems likely that
renin is, in some way, involved in the pathogenesis of hypertension.
The most important consequence of ADPKD is renal failure. This is rare
under the age of 30, but end-stage renal disease is present in 50-75% of patients by
the age of 70 years (Churchill et al., 1984; Parfrey et al., 1990), the mean age of
onset being 59 years (Parfrey et al., 1990). As in other forms of chronic renal failure,
the rate of decline of renal function is adversely affected by hypertension.
Extrarenal involvement is common in ADPKD. Liver cysts are found in 29%
of patients with ADPKD over the age of 10 years (Milutinovic et al., 1980). They are
not found in patients at risk for ADPKD who have not yet developed renal cysts. The
prevalence of liver cysts increases with age and with decreasing GFR. They are
generally asymptomatic but can cause pain if they are very large or become
infected. Impaired liver function is rare. Cysts are also found in other organs such
as pancreas, spleen and ovary (Dalgaard, 1957).
According to post mortem studies, the prevalence of intracranial aneurysms
in patients with ADPKD is 10-30% (Levey et al., 1983). Rupture of such aneurysms
is one of the most serious complications ofADPKD, and may occur early in the
third decade before hypertension or renal failure have developed (Chauveau el al.,
1990). Patients from families with a history of subarachnoid haemorrhage are at a
higher risk of intracranial aneurysm than those without a family history (Kaehny et
al., 1987), and patients who have had a ruptured aneurysm are at high risk of a
recurrence (Chauveau et al, 1990). Routine screening of asymptomatic patients is
not cost effective when the method of screening is cerebral angiography (Levey et
al., 1983), and is unlikely to be so even with non-invasive techniques such as
magnetic resonance imaging (Wiebers and Torres, 1992). However, screening
should be offered to certain subgroups of patients, e.g. those with a family history
of intracranial aneurysm or subarachnoid haemorrhage, those undergoing major
elective surgery with anticipated haemodynamic instability and those with
symptoms suggesting the presence of an aneurysm (Wiebers and Torres, 1992). Up
to 20% of patients also have other cardiovascular abnormalities, the most common
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of which are structural defects of the aortic and mitral valves, potentially leading to
valve regurgitation and heart failure. There is also an increased frequency of
congenital cardiac defects, e.g. bicuspid aortic valves (Leier etal., 1984). Histology
of the affected valves shows myxomatous degeneration with loss and disruption of
collagen fibres. A similar histological picture and an increase in bicuspid and floppy
valves are also seen in Ehlers-Danlos syndrome types I and III, in which there are
known to be abnormal collagen fibrils.
1.3.4 Prognosis of ADPKD
In a recent study of patients with ADPKD by Gabow et al. (1992), 71% were alive at
age 50, 53% at age 58, and 23% at age 70. This is in keeping with other studies
(Churchill et al., 1984; Parfrey et al., 1990). Children diagnosed in the neonatal
period appear to have a poor prognosis, whereas those diagnosed later in childhood
seem to have a benign early course (Sedman et al.. 1987). The most common cause
of death directly attributable to ADPKD is end-stage renal disease, although
rupture of an intracranial aneuiysm can cause early death in some patients, prior
to the onset of renal failure. Gabow et al. (1992) found that the following variables
were associated with a worse prognosis as regards progression to renal failure:
younger age at diagnosis, male gender, hypertension, increased left ventricular
mass, hepatic cysts in females, more than three pregnancies, gross haematuria,
urinaiy tract infections in men, renal size, and inheritance of the PKD1 mutation.
The following were not associated with a worse renal prognosis: gender of the
affected parent, mitral valve prolapse, intracranial aneurysm, less than three
pregnancies, hepatic cysts in men, and urinary tract infections in females.
Reproductive fitness in ADPKD appears to be high. Dalgaard (1957) found
that 65% of women with ADPKD became pregnant one or more times, and a high
percentage of live births resulted. A more recent study has shown that, in patients
with ADPKD, reproduction rate, spontaneous abortion, stillbirth and symptoms
consistent with a urinary tract infection were no different from those in normal
women (Milutinovic etal, 1983).
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In general terms, it is difficult to find any clinical distinction between
ADPKD linked to chromosome 16p (PKD1) and the form of ADPKD that is unlinked
to chromosome 16 (PKD2). The two families in which non-linkage to chromosome
16 was first identified (Romeo et al., 1988; Kimberling et al., 1988) had clinically
typical ADPKD. Parfrey et al. (1990), however, found the average age of onset of end-
stage renal disease to be 57 years in PKD1 patients compared with 69 years in non-
PKD1 patients. Renal cysts also tended to develop later in life, and hypertension
and renal impairment were less frequent and occurred later. In this study, however,
PKD1 was not invariably more severe, and the observations on non-PKDl patients
came from only two, albeit large, families. This could therefore reflect allelic
heterogeneity rather than locus heterogeneity. Further evidence for a difference in
prognosis between PKD1 and PKD2 comes from Bear et al. (1989), who noted that
the proportion of individuals at 50% risk of ADPKD who had cysts was lower at
every age in PKD2 families than in PKD1 families. Ravine et al. (1992) studied 18
PKD1 and 5 non-PKDl families, and found that non-PKDl patients lived longer
than PKD1 patients, had a lower risk of progressing to renal failure or developing
hypertension, were diagnosed at an older age and had fewer renal cysts at
diagnosis. In all of these studies an ascertainment bias could be present, since an
unknown proportion of PKD1 and PKD2 families may have mild disease which does
not require referral to a renal clinic.
1.3.5 Treatment of ADPKD
No specific treatment is available to retard the progression of cyst formation.
Effective control of blood pressure provides one of the few means of delaying the
progression of renal failure. In view of the postulated involvement of the renin-
angiotensin axis, angiotensin converting enzyme (ACE) inhibitors seem a logical
choice of drug in the management of hypertension. The fact that Lisinopril, an ACE
inhibitor, produces an acute fall in renal vascular resistance without a fall in GFR
(Watson et al., 1992) adds weight to the suggestion that ACE inhibitors may be of
particular value in the treatment of hypertension associated with ADPKD. In
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general, however, hypertension is treated as it would be in essential hypertension,
the main aim being good control of blood pressure.
Conservative management of chronic renal failure includes strict attention
to blood pressure control, dietary restriction, particularly of protein and phosphate,
and treatment of acidosis and anaemia. Sooner or later, end-stage renal disease will
occur and patients will then require long term renal replacement therapy (dialysis)
or renal transplantation.
If cysts are extremely large, decompression may relieve pain but it does not
slow the progression of renal failure. Cysts may become infected, and any infections
must be rigorously treated with appropriate antibiotics.
Therefore, although measures such as the control of hypertension and the
availability of renal replacement therapy and transplantation have greatly improved
the prognosis ofADPKD, the hope is that the localisation of the gene, followed by an
understanding of the biochemical defect resulting from mutation within it, will
allow the development of treatments to actually retard cyst formation.
1.3.6 Genetic counselling in ADPKD
As in any disease inherited as a fully penetrant autosomal dominant trait, every
offspring of an affected parent has a 50% chance of developing the disease. Since
patients with ADPKD usually do not develop symptoms until the third or fourth
decade of life, the ability to diagnose the disease at an early stage is of great benefit
when counselling individuals regarding their prognosis. The mainstay of early
diagnosis is ultrasound scanning; the rates of false negative diagnosis being
estimated as 36% below the age of 10 years, 8% or less thereafter until the age of 30
years when false negative diagnosis is unlikely (Bear et al., 1992). Linkage of PKD1
to 3'HVR (D16S85) and the development of flanking markers around this gene
permit accurate identification of individuals at risk of developing the condition,
provided that the kindred is large enough to establish linkage and the disease
haplotype. In non-recombinants, the accuracy of diagnosis in PKD1 families was
estimated to be 99% using flanking markers (Breuning et al., 1990b). In families
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where the disease is unlinked to chromosome 16, no such genetic diagnosis is
possible at present.
Early diagnosis has both advantages and disadvantages (Watson et al,
1990). It allows screening for the development of hypertension and, if appropriate,
for the presence of intracranial aneurysms. Disadvantages include difficulty in
obtaining employment and loading of life assurance premiums. The availability of
ante-natal diagnosis raises other ethical problems. Although the majority of
patients are in favour of ante-natal diagnosis, few would consider termination of
pregnancy on the basis of the result (Macnicol et al., 1991). Parental curiosity is
unlikely to be in the best interests of the child and, in view of the potential
disadvantages, it is only in rare cases that the diagnosis need be established under
the age of 18 years (Watson et al., 1990). Counselling, particularly with a view to
educating patients with regard to polycystic kidney disease, is very effective in
improving knowledge and understanding of the disease, thereby affecting attitudes
towards diagnosis and treatment (Macnicol etal, 1991).
1.4 GENETICS OF ADPKD
1.4.1 Linkage analysis
Genetic linkage is present when a genetic marker is found to segregate non-
randomly with a disease or other genetic phenotype in families. It occurs when two
loci lie close enough on the same chromosome that they tend to be inherited
together. Linked loci may segregate apart as a result of physical exchange of genetic
material between paired chromosomes during meiosis. The frequency of such
recombination between two loci is a measure of the genetic distance between them.
Recombination frequencies can also be used to order loci in relation to each other,
and thereby establish their position within a specific chromosomal region.
The lod score statistic (Z) is a measure of the likelihood that linkage is
present, and the maximum likelihood value of the lod score (Zmax) ls
conventionally used to indicate the recombination fraction (0max' between two loci.
The lod score is calculated as:-
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likelihood of linkage data assuming a specified recombination
fraction (0)
Z (0) = log 10
likelihood assuming the loci are unlinked (i.e. 0 = 0.5)
Linkage was first detected between ADPKD and the DNA probe 3'HVR, in a
study of nine families with the typical clinical features of the disease (Reeders el al.,
1985). The 3'HVR (D16S85) locus is a highly polymorphic microsatellite sequence
which is located 8 kb downstream of the a-globin locus (Jarman et al., 1986). The
a-globin locus had been mapped to the short arm of chromosome 16 (Barton et al,
1982), and is now known to lie between 170 and 450 kb from the telomere (Wilkie et
at, 1991). It consists of an array of 17 base-pair tandem repeats, and polymorphism
at the locus is attributed to variability in the number (70-450) of these repeats
(Jarman et al., 1986). The maximum likelihood lod score for linkage of ADPKD to
3'HVR was 7.31 at a recombination fraction (0) of 0.07 in males and 16.41 at
0 = 0.04 in females: this gave a combined lod score of 25.85 at 0 = 0.05 (Reeders et
aL, 1985), suggesting that 3'HVR and ADPKD are separated by approximately five
centiMorgans (5cM). Linkage ofADPKD to the short arm of chromosome 16 (16p)
was confirmed by the presence of tight linkage with the phosphoglycolate
phosphatase (PGP) locus (Reeders et al., 1986; Watson etal, 1987). No
recombinants were found between the disease and PGP in either study. Breuning et
al. (1987a) mapped human a-globin to 16pter-pl3.3 distal to PGP, using an
unbalanced translocation which carried one allele at the 3'HVR (D16S85) locus and
two alleles at the PGP locus.
The ADPKD disease gene located on chromosome 16 has been designated
PKD1. The position of the PKD1 locus relative to 3'HVR (D16S85) was shown in a
multipoint linkage analysis (Reeders et aL, 1988), which indicated that the odds in
favour of PKD1 lying proximal to 3'HVR (D16S85) were greater than 10,000 : 1
compared with a distal location. By a combination of linkage and somatic cell
hybrid analyses, this group also showed that the DNA markers CRI-0327 (D16S63)
and CRI-090 (D16S45) were located proximal to both 3'HVR (D16S85) and PKD1,
this order being 170 times more likely than an order placing PKD1 between CRI-
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0327 (D16S63) and CRI-090 (D16S45). The disease gene was found to be flanked by
3'HVR (D16S85) distally and 24-1 (D16S80) proximally with a recombination rate of
8% between the two markers (Breuning et al., 1987b), this order being at least 1000
times more likely than either of the other two possibilities. The detection of flanking
markers allowed improved diagnosis by genetic linkage analysis. The positions of
markers located on chromosome 16p are shown in Figure 1.3.
Once linkage to a particular region of a chromosome has been established,
detailed genetic and physical mapping is required. Using a combination of cell lines
containing rearranged chromosomes, cytogenetically-defined breakpoints and
multipoint linkage analysis, genetic and physical maps of an array of polymorphic
markers flanking PKD1 have been constructed (Reeders et al., 1988; Breuning el
al., 1990a; Germino et aL, 1990). The genetic localisation of PKD1 was further
refined by the identification of recombination events between close flanking
markers and PKD1 (Somlo et al., 1992b). Three crossovers were identified that
placed PKD1 proximal to GGG1 (D16S259), and two that placed PKD1 distal to 26-6
(D16S125). All these crossovers were in affected individuals from unequivocal PKD1
families. PKD1 was therefore localised to a region between GGG1 (D16S259) and
26-6 (D16S125). Within this span, only 92.6SH1.0 recombines with the disease
locus, and three recombinants from different families have been identified. In the
same two meioses that place PKD1 distal to 26-6 (D16S125), the data also place
PKD1 distal to 92.6SH1.0, while in a single unaffected case (negative ultrasound at
age 33 years) the disease locus appears to be proximal to 92.6SH1.0.
1.4.2 Genetic heterogeneity of ADPKD
A reliable diagnosis based on linkage analysis assumes that the disease is caused
by mutation(s) at only one locus. The original localisation of ADPKD to chromosome
16 was made by demonstrating linkage to 3'HVR (D16S85) and PGP in only nine
families (Reeders et al., 1985 and 1986). Other early studies confirming PKD1
linkage were also carried out on similarly small numbers of families (Watson et al..
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1987; Lazarou et al., 1987). None of these studies found any evidence to suggest
genetic heterogeneity of ADPKD.
The presence of genetic locus heterogeneity would lead to problems in ante¬
natal and pre-symptomatic diagnosis, genetic counselling, and in the molecular
characterisation of the disease gene itself. It is therefore veiy important to establish
whether or not heterogeneity is present and, if so, what proportion of families is
unlinked to chromosome 16. In order to answer this question, Reeders et al. (1987)
extended their original study to analyse 28 northern European pedigrees, and again
found no evidence to suggest the presence of a second locus for ADPKD. Following
this, analysis of two large families of Italian origin raised the possibility of
heterogeneity (Romeo et al, 1988; Kimberling et al, 1988). Both families had
polycystic kidney disease with clinical features indistinguishable from those seen in
families linked to chromosome 16. Linkage analysis, however, provided no evidence
of linkage to 3'HVR (D16S85) in either pedigree. These original reports have been
followed by other case reports detailing single kindreds with ADPKD which show no
linkage to chromosome 16 (Brissenden et al., 1989; Bachner et al. 1990; Norby and
Schwartz, 1990). Further studies oflinkage heterogeneity in the Italian population
(Mandich et al., 1990; Turco et al, 1991) have failed to show any evidence of
heterogeneity, suggesting that the proportion of unlinked families is small. Studies
of seven Icelandic families with ADPKD revealed that four were PKD1 families
showing linkage to chromosome 16p. and that three were non-PKDl families
unlinked to chromosome 16 (Fossdal etal, 1993).
The above reports of unlinked families argue convincingly for the presence of
a second locus for ADPKD, although two authors have argued that
"recombinational heterogeneity", i.e. an unusual clustering of recombination in a
minority of families, should be considered as an alternative explanation (Hulten,
1988; Elles et al., 1990). The more families that are found to be unlinked to
chromosome 16, the less likely is this explanation, and the more likely that there is
indeed at least one other locus responsible for the ADPKD phenotype.
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Studies with larger numbers of families in different populations are required
to establish the proportion of ADPKD families that are unlinked to chromosome 16.
A study of 42 families by Pieke et al. (1989) obtained an estimate of 96% of families
linked to chromosome 16 (with a lower 95% confidence limit of 93%). Peters and
Sandkuijl (1992) analysed data from 328 ADPKD families (available as a result of
the European Concerted Action on polycystic kidney disease and including data
presented in this thesis) and obtained a value of 86% linked to 16p, although the
95% confidence limits were wide (79-91%).
The presence of genetic heterogeneity means that caution must be exercised
in providing ante-natal and pre-symptomatic diagnosis. Flanking markers are of
value in separating linked from unlinked families by discriminating between single
and double recombinants. In small families where there is insufficient data to
establish linkage with a-globin, genetic prediction will have an error roughly equal
to the proportion of unlinked families.
1.4.3 Genetic Localisation of PKD2
Until veiy recently, little progress had been made in defining the chromosomal
location of the gene or genes responsible for ADPKD in families where there is no
demonstrable linkage to chromosome 16. Norby and Schwartz (1990) have reported
a possible locus on chromosome 2. In a large Danish family with ADPKD unlinked
to a-globin, a positive but not statistically significant lod score of 2.12 was obtained
between the disease and YNH24 (D2S44), a marker on the short arm of
chromosome 2. A large Sicilian ADPKD kindred of over 250 members, shown to be
unlinked to chromosome 16, was analysed using 29 marker loci on 11 autosomes
(Kumar et al.. 1991). In this family, the data exclude linkage of the disease locus to
17 marker loci, including YNH24 reported above, and show no evidence of close
linkage with the other loci. Peters et al. (1993) have now reported evidence for
linkage between PKD2 and the chromosome 4 markers D4S423 and D4S231. The
map locations of these markers are 4q21-4q23 (Weissenbach et ai. 1992) and 4q21-
4q24 (Mills et al.. 1992) respectively. Two-point analysis of eight families gave a
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cumulative lod score of 20.11 at 8% recombination for D4S423 and of 16.04 at 5%
recombination for D4S231. The family reported by Norby and Schwartz (1990) as
showing linkage to YNH24 (D2S44), provides stronger evidence of linkage to
chromosome 4 with a maximum lod score of 4.26 (Peters et al, 1993).
PKD2 has therefore been localised to chromosome 4q, although mutations at
more than two loci may yet be responsible for the ADPKD phenotype.
1.4.4 Physical mapping of PKD1
As mentioned above, once detailed genetic maps of the region had been established,
physical mapping techniques were used to verify the position of markers in relation
to each other, and to determine the physical distances between them. The probe
CMM65 (D16S84) was found to show no genetic recombination with PKD1, and thus
somatic cell hybrids containing spontaneous chromosomal breakpoints were used to
construct a physical map of this region (Germino et al, 1990). This group localised
CMM65 (D16S84) to between CRI-0327 (D16S63) proximally and a-globin distally
with odds of >1000 : 1, EKMDA2 (D16S83) to between CMM65 (D16S84) and 3'HVR
(D16S85) also with odds of >1000 : 1, and PKD1 to between EKMDA2 (D16S83) and
CRI-0327 (D16S63) with odds of >500 : 1, the most likely location being at the
CMM65 (D16S84) locus. Harris et al. (1990) constructed a library from DNA enriched
for a 320 kb IVod fragment containing CMM65 (D16S84). New probes from this
region were isolated and used together with existing markers to construct a long
range restriction map that encompassed the distal markers for PKD1, including a-
globin. DNA surrounding the a-globin complex is GC-rich, and this GC-rich region
was found to extend for more than 2 Megabases proximal to a-globin (Harris et al,
1990). Since unmethylated CpG islands have been correlated with the presence of
genes (Lindsay and Bird, 1987), it is probable that this region will be rich in
transcribed sequences.
As discussed above, Somlo et al (1992b) localised PKD1 to between GGG1
(D16S259) distally and 26-6PROX (D16S125) proximally, after identifying
recombinants with these loci. A long range restriction map linking these two
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markers has been constructed (Germino et al., 1992). A Noll linking library for this
region was made from a radiation hybrid containing fragments of human
chromosome 16, and the clones mapped onto a panel of somatic cell hybrids
(Himmelbauer et al., 1991). Bi-directional cosmid walking was then initiated from
three DNA markers (CMM65, 26-6, and VK5) and four of the Notl linking clones
(Germino et al., 1992). Three contigs of 500 kb, 150 kb and 60 kb have been
obtained, separated by gaps of less than 20 kb and approximately 60 kb. The
maximum distance between the flanking markers GGG1 (D16S259) and 26-6PROX
(D16S125) was found to be less than 750 kb (Germino et al., 1992). Two probes,
originally thought to recognise single-copy loci, were discovered to hybridise to
more than one locus on chromosome 16 (Germino et al., 1992). 26-6 (D16S125)
recognises two loci, 26-6PROX and 26-6DIS, less than 150 kb apart. 26-6PROX is
the polymorphic locus (Gillespie et al., 1990). There is also a 40 kb segment,
beginning approximately 10 kb telomeric to the Noll clone N54, that is present in
several copies on chromosome 16 (Germino et al., 1992). Cosmids representing
several of these repetitive loci were found in chromosome 16 enriched libraries. The
copy within the PKD1 region can be distinguished from all others by virtue of a
different sized EcoRI fragment that hybridises to a BamHI subclone of the repetitive
segment (pBB1.9).
Restriction analysis of genomic and cosmid DNA identified a high density of
rare cleavage sites within the PKD1 region (Harris el al., 1990; Germino el al.,
1992), many of which represent unmethylated CpG islands. CpG islands usually
coincide with the 5' end of genes (Lindsay and Bird, 1987), and can therefore be
used as markers to speed up the search for genes. However, since not all genes are
associated with CpG islands, this approach runs the risk ofmissing some genes.
The large number of CpG clusters mapped to the interval suggests that the PKD1
region will be gene-rich, and already at least 20 sets of non-overlapping cDNA
clones have been isolated from the region (Germino et al., 1992).
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1.4.5 Human - mouse homology
Groups of genes tend to remain physically associated in different species during
evolution, and many of these conserved linkage groups have been identified
between human and mouse. The presence of a conserved linkage group may benefit
the search for a human gene in several ways. A correlation may be established
between a known mouse mutation and a human hereditary disease with a similar
phenotype. For example, as discussed below, the cpkmouse is a good model for
human ARPKD, and the mutation causing polycystic kidneys in that strain has
been mapped to mouse chromosome 12 (Davisson etal., 1991). This would suggest
that the homologous human ARPKD gene could be localised to either human
chromosome 2p23-p25 or 7q22-q31. Alternatively, homologous candidate genes
may be identified if a mouse mutant with a similar phenotype has been attributed
to a particular gene.
The gene for human ADPKD that is linked to the a-globin locus on
chromosome 16 (Reeders et al., 1985) is reported to be located in a 750 kb region
flanked by GGG1 (D16S259) and 26-6 (D16S125) (Germino etal., 1992).
Himmelbauer et al. (1992), took two Noll linking clones and two human cDNA
clones from this 750 kb region, along with the two flanking markers, and found that
all of them mapped to mouse chromosome 17. There is, therefore, an area of linkage
conservation between human chromosome 16p and mouse chromosome 17, and it
is likely that the mouse homologue of PKD1, if it exists, will be included in the
conserved region. It is of interest that the expressed a-globin gene, on the distal
side of PKD1 in the human, is located on chromosome 11 in the mouse, whereas
Hba-ps4, an a-globin pseudogene, is located near to the conserved region on mouse
chromosome 17, but has no equivalent in the human genome.
1.5 ANIMAL MODELS OF POLYCYSTIC KIDNEY DISEASE
1.5.1 Murine models
There are no naturally occurring mouse models with a similar phenotype to
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chromosomal location of the genes involved in human ADPKD and various mouse
models.
CFWwd mouse - this strain ofmouse develops a form of ADPKD, with progressive
development of cystic lesions in Bowman's capsule, proximal and distal collecting
tubules (Werder etal., 1984). The cystic disease is inherited as an autosomal
dominant trait with reduced penetrance. There is clear environmental modulation of
cyst formation and enlargement since only 4% of animals raised in a genn-free
environment develop PKD compared with 70% in a standard environment.
C57BL/6J-cpk/cp/c fcpk) mouse - this strain transmits a lethal form of PKD in an
autosomal recessive fashion. The cpkmouse model has been the one most
intensively studied since its clinical and gross morphological characteristics closely
resemble those of human ARPKD, although abnormalities are limited to the kidney.
The cpkmutation has been mapped to mouse chromosome 12 (Davisson et ai,
1991).
DBA/2-pcu/pcu (dcli) mouse - this strain develops slowly progressive PKD similar to
human ADPKD, but transmitted in an autosomal recessive manner (Takahashi et
al, 1986). Renal cysts develop in all segments of the nephron, and progressively
enlarge with age. No extrarenal cysts are seen.
CBA/N mouse - this mouse strain has an immunodeficiency phenotype mapped to
a recessive mutation (xid) on the X chromosome. Renal cystic lesions occur which
closely resemble those seen in human ADPKD: all animals greater than 3 months
old show cystic dilatation affecting all segments of the nephron. The renal cyst ic
lesions also appear to be X-linked (Rahilly et al.. 1992).
SV40 T-antigen fT-ag) model - mice transgenic for the complete SV40 early region
encoding the small and large T-antigen display a phenotype characterised by
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choroid plexus tumours leading to death by 3 or 4 months of age. They also display
renal abnormalities including focal glomerulosclerosis and tubular cysts, with renal
expression of the SV40 large T-ag (MacKay et al., 1987).
SBM transgenic mouse - SBM mice were produced by microinjection into the
mouse genome of a hybrid construct containing the SV40 enhancer, p globin
promoter, and murine c-myc proto-oncogene (Trudel etcd., 1991). They consistently
develop PKD and die of renal failure. The phenotype resembles human ADPKD in
autosomal dominant transmission, complete penetrance, bilateral renal cysts
occurring throughout the nephron, epithelial hyperplasia and progressive renal
insufficiency. Differences include the absence of extrarenal manifestations of
ADPKD and the presence of haemopoietic malignancies in some mice.
Chimaeric mouse - the introduction of SR2-3 embiyonic stem cells into mouse
embryos leads to the production of chimaeric mice, which reproducibly exhibit the
characteristics ofADPKD, i.e. the formation of fluid-filled cysts in the kidney
transmitted in a dominant manner (Boulter et al., 1992). The cysts are lined with
epithelial cells and occur in both medulla and cortex. SR2-3 cells have a single
integrated copy of the v-src oncogene within the SR2 retroviral vector. Again, the
model differs from human PKD in that no cysts are seen in other organs, despite
the fact that these tissues were found to be chimaeric. The integrated oncogene may
itself be responsible for the disorder, and there are parallels with transgenic mice
over-expressing the c-myc proto-oncogene. Alternatively, the disease may result
from a dominant mutation at the ADPKD locus, either arising spontaneously in the
SR2-3 cell line or caused by the insertion of the retroviral vector. The site of
insertion of the transgene has now been mapped to mouse chromosome 11.
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1.5.2 Rat models
A colony of Sprague-Dawley rats (Han: SPRD) has been bred which inherits
polycystic kidney disease as an autosomal dominant trait. It has several features
resembling human ADPKD including chronic progressive uraemia, renal tubular
basement membrane abnormalities, development of cysts in all nephron segments,
and evidence of abnormal cell proliferation with increased expression of the c-myc
proto-oncogene in cystic epithelium (Cowley et al., 1993). It is possible to breed two
sub-strains of Han: SPRD, one that exhibits polycystic degeneration of the kidneys
and a rapid rise in serum urea, serum creatinine and blood pressure, and one that
exhibits the typical histological features of ADPKD but no loss of renal function or
rise in blood pressure. Since they have a larger circulating blood volume than mice,
they are particularly useful in animal studies of progression of renal failure (Gretz
etal, 1992).
1.5.3 Feline model
A model for ADPKD is available in a Persian cat (Biller and Pflueger, 1990) which
closely resembles human ADPKD in its phenotype and genetic transmission.
1.5.4 Cell culture models
Human monolayer ADPKD epithelia - human ADPKD cells grow easily in culture
(Wilson et al., 1986). Although the epithelial cells contain few organelles, they
remain polarised with apical tight junctions and microvilli facing upwards in the
dish. They have been validated as a model system for the analysis of cellular
alterations in PKD.
MDCK (Madin-Darbv canine kidnev) cell line in collagen gel - this is a model for
cysfogenesis using dog kidney cells. Three-dimensional clonal growth in a hydrated
collagen gel yields spherical monolayered cysts. They exhibit epithelial cell
proliferation, intracavity fluid accumulation, and matrix remodelling (Grantham et
al., 1989). Only about 7% of the cultured MDCK cells participate in cyst formation.
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1.6 PATHOPHYSIOLOGY OF ADPKD
The pathophysiology of cyst formation is not understood, but several studies
looking at different aspects of cyst biology have provided insights into the kind of
processes likely to be involved (reviewed by Gabow, 1991). A renal tubule cyst is an
enlarged segment of the nephron consisting of a fluid-filled sac lined by a single
layer of epithelium. It seems that cysts can form in response to genetic, non-
genetic, and toxic influences, and therefore it is likely that several pathogenetic
pathways converge to produce a single phenotype. Cysts are separated by
apparently normal areas of renal parenchyma and it seems that renal failure
develops because the enlargement of established cysts compromises the function of
adjacent tubules, rather than because more tubules become involved in the cystic
process (Grantham et al., 1987). Microdissection studies of ADPKD kidneys in the
early stages of cystic change show that cysts can originate from any segment of the
nephron, and are randomly distributed with normal nephrons between them (Baert,
1978). Aspiration of renal cysts from ADPKD patients reveals that some cysts
contain fluid with concentrations of sodium and creatinine approximately equal to
those of plasma, whereas others have veiy low concentrations of sodium but
increased concentrations of creatinine (Gardner, 1969). These patterns resemble
those found in fluid from normal proximal and distal renal tubules respectively.
Electron microscopic studies show that a relatively small proportion of cysts
remain attached to the tubule segments, and thus transepithelial net solute and
fluid secretion into the cavity must occur (Grantham et al., 1987). The same study
showed that mean cell surface area did not increase in direct proportion to cyst
diameter, and thus epithelial hyperplasia must be a central element in the
progressive enlargement of cysts. In some cysts this hyperplasia was accentuated
by projections into cyst lumina of polyps, and cord-like arrangements of cells.
Cellular proliferation without secretion would lead to solid tumour
formation, whereas increased cellular proliferation accompanied by increased
cellular secretion, which in turn is accompanied by increased intracyst pressure
(Grantham et al., 1989), would produce outward expansion yielding a cyst.
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Therefore, it seems that the two basic criteria necessary for cyst formation are
increased epithelial cell proliferation and altered fluid transport. Epithelial
proliferation can be the result of alteration of extracellular matrix composition;
altered susceptibility to, or synthesis of, peptide growth factors; or abnormal
expression of growth-related genes including proto-oncogenes. Fluid accumulation
in renal cysts could be the result of alterations in ion pumping, or reflect changes
in polarity of cell structure or function.
1.6.1 Epithelial cell hyperplasia
As discussed above, epithelial cells proliferate during cyst formation (Grantham et
al., 1987). Primary cultures ofADPKD cystic epithelial cells show an increased cell
growth potential when compared with normal cells (Wilson et al., 1986). These cells
are also able to attach and proliferate without extracellular matrix, a prerequisite
for normal renal tubular cell growth (Wilson et al., 1992). Epithelial cell hyperplasia
is also seen in the kidneys of SBM transgenic mice (Trudel et al., 1991).
1.6.2 Growth factors in ADPKD
Epidermal growth factor (EGF) is a potent mitogen, acting via a high affinity
receptor that possesses intrinsic tyrosine kinase activity. Wilson and Sherwood
(1991) demonstrated an exaggerated proliferative response to EGF in cultured
ADPKD cystic epithelium, and also found EGF to be present in cyst fluid and cystic
epithelial cells. They also showed that transforming growth factor p (TGFp), an
inhibitor of renal tubular proliferation, did not produce the expected inhibition in
cultured ADPKD cystic epithelium.
1.6.3 Oncogenes in ADPKD
Elevated proto-oncogene expression is common to a number of different models of
polycystic kidney disease, such as the c-myc transgenic (SBM) mouse, SV40 large
T-antigen transgenic mouse, cp/cmouse and Han: SPRD rat. SBM kidneys contain
markedly elevated levels of c-mycmRNA in comparison to other transgenic organs
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and normal mouse kidney controls. While the SV40 enhancer sequence contains an
element known to cause expression in kidney cells, the entire SV40 enhancer has
been shown to be active in many cell types in vitro, and in a variety of tissues in
transgenic mice. Trudel et al. (1991) postulated that the novel coupling of the p-
globin promoter sequences and the SV40 enhancer in the SBM construct modifies
the tissue specificity of the enhancer. The restriction of cystic changes to the kidney
therefore parallels the apparent renal-limitation of transgene expression. The
identification of revertant mice with mutations in the transgene provides evidence
that the PKD phenotype is a direct result of the SBM transgene, with
overexpression of c-myc in the renal tubular epithelium and consequent abnormal
cell proliferation. This strongly suggests that cyst formation can arise through the
dysregulation of tubular epithelial cell proliferation.
In the Han: SPRD rat strain, there is increased epithelial cell proliferation
overlying areas of basement membrane thickening. In situ hybridisation
demonstrates high levels of c-mycmRNA in cyst epithelia (Cowley et al., 1993). In
addition, the cpkmouse strain, which models ARPKD, shows elevated expression of
the c-myc oncogene with a 2-6 fold increase in c-mycmRNA at 2 weeks, and a 25-
30 fold increase in c-mycmRNA at 3 weeks of age (Cowley et al, 1987). Since the
cystic kidneys show only a minimal increase in cell proliferation over normal
kidneys, the level of c-myc expression is out of proportion to the level of cell
proliferation, suggesting that elevated c-myc expression may be involved in the
pathogenesis of PKD. Oncogene expression was also induced to a lesser degree by
other stimuli to renal cell growth, such as folic acid treatment and unilateral
nephrectomy with consequent compensatory hypertrophy of the other kidney.
The SR2-3 cell line has integrated into its genome a retroviral vector
carrying the v-src oncogene. Chimaeric mice derived from this cell line develop
polycystic kidneys, but the role of v-src expression is unclear, since the levels of v-
src activity in the kidneys are low. Moreover, a chimaeric mouse derived from a
second ES cell line carrying the same retroviral vector had a similarly low level of v-
src activity in the kidneys but no evidence of cystic kidney disease (Boulter et al,
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1992). This would suggest that the v-src oncogene does not have a direct role in
cyst formation in this model.
1.6.4 Fluid transport defects in ADPKD
A series of experiments by Mangoo-Karim et al. (1989) focused on the role of cyclic
AMP (cAMP) as a chemical mediator of secretion. In the absence of cAMP, the MDCK
cells did not form cysts. If a cAMP phosphodiesterase inhibitor was added, allowing
low levels of cAMP to accumulate, cell proliferation was initiated, although this only
resulted in balls of cells, not cysts. Substances such as prostaglandin E i (PGE^)
and cholera toxin, which markedly increase intracellular cAMP, did however result
in large fluid-filled cysts. It therefore seems that although low levels of cAMP were
able to cause proliferation, it was the fluid secretion generated by high levels of
cAMP which led to cyst formation.
In the above study, it was also noted that ouabain completely inhibited fluid
secretion. Human cystic ADPKD epithelial tissue appears to demonstrate altered
cellular polarity with Na+-K+-ATPase located exclusively on the apical rather than
the basolateral cell surface (Wilson et al.. 1991). Actin and the ankyrin-fodrin
complex, which are believed to be involved in the anchoring of Na+-K+-ATPase in
the appropriate membrane, co-localised with Na+-K+-ATPase at the apical surface: a
variety of other basolateral and apical proteins maintained their appropriate
positions. Avner et al. (1992) studied cyst formation in the cpkmouse, and found
that in control and cystic proximal tubules Na+-K+-ATPase distribution was
restricted to the basolateral membrane of cells. However, during early formation of
both normal and cystic collecting tubules, there was apical membrane distribution
which was transient in the normal cells but persistent in the cystic epithelial cells.
Thus, apical expression of Na+-K+-ATPase seems to be a normal transient feature of
early collecting tubule development, and its persistence in cystic epithelial cells
may be a manifestation of the relatively undifferentiated phenotype of epithelial
cells lining cysts. Na+-K+-ATPase maintains its function in this altered location.
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and there is thus an altered direction of cellular sodium transport from the
basolateral to the apical cell surface (Wilson et al., 1991).
1.6.5 Extracellular matrix abnormalities in ADPKD
Wilson et al., (1986), demonstrated that ADPKD cells in culture produced greater
amounts of extracellular matrix than normal human kidney epithelia. At least one
component of the increased matrix appeared to be a proteoglycan. The alteration in
extracellular matrix could contribute to cystogenesis via alterations in cell-matrix
interactions, such as adhesion, growth and differentiation. Wilson and Sherwood
(1991) have shown that type IV collagen mRNA levels increase late in the course of
ADPKD. Actin is also excessively abundant in ADPKD renal tissue (Wilson and
Sherwood, 1991), as well as being mislocated. Rocco et. al. (1992) studied levels of
transcripts in cpkmice, and found that those for growth factors, structural
proteins, and fibronectin and laminin receptors were normal. However, there was an
early reduction ofmRNA levels in the kidney for E-cadherin (uvomodulin) and N-
CAM (N-cell adhesion molecule). The presence of E-cadherin and N-CAM appears to
guide the sequential differentiation and polarisation of normal renal epithelia, and
their attenuated expression in the kidneys of cpk mice may be a factor in the
pathogenesis of cyst formation.
Thus, many possible mechanisms have been implicated in cystogenesis, but little
information is available concerning the sequence of events resulting in the
phenotypic expression of renal tubular cysts. The postulated involvement of the
extracellular matrix and cytoskeleton in the pathogenesis of ADPKD is particularly
attractive in that it may help to explain the extrarenal manifestations of ADPKD.
Once the abnormal gene and its function have been identified, this must be related
to the abnormal cellular events in order to determine which are primary and which
are secondary; and to determine how they relate to the non-renal manifestations of
the disease.
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The question remains as to why less than 5% of nephrons undergo cystic
change (Grantham et al., 1987) despite, presumably, the expression of the gene in
all cells. One possibility, is that ADPKD could be an example of a "two-hit" model of
pathogenesis (Reeders, 1992). The model for this mechanism is retinoblastoma
(Knudson, 1971). This suggests that, in addition to the inherited predisposition, a
second sporadic event is required to initiate cyst formation; the sporadic event , for
example, being a somatic mutation in the chromosome that does not carry the
inherited mutation (Reeders, 1992). Another possibility is that the PKD1 gene
contains an heritable unstable repeat element such as that seen in fragile X
syndrome, myotonic dystrophy and Huntington's Disease. In this case, repeat
number instability at the somatic level may explain the sporadic distribution of
cysts (Reeders, 1992). One of the features of the above disorders, however, is
anticipation which classically does not occur in ADPKD.
1.7 ISOLATION OF CANDIDATE GENES
Once a disease gene has been localised to a particular chromosomal region,
isolation of the gene requires cloned DNA. Standard DNA technology makes use of
bacteriophage lambda (>.) and cosmid cloning vectors. Bacteriophage X is a complex
virus of Escherichia coli (E. coli) which will accept up to a maximum of 23 kb of
foreign DNA. Cosmid vectors have been constructed from plasmids containing a
fragment of X DNA which includes the cos site, and they are able to accept foreign
DNA inserts of 32-47 kb. Use of these vectors to clone a gene-containing region of
DNA therefore requires that this region is first reduced to a manageable size,
preferably a few hundred kilobases and certainly less than 1 Megabase (1000 kb) of
DNA. In 1987, Burke et al. described yeast artificial chromosomes (YACs) capable of
cloning several hundred to over one thousand kilobase pairs of DNA in the host
Saccharomyces cerevisiae. This theoretically allows large regions of the human
genome to be cloned much more quickly and easily. They can also be used for the
stable cloning of DNA fragments that have proven impossible to isolate from cosmid
libraries (Coulson etal, 1988). Several YAC libraries have been constructed, both
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total genomic and chromosome-specific, and some of these libraries are available for
screening. Once one or more cosmids or YACs have been obtained, they can be
used to screen tissue-specific cDNA libraries in a variety of ways in order to detect
transcribed sequences. These transcribed sequences are candidate genes. Mutation
screening is then performed in order to either prove or disprove an association with
a disease phenotype.
1.7.1 Candidate genes for PKD1
More than 20 non-overlapping cDNAs have been identified, and these appear to
encode parts of at least 18 transcripts, most of which are associated with CpG
islands (Somlo et al., 1992a). Northern analysis suggests that most of the genes in
the PKD1 region are expressed in many tissues, including the kidney.
Housekeeping genes are generally associated with CpG islands, so that identifying
genes on the basis of proximity to islands may bias against the identification of
tissue-specific genes. Many tissue-specific genes also have islands, however,
although the proportion that do so is still unknown. Therefore, in selecting genes
for further study from amongst such a large number, suggested functions based on
sequence analysis become important. Sequence analysis ofmost of the cDNAs in
the PKD1 region has not suggested likely functions for most of them {Somlo et al.,
1992a). However, one of the genes (AJ1) associated with a CpG island, identified by
a combination of cosmid walking and chromosome jumping (Gillespie et al, 1990),
shows 77% sequence homology with the gene encoding the 16-kiloDalton
proteolipid subunit of bovine chromaffin granule H+-ATPase (Gillespie etai, 1991).
In a region where there are major differences between the human and bovine
sequences, there is complete identity between the human, Drosophila, Torpedo, and
yeast sequences. In view of possible mechanisms of cyst formation (discussed
above), AJ1 seemed an ideal candidate gene. However, the coding region was not
mutated when compared with allelic cDNAs isolated from a primary culture of cyst
epithelium obtained from an ADPKD patient, and Northern blot analysis suggests
that there are no differences in expression of this gene in normal compared with
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ADPKD kidneys. These data, and the finding of two recombinants with 92.6SH1.0
placing PKD1 distal to this marker (Somlo et al., 1992b), were felt to exclude AJ1 as
the PKD1 gene. It should be noted, however, that DNA from only one patient was
screened for the presence of a mutation, and it is conceivable that this patient may
be from a PKD2 family especially as the linkage data is not shown. The evidence for
the exclusion ofAJ1 as a candidate gene for PKD1 is therefore inconclusive.
Using the series of cosmids isolated by Germino et al. (1992), the same
group searched for deletions, insertions or other rearrangements by screening
digested genomic DNA with a minimally overlapping set of cosmids between GGG1
(D16S259) and 26-6 (D16S125) and looking for identifiable restriction fragment
length differences. Between 10 and 30 mutated chromosomes from unrelated
affected individuals were studied, and no rearrangements detected, although three
small segments were not effectively screened (Somlo et al., 1992a). It is therefore
likely that techniques capable of detecting single base alterations will be required to
detect PKD1 mutations.
1.8 AIMS OF THE PROJECT
This project is concerned with the gene for ADPKD which has been localised to the
short arm of chromosome 16 (PKD1). The aims of the project fall broadly into two
categories: -
1. Extension of genetic mapping studies in central Scottish ADPKD families, with
two-point and multipoint analyses to (i) confirm localisation of the PKD1 gene, (ii)
search for evidence of genetic heterogeneity in this population, (iii) identity and
assess new PKD 1 recombinants, and (iv) search for evidence of linkage
disequilibrium.
2. Isolation of yeast artificial chromosomes by screening of the available YAC
libraries with a series of probes from the region of 16p known to flank PKD1.
Characterisation of the YACs obtained would be followed by screening of cDNA





2.1.1 Ascertainment and diagnosis of family members
Families were ascertained through the Medical Renal Unit, Royal Infirmary of
Edinburgh and the Renal Unit, Western Infirmary, Glasgow. Diagnostic criteria
included a family history of ADPKD (more than one affected member) and
ultrasound findings of two or more cysts greater than 0.5 cm in diameter in one
kidney and at least one such cyst in the contralateral kidney (Watson et al.. 1987).
Pedigrees were drawn up after interviews with patients and were checked against
the centralised Register for Births, Marriages, and Deaths for Scotland. Ethical
approval was secured and, after obtaining informed consent, 30-50 ml EDTA-
anticoagulated blood was drawn and frozen at -70°C prior to DNA extraction.
Thirty-five probands and 343 family members were initially ascertained, and their
relatives sampled for biochemical and DNA analysis and examined clinically as
described previously (Watson et al.. 1987). Ultrasound examinations were then
arranged and carried out by experienced sonologists, one in each centre. Positive
scans were graded according to the following criteria:-
Grade 1 1-5 cysts bilaterally
Grade 2 6-10 cysts bilaterally
Grade 3 11-15 cysts bilaterally
Grade 4 > 16 cysts bilaterally.
2.1.2 Extraction of DNA from blood
DNA extraction from EDTA-anticoagulated frozen blood was carried out by Mrs. M.
Deans according to the method of Kunkel et al. (1982). DNA samples were stored at
-70°C in TE buffer (10 mM Tris-HCl. ImM EDTA pH 8).
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2.1.3 Markers used in linkage analysis
Probes 3'HVR (D16S85), CMM65 (D16S84), and VK5 (D16S94) were used to type all
family members as described by Pignatelli et al. (1992). 3'HVR is a hypervariable
locus located in 16pl3.3 which detects multiple alleles with several restriction
enzymes (Jarman et al., 1986). DNA samples were digested with PuuII and allele
frequencies were each set at 0.1 in the linkage programs. CMM65 (D16S84) is
localised to 16pl3.3 and, on probing DNA digested with PuuII. detects two alleles of
size 3.5 kb (allele 1) and 1.3 kb (allele 2), with frequencies of 0.37 and 0.63
(Nakamura etal., 1988). VK5 (D16S94), also localised to 16pl3.3, detects alleles of
1.6 kb (allele 1) and 1.3 kb (allele 2) with the enzyme Mspl, with frequencies of 0.55
and 0.45 (Hyland et al., 1990). The majority of these typings were done by Ms. P.
Pignatelli.
26-6 is a single copy 432 bp PstI subclone in pKUN which detects a Taql
RFLP on 16pl3.3 (Breuning et al, 1990c). Alleles El and E2 have frequencies of
0.27 and 0.73 respectively (Breuning et al, 1990a). Approximately 10 kb of this
locus is duplicated, with about 120 kb between these duplicated segments
(Gillespie et al., 1990). PCR primers have been designed which allow amplification
of both loci (Saris et al., 1990), and rapid detection of a RFLP (El, E2) in the




BstNl* Taql* Taql \
_1 y/ 1 1
polymorphic
site
The 26-6 PCR primers amplify both the proximal (26-6PROX; D16S125) and distal
(26-6DIS) loci. The polymorphic BstNl site is present in the proximal locus some
200 bp from the polymorphic Taql site, which is outside the amplified fragment (M.
H. Breuning, unpublished results). The distal locus contains a non-polymorphic
Taql site.
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The families were typed for 26-6 (D16S125) using PCR amplification and digestion
of the PCR product with Taql and BsiNl, as described below.
SM7 (D16S283) is a polymorphic microsatellite (Harris etal., 1991), and
families were typed using PCR amplification of the CA repeat followed by separation
of the alleles on a 6% polyaciylamide sequencing gel. There are eleven alleles of the
following sizes with their frequencies shown in brackets: 107 bp (0.005), 101 bp
(0.015), 99 bp (0.06), 97 bp (0.045), 95 bp (0.055), 93 bp (0.04), 91 bp (0.565), 89 bp
(0.14), 87 bp (0.025), 85 bp (0.045) and 81 bp (0.005) (Harris et al., 1991). In typing
the families, the reference allele (0) was taken to be the 91 bp allele. In order to
allow the multipoint linkage analysis to run using the LINKMAP program, the SM7
(D16S283) results were entered into the pedigree files using a maximum of five
alleles. Alleles typed as -2, 0, +2, +4, or +6 were left as such, and the less common
alleles re-designated as one of the above so that full informativeness was
maintained in each family.
2.1.4 Programs used for linkage analysis
Linkage results were analysed using the LINKAGE program package version 5.03
(Lathrop et al, 1984). The ADPKD gene frequency was set at 0.0005, and male and
female mutation rates assumed to be equal at 5 x 10"^ per locus per gamete. The
female : male recombination ratio was assumed to be constant and was found to
maximise the likelihood at a ratio of 0.2. This value was used for the LINKMAP
runs. MLINK was unable to support a fixed ratio of recombination in the two sexes,
so sex averaged values were obtained. The probabilities of ultrasonographic
detection in gene carriers were assumed to be 0.64, 0.92, and 1.00 for ages 0-10
years, 10-30 years and over 30 years respectively (Bear et al, 1992).
Two-point linkage analyses were obtained using the MLINK subroutine.
Multipoint analyses were run using LINKMAP with a fixed order ofmarker loci as
follows: D16S85-0.06-D16S84-0.01-D16S283-0.005-D16S125-0.005-D16S94. The
Turbo-Pascal source code was modified and recompiled as required. Heterogeneity
analyses were carried out by P. Teague using the HOMOG program (Ott, 1985).
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2.2 POLYMERASE CHAIN REACTION
Unless otherwise stated, PCR was carried out using 1 unit of Promega Taq DNA
polymerase in 1 x Promega PCR buffer (50 mM KC1, 10 mM Tris-HCl pH 9.0, 1.5 mM
MgCl2, 0.1% Triton X-100), with 200 pM each dNTP (Pharmacia, Ultrapure), and
1.0 pM each primer in a total volume of 25 pi or 50 pi. Samples were overlaid with
mineral oil (Sigma) and cycled in either a Cetus or a Hybaid DNA thermal cycler.
2.2.1 Extraction of PCR primers
The majority of primers were made within the Unit (Medical Research Council,
Human Genetics Unit, Edinburgh), and were extracted from the deprotected
ammonium hydroxide mixture using the following protocol. To 350 pi
oligonucleotide mix were added 0.1 volumes 3M sodium acetate pH 6.0, followed by
2 volumes absolute ethanol. The oligonucleotides were allowed to precipitate at
-20°C for 30 minutes, and collected by centrifugation at 12,000 rpm for 15 minutes
at 4°C. The supernatant was carefully removed and the pellet washed twice using
80% ethanol. Traces of ethanol were removed using a vacuum dessicator, and the
pellet resuspended in 200 pi TE buffer. The absorbance of light at 260 nm (A260)
was measured, and the concentration of primer calculated according to the
following formula:-
Concentration = A260/ml
[nAx 16,000]+[nG x 12.000]+[nC x 7,000]+[nT x 9,600]
where n = the number of bases (A, G, C and T) present in the oligonucleotide.
Biotinylated primers were obtained from Oswel DNA Services Ltd.,
University of Edinburgh, and were HPLC purified and delivered ready for use.
2.2.2 PCR amplification of 26-6 (D16S125)
The duplicated 26-6 locus was amplified from 500 ng genomic DNA using the
primer sequences below:-
Rl: 5' CTG CAG AAT AAA CAA GTG TGT GGT TTC 3'
M4: 5' GGG AAA AAA CAG GTT AAA GAA TGG GAC 3'
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The total volume was 25 pi, and MgCl2 concentration 2.5 mM. PCR was carried out
for 30 cycles with 1 min at 94°C, 1 min at 65°C, and 2 min at 72°C.
Once the PCR reaction had terminated, the mineral oil was removed, 3 pi 10
x buffer 'B' (Boehringer Mannheim) added, and the amplified DNA digested at 65°C
for 1 hour with 5 units Taql (Boehringer Mannheim). 3.5 pi 10 x NEB buffer 2 was
then added, and the DNA digested for 2 hours at 37°C with 5 units BstNl (New
England Biolabs). The products were then separated on a 3% Nusieve (FMC): 1%
LMP agarose gel (Figure 2.2).
Figure 2.2 BstNl polymorphism of the 26-6PROX (D16S125) locus
BstNl polymorphism of unrelated individuals, showing the El and E2
alleles of 26-6 (D16S125). The DNA marker V (Boehringer Mannheim) is
Haelll-digested pBR322
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2.2.3 PCR amplification of SM7 (D16S283)
The SM7 microsatellite CA repeat was amplified from 25 ng genomic DNA using the
primer sequences shown below: -
TG strand 5' ACA TAT GTA GTC TTC TGC AGG 3'
AC strand 5' ACA AGA GTG AAT CTC TGA CAG 3'
1 pCi [a-32p]-dCTP (-6000 Ci/mmol; Amersham) was added to each PCR reaction,
in a total volume of 25 pi. PCR was carried out for 29 cycles with 1 min at 94°C,
1 min at 55°C, and 1 min at 72°C, followed by 1 cycle with 1 min at 94°C, 1 min at
55°C, and 10 min at 72°C.
4 pi PCR product was mixed with 4 pi stop dye (95% formamide, 5% TBE,
0.1% xylene cyanol, 0.1% bromophenol blue), and 6 pi of this was then used to load
the gel. Samples were run on 6% polyacxylamide (20:1; acrylamide:bisacrylamide) /
46% urea denaturing sequencing gels in a vertical electrophoresis unit (BRL) in 1 x
TBE running buffer (90 mM Tris-borate, 2mM EDTA). Prior to loading, the samples
were denatured at 95°C for 10 minutes and cooled on ice. Gels were run at a
constant power of 70 W until the bromophenol blue dye had just run off the end of
the gel (approximately 2 hours). Gels were then dried on a horizontal slab gel drier
(BioRad) and exposed to Kodak XAR-5 X-Omat X-ray film in a cassette with double
intensifier screens for 48 hours prior to automated developing. Individuals from
family PK 2 were typed by Dr. P. Harris (Oxford), and some individuals from this
family were loaded onto each gel to act as size markers.
2.2.4 PCR primers and conditions for YAC library screening
Each pair of primers was tested against total human genomic DNA, ThyBl-33-12/3
(ThyBl) mouse DNA and yeast DNA (AB1380) prior to screening of the libraries.
None of the primer pairs gave a product when used on AB1380 alone.
2.2.4.1 PCR amplification of GGG1 (D16S259)
Primer sequences and starting conditions were supplied by Dr. M. H. Breuning
(Leiden). The forward (M3) and reverse (R2) primer sequences are as follows:-
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R2: 5' TCT GGG AAA GGA AGG GGT GGG CTC 3'
M3: 5' GTT GGG CAG GGC AGG GCG TGG TAG 3'
PCRwas carried out for 1 cycle with 2 min 30 sec at 94°C, 1 min at 68°C and 3 min
at 72 °C, followed by 27 cycles with 1 min at 94°C, 1 min at 68°C and 3 min at
72°C. The PCR product is approximately 1 kb in size, and samples were run on a
1% agarose gel in 0.5 x TBE using a horizontal electrophoresis tank. No product
could be obtained using ThyBl as a template.
2.2.4.2 PCR amplification of 26-6 (D16S1251
PCRwas carried out as in section 2.2.2. The annealing temperature was reduced to
60°C for screening the mouse YAC library. The PCR product is 430 base pairs in
size, and samples were identified by electrophoresis on a 3% Nusieve: 1% LMP
agarose gel.
2.2.4.3 PCR amplification of SM33d22
Primer sequences and starting conditions were supplied by Dr. M. H. Breuning
(Leiden). The forward (148L) and reverse (147L) primer sequences are as follows:-
148L 5' GCC CCC GGC CCC GCG CGC CCC GCC CTG AGG AGC AGG GAG CAG
AGG AAA C 3'
147L 5' ATG CGT GGC GTATTC CTC TGG G 3'
PCR was carried out for 2 min at 94°C, followed by 28 cycles with 1 min at 94°C
and 2 min at 66°C, finishing with 5 min at 72°C. The annealing temperature was
reduced to 60°C for screening the mouse YAC libraiy. The PCR product is 360 bp in
length and was identified by electrophoresis on a 3% Nusieve: 1% LMP agarose gel.
2.2.4.4 PCR amplification of ATPL
As described in Chapter 5, forward (CI8) and reverse (CI9) primers were designed
to the 3' untranslated region of the sequence for AJ1 cDNA, an ATPase-like vacuolar
proton channel gene which is located approximately 50 kb distal to 26-6DIS
(Gillespie etal., 1991). The primer sequences are as follows:-
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C18 5' CCC GCC CCC AGT AGT TGG TC 3' (Tm = 68.1°C)
C19 5' AAC AGG AAC CCA CAA GGC GAC A 3' (Tm = 68.2°C)
PCR was carried out for 1 cycle with 2 min 30 sec at 94°C, 30 sec at 63°C and 1 min
30 sec at 72°C; followed by 25 cycles with 1 min at 94°C, 30 sec at 63°C and 1 min
30 sec at 72°C plus 3 sec extension per cycle; finishing with 1 cycle of 1 min at
94°C, 30 sec at 63°C and 5 min at 72°C. The annealing temperature was reduced to
57°C for screening the mouse YAC library. The PCR product is 295 bp in size, and
was identified by electrophoresis on a 3% Nusieve: 1% LMP agarose gel.
2,2.4.5 PCR amplification ofVK5 (D16S941
VK5 (D16S94) is a 7 kb EcoRI-BamHI fragment in pBR322 (Breuning et ai, 1990a;
Hyland et al, 1990). As described in chapter 5, forward (VF1) and reverse (VR1) PCR
primers were designed, thereby allowing PCR amplification of a 1.3 kb segment of
VK5 (D16S94). The primer sequences are as follows:-
VF1 5' GGC CGC GTGTTTTGCTTTTG 3'
VR1 5' AGA AGG CAA CGA GGG CTG GC 3'
The MgCl2 concentration in each reaction was 1.0 mM. PCR was carried out for 1
cycle with 2 min 30 sec at 94°C, 30 sec at 63°C and 1 min 30 sec at 72°C; followed
by 25 cycles with 1 min at 94°C, 30 sec at 63°C and 1 min 30 sec at 72°C plus 3 sec
extension per cycle; finishing with 1 cycle of 1 min at 94°C, 30 sec at 63°C and
5 min at 72°C. The annealing temperature was reduced to 60°C, and the MgCl2
concentration increased to 1.5 mM for screening the mouse YAC library. The PCR
product is 1.3 kb in length, and was separated on a 1% agarose gel.
2.2.5 Alu PCR
Primers used for Alu PCR were:-
TC-65 5' AAG TCG CGG CCG CTT GCA GTG AGC CGA GAT 3'
517 5' CGA CCT CGA GAT CTY RGC TCA CTG CAA 3' (where Y is a
pyrimidine and R is a purine).
153 5' GGG ATTACAGGC GTG AGC CAC 3'
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154 5' TGC ACT CCA GCC TGG GCA 3'
450 5' AAA GTG CTG GGA TTA CAG G 3'
451 5' GTG AGC CGA GAT CGC GCC ACT GCA CT 3'
TC-65 and 517 are from Nelson et cd. (1989); 153, 154, 450 and 451 from
Breen et al. (1992). PCR was carried out as follows: 1 cycle with 3 min at 94°C, 1
min at 60°C and 1 min at 72°C, followed by 35 cycles with 45 sec at 92°C, 1 min at
60°C and 1 min at 72°C plus 6 sec extension per cycle, and finishing with 1 cycle of
45 sec at 92°C, 1 min at 60°C and 10 min at 72°C.
2.2.6 PCR amplification of catch-linkered YAC material
962L 5' GTC AAG AAT TCG GTA CCG TCG AC 3'
Catch-linkered material was amplified using the 962L primer under the usual
reaction conditions, except that the primer concentration was 0.8 pM. PCR was
carried out for 1 cycle with 2 min 30 sec at 94°C, 30 sec at 64°C and 2 min at 72°C,
followed by 35 cycles with 30 sec at 94°C, 30 sec at 64°C and 2 min at 72°C, and
finishing with 1 cycle of 30 sec at 94°C, 30 sec at 64°C and 5 min at 72°C.
2.2.7 PCR of YAC plugs
Following treatment with PMSF, 400 pi TE8 was added to each plug, and the plug
melted at 65°C for 15 minutes. 1-5 pi of this was used in each PCR reaction.
2.2.8 PCR of YAC colonies
After Ross et cd. (1992). A small amount of colony was picked into 20 pi lysis buffer
(1% Triton X-100, 20 mM Tris HC1 pH 8.3, 2 mM EDTA) and incubated at 100°C for
10 minutes. Cell debris was pelleted at 12,000 rpm in a microfuge for 5 minutes,
and 5 pi of the supernatant used per PCR reaction.
2.2.9 PCR of recombinant DH5a colonies
Using a toothpick, a small amount of colony was placed in 20 pi sterile deionised
water, vortexed, 20 pi phenol:chloroform:isoamyl alcohol (25:24:1 v/v) added.
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vortexed again, and spun briefly in an Eppendorf centrifuge. 100 pi Phase Lock
Gel™ (5Prime—>3Prime Inc.) was added, the tube spun for 5 minutes and the
supernatant removed. 1 pi of the supernatant was used in a PCR reaction with M13
universal and reverse primers.
2.3 PREPARATION OF DNA
2.3.1 Small scale preparation of plasmid and cosmid DNA (minipreps)
Rapid boiling method, after Holmes and Quigley (1981).
Cells from a 10 ml overnight L-broth cultures were harvested by centrifugation at
3,000 rpm for 10 minutes in a Sorvall RT6000B centrifuge, resuspended in 500 pi
STET (8% w/v sucrose, 10 mM Tris-HCl, 50 mM Na2EDTA, 0.5% v/v Triton X-100,
pH 8.0) and transferred to a 1.5 ml microfuge tube. After addition of 15 pi lysozyme
solution (lOmg/ml lysozyme in STET), the tube was placed in a boiling water bath
for 40 seconds. The lysate was then centrifuged for 10 minutes at 12,000 rpm, and
the supernatant decanted into a clean tube. The volume of the supernatant was
made up to 0.5 ml with sterile deionised water and extracted with an equal volume
of phenol chloroform: isoamyl alcohol (25:24:1 v/v). The aqueous layer was removed
and extracted with an equal volume of chloroform:isoamyl alcohol (24:1 v/v). The
aqueous layer was removed, and the nucleic acids were precipitated with 0.1
volumes 3M sodium acetate (pH 6.0) and 0.6 volumes isopropanol, and collected by
centrifugation at 12,000 rpm for 20 minutes at 4°C. After a 70% ethanol wash, the
resulting pellet was dried and resuspended in 30 pi TE8 + RNAse A (10 pg/ml).
1-5 pi of this miniprep solution was usually sufficient for restriction enzyme
analysis.
2.3.2 Preparation of DNA for sequencing
Cells from a 3 ml overnight Terrific broth (TB) culture were harvested by
centrifugation at 12,000 rpm in an Eppendorf centrifuge for 5 minutes, and
resuspended in 200 pi TE/0.1M NaCl. An equal volume of phenol:chloroform:
isoamyl alcohol (25:24:1 v/v) was added, the microfuge tube vortexed hard, and
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then centrifuged at 12,000 rpm for 7 minutes. The aqueous phase was removed,
and 5 M ammonium acetate added to a final concentration of 2 M. DNA was
collected by centrifugation at 12,000 rpm for 30 minutes, after precipitation with
1 ml ice-cold ethanol. The resulting pellet was washed with 70% ethanol, dried, and
resuspended in 15 pi TE8 + RNAse A (10 pg/ml). 7-10 pi of this solution was used
per sequencing reaction.
2.3.3 Preparation of yeast DNA plugs
10 ml of Casamino broth (-URA, -TRP) was inoculated with a loopful of yeast which
had previously been streaked out on to a Casamino agar (-URA, -TRP) plate. The
culture was incubated at 30°C with shaking at 200 rpm overnight, added to 90 ml
YPD broth and incubated under the same conditions for a further 24 hours. The
culture was decanted into two 50 ml Falcon tubes and the cells harvested by
centrifugation in a Sorvall RT6000B at 3000 rpm (take up to speed and then stop).
The cells were washed once with 50 mM EDTA pH 7.5 under the same centrifuge
conditions and resuspended in 6 ml CPES (40 mM Citric acid, 120 mM Na2HPC>4
pH 6.0. 1.2 M sorbitol dissolved together, pH adjusted to 6.0, made up to volume
and autoclaved. 20 mM EDTA pH 7.5 added from autoclaved stock, and 5mM
dithiothreitol (DTT) added from frozen 1 M stock just before use).
40 mg of Novo Zym 234 (Novo Industries AS, Denmark) was added to 10 ml
1% low melting-point (LMP) agarose in CPE (as CPES but without sorbitol or DTT)
held at 38-42°C, and mixed well. This was added to the cells/CPES, mixed by
inversion and placed in a water bath at 42°C to prevent premature solidification.
100 pi aliquots were pipetted into block formers (stored in 0.1 M HC1 and washed
with copious amounts ofwater prior to use) which had been sealed with tape and
placed on ice. After setting, the plugs were removed and incubated at 30°C for 1
hour in CPE (about 1 ml CPE per block without shaking). The CPE was replaced
with 1 ml/plug of Solution 3 (0.45 M EDTA pH 9.0, 10 mM Tris HC1 pH 8.0, 1%
sodium lauryl sarcosyl, 1 mg/ml proteinase K; made up from stocks just before use)
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and the plugs incubated overnight at 50°C with gentle shaking. The CPE was then
removed and the blocks stored at 4°C in 0.5 M EDTA pH 9.0.
Prior to use for PCR or restriction enzyme digestion, plugs were washed x4
in TE buffer pH 8.0 and then treated with PMSF. A 1000 x stock was made up by
dissolving 40 mg PMSF in 1 ml 98% ethanol, and then a working solution was
made of 0.04 mg/ml PMSF in TE8. Plugs were incubated in this solution at 50°C for
30 minutes (1 plug/ml) with gentle shaking, washed four times with TE8 and stored
in TE8 until required for use (short-term storage only).
2.4 DNA MANIPULATIONS
2.4.1 Digestion of DNA
All enzymes used were obtained from Boehringer Mannheim unless otherwise
stated. Digests were performed in a total volume of 20 pi, with 2 pi appropriate 10 x
restriction enzyme buffer and an appropriate amount of enzyme. YAC plugs were
treated with PMSF, washed in TE8 and equilibrated with 1 x buffer prior to the
addition of enzyme.
2.4.2 Ligation reactions
Unless otherwise stated, ligations were performed in 10 pi total volume using 1 unit
T4 DNA ligase (Boehringer Mannheim), 100 ng digested and phosphatased
pBluescript and an excess of insert. Ligation was carried out overnight, at 12°C for
fragments with cohesive ends and at room temperature for fragments with blunt
ends, using the manufacturers buffer.
2.4.3 Preparation of PCR fragments for subcloning
50 pi PCR product was removed and Taq polymerase inactivated by heating to 95°C
for 15 minutes, and then cooling to room temperature to renature the PCR
products. In order to create "flush ends", 1 pi Klenow enzyme (Boehringer
Mannheim) and 5 pi 2 mM dNTPs were added and the mixture incubated at 37°C for
15 minutes. The PCR product was purified using Geneclean™ (Bio 101 Inc.),
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according to the manufacturer's instructions, and resuspended in 10 pi TE8. 2 pi of
product was electrophoresed in an agarose gel to check the concentration. 1 pi
Polynucleotide kinase (10 units/pl; Boehringer Mannheim) was added to 0.5 pg
product, and 10 x ligase buffer to a final concentration of 1 x. Samples were
incubated at 37°C for 30 minutes and then 65°C for 15 minutes to inactivate the
kinase.
2.4.4 Phosphatasing of pBluescript
pBluescript was digested with the appropriate enzyme to produce either compatible
cohesive ends or blunt ends, and the number of picomole (pmol) ends calculated. 1
unit of bacterial alkaline phosphatase (BAP) was used per 2 pmol of ends. Tris HC1
pH 8.0 was added to a final concentration of 50 mM, and the solution incubated at
37°C for 15 minutes. A further aliquot of BAP was added and incubated at 55°C for
45 minutes. SDS was added to a final concentration of 0.5%, EDTA to 5 mM and
proteinase K to 100 pg/ml, and the tube incubated at 50°C for 30 minutes. DNA
was extracted with an equal volume of phenol:chloroform:isoamyl alcohol (25:24:1
v/v) then with an equal volume of chloroform:isoamyl alcohol (24:1 v/v), and
precipitated with 0.1 volumes 3 M sodium acetate pH 7.0 and 2 volumes ethanol.
DNA was collected and washed as forminiprep DNA, and resuspended in TE pH 7.5
at a final concentration of 100 pg/ml. The vector was stored in aliquots at -20°C.
2.4.5 DNA sequencing
Sequencing reactions were performed using the Sequenase 2.0 DNA sequencing kit
(USB). Plasmid DNA was prepared according to the protocol in section 2.3.2. For
each plasmid, 10 pi DNA was added to 10 pi distilled water and 20 pi 2 x denaturing
buffer (0.4 M NaOH, 0.4 M EDTA), and incubated at 37°C for 30 minutes. To this
was added 4 pi 3 M sodium acetate and 88 pi absolute ethanol, and the denatured
DNA precipitated at -70°C for 15 minutes. The DNA was pelleted by centrifugation
for 20 minutes, washed with 70% ethanol and dried in a vacuum dessicator. The
pellet was resuspended in 7 pi distilled water, 2 pi reaction buffer and 1 pi primer.
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The primer was annealed at 37°C for 20 minutes, and then the Sequenase protocol
was followed exactly for the labelling reactions.
Samples were run on 6% polyaciylamide / 46% urea denaturing sequencing
gels in a vertical electrophoresis unit (BRL) in 1 x TBE running buffer (90 mM Tris-
borate, 2 mM EDTA). Prior to loading, the samples were denatured at 95°C for 3
minutes and cooled on ice. Gels were run at a constant power of 70 W for 1 Vi hours
for the short run and 4 hours for the long run. Gels were then dried on a horizontal
slab gel drier (BioRad) and exposed to Kodak XAR-5 X-Omat X-ray film in a cassette
with double intensifier screens for 36 hours.
2.5 TRANSFORMATION
2.5.1 Preparation of competent cells
A 10 ml culture of DH5a in L-broth was grown overnight, 0.5 ml of this was added
to a fresh 10 ml of L-broth and grown for IV2 hours. The cells were spun down, the
supernatant removed and the cells resuspended in 1 ml ice-cold 100 mM CaCl2
(filter-sterilised) and placed on ice for 10 minutes. The above steps were repeated,
the cells spun a third time and resuspended in 200 pi 100 mM CaCl2 ready for
transformation.
2.5.2 Transformation of DH5a
200 pi competent DH5a cells were made fresh (see 2.6.1) or thawed (Gibco BRL),
and left on ice for 10 minutes. 3-5 pi ofligation mix was added and the tube left on
ice a further 30 minutes. After heat shock at 42°C for 90 sec, the tube was placed
on ice for 2 minutes. Three volumes of SOC were added and the cells incubated
with shaking at 37°C for 1 hour, spun down for 30 sec and resuspended in 200 pi
SOC. 100 pi of cells were plated on L-agar plates spread with 80 pi ampicillin
(25 mg/ml), 40 pi 5-bromo-4-chloro-3-indolyl-p-D-galactoside (X-gal, 20 mg/ml in
dimethylformamide) and 4 pi isopropylthio-p-D-galactoside (IPTG, 200 mg/ml in
H2O, filter-sterilised) and incubated at 37°C overnight.
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2.6 SOUTHERN TRANSFER
After electrophoresis in agarose gels, DNA was transferred to Hybond-N+
membranes (Amersham) by the alkali blotting method as described in the Hybond-
N+ protocol booklet. A capillary blot was set up using 0.4 M NaOH as the transfer
buffer, and transfer allowed to proceed overnight. The filter was rinsed in 2 x SSC,
and was then ready for hybridisation.
2.7 HYBRIDISATION PROTOCOL
All hybridisations were based on the following protocol, and any changes are noted
in the relevant sections.
Filters were prehybridised at 65°C for 3 hours in double sealed plastic bags
with 10-20 ml hybridisation fluid [7% (w/v) sodium dodecylsulphate (SDS), 0.5 M
Na2P04 pH 7.4, 1% (w/v) bovine serum albumin (BSA)] and 0.1 mg/ml denatured
salmon sperm DNA. Probes were labelled with [a-^^P]-dCTP (-6000 Ci/mmol) using
a random priming kit (Boehringer Mannheim), and unincorporated counts were
separated by gel filtration. Filters were then hybridised in the same mixture
containing 1 x 10® cpm/ml (1-3 ng/ml) of labelled probe. After overnight
hybridisation at 65°C, filters were washed in 2 x SSC/0.1% SDS down to a final
stringency of 0.1 x SSC/0.1% SDS at 65°C. Filters were used to expose Kodak XAR-
5 films in cassettes with double intensifier screens for 1-14 days at -70°C.
Filters were stripped of probe by boiling for 10 minutes in 0.5% (w/v) SDS
and allowing to cool to room temperature.
2.8 SCREENING OF YAC LIBRARIES
The YAC libraries were primarily screened using the polymerase chain reaction
(PCR), based on Green and Olson (1990), with the sensitivity increased by Southern
blotting the gels on which the PCR products were separated, and probing the filters.
Some of the CEPH libraiy secondary screening was performed by colony
hybridisation. PCR primers and conditions are described in section 2.2.4.
i&hs,
2.8.1 CEPH YAC library (Albertsen et al., 1990)
This library was obtained from CEPH with the kind permission of Dr. D. Le Pastier.
The 113 master pools were sent as 500 ng lyophilised DNA which was resuspended
in 50 pi ultra-pure sterile distilled water. 10 ng (1 pi) was used for each PCR
reaction: all reactions were carried out in a total volume of 10 pi using the primers
and conditions detailed below. Each master pool contained 384 clones (4 x 96-well
plates), and secondary screening was performed by colony hybridisation. Later in
the project, subpools consisting of rows x columns became available for secondary
screening and 5 pi of this DNA was used in each 25 pi PCR reaction. The CEPH YAC
library was screened using primers to the GGG1 (D16S259), ATPL and VK5
(D16S94) loci.
2.8.2 ICI YAC library (Anand et al., 1990)
This library was initially obtained from Dr. R. Anand (ICI Diagnostics), and the
latter stages of screening were performed with the help of Dr. R. Elaswarapu (HGMP
Resource Centre). The library consists of 40 master pools each representing 9
subpools, and each subpool represents a 96-well microtitre plate. The master pools
and subpools were obtained as DNA plugs, and these were washed in TE buffer
under sterile conditions. 500 pi TE was added to each plug which was then melted
at 65°C. 2 pi of plug DNA was used in each PCR reaction. Following the
identification of positive subpools, rows x columns for the relevant 96-well plate
were sent as a cell suspension from the HGMP Resource Centre. 3 pi of the cell
suspension was used in each PCR reaction. All reactions were carried out in a total
volume of 50 pi. The ICI YAC library was screened using primers to the GGG1
(D16S259), 26-6 (D16S125), SM33p22, ATPL and VK5 (D16S94) loci.
2.8.3 St. Mary's Hospital Medical School mouse YAC library (Chartier et al.,
1992)
This library was obtained by kind permission of Dr. S. D. M. Brown, and distributed
by Dr. F. L. Chartier. The library consists of 16 complex pools, each corresponding
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to 1920 different clones made up from 10 simple pools. The simple pools
correspond to 2 microtitre plates, and the final set of screening is done by preparing
rows x columns of pools in individual microtifre plates. 5 pi of DNA per 50 pi
reaction was used in screening of the complex pools, and 2 pi of DNA per 25 pi
reaction for the simple pools. Prior to the preparation of rows x columns PCR pools,
the microtitre plates were duplicated using a sterile 96-pronged replicator. The YAC
colonies were grown up for 24-48 hours. Twenty-eight Eppendorf tubes were
labelled, 1-12 for columns and A-P for rows. Under sterile conditions, 200 pi YPD
broth was added to each well and the yeast resuspended. 80 pi was then distributed
into the row tube, and 80 pi into the column tube. The tubes were spun for 5
minutes in an Eppendorf centrifuge, the supernatant removed, the cells
resuspended in PCR quality water, and the tubes spun again. Finally the cells were
resuspended in 200 pi lysis buffer (50 mM KC1, 10 mM Tris HC1 pPI 8.0, 1.4 mM
MgCl2- 0.01% gelatin, 0.45% Tween-20, 0.45% NP-40, 1 U/pl yeast lytic enzyme.
The Tween-20 and NP-40 are added after autoclaving, and the yeast lytic enzyme
just prior to use), transferred to PCR tubes and incubated at 37°C for at least 1
hour, followed by 100°C for 10 minutes. 2 pi of each pool was used per 25 pi PCR
reaction. This mouse YAC library was screened with primers to the 26-6 (D16S125),
SM33p22, ATPL and VK5 (D16S94) loci. The primers were tested on ThyBl (mouse)
DNA, and annealing temperatures adjusted as required, prior to screening of the
library.
2.8.4 Probing of PCR products
The PCR products were electrophoresed in agarose gels along with a control sample
of genomic DNA that had been PCR amplified at the same time. DNA was
transferred to Hybond-N+, and filters prehybridised. For each locus, genomic DNA
was PCR amplified, the product purified using Geneclean™ (Bio 101 Inc.), and
diluted to 25 ng/pl for use as a probe. Filters were hybridised as per the protocol
and used to expose Kodak XAR-5 films in cassettes for 1-7 days at -70°C.
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2.8.5 Secondary screening by colony hybridisation
14 cm diameter petri dishes were poured using Casamino agar (-URA, -TRP) with
added ampicillin (100 gg/ml). Each 96-well plate was inoculated onto one petri dish
using a sterile toothpick and grid. Colonies were grown to 1 mm in diameter by
incubation at 30°C (approximately 36 hours). Nytran filters (Schleicher and Schuell)
were labelled after sterilisation by autoclaving, placed over the colonies and
orientated. Colonies were transferred by pressure using a sterile glass spreader, and
the filter was then placed colony side up on another agar plate. Both master and
replica plates were incubated at 30°C until the colonies were of the appropriate size.
Once the master plate had recovered, a second replica lift was performed.
The filters were then prepared for hybridisation as per the following protocol.
Filters were placed in large square petri dishes, colony side up on 3MM Whatmann
paper soaked in SCE (1 M sorbitol, 600 mM EDTA, 0.1 M sodium citrate) with
4 mg/ml Novo Zym and 10 mM DTT. The petri dishes were sealed in polythene to
avoid evaporation, and incubated at 37°C overnight. Filters were then placed on
3MM Whatmann paper soaked in denaturing solution (0.5 M NaOH, 1.5 M NaCl) for
20 minutes, removed and dried for 10 minutes, floated colony side up on 1 M Tris
HC1 pH 7.6/1.5 M NaCl for 5 minutes, then 0.1 M Tris HC1 /0.15 M NaCl for 5
minutes. Filters were then submerged in 0.1 M Tris HC1 /0.15 M NaCl with
250 pg/ml proteinase K (Boehringer Mannheim) and incubated at 37°C for 60
minutes. Any remaining debris was wiped off the filters with a soft tissue soaked in
0.1 M Tris HC1 /0.15 M NaCl, prior to submerging in 50 mM Na2HP04-2H20 pH
7.2, drying, and baking at 80°C for 30 minutes. Hybridisation was performed as in
the usual protocol, and filters used to expose Kodak XAR-5 films in cassettes for 12
days at -70°C.
2.9 PULSED FIELD GEL ELECTROPHORESIS (PFGE)
All PFGE was done in a Pharmacia LKB 2015 CHEF electrophoresis unit using the
LKB 2015 pulsaphor plus control unit and LKB 2301 macrodrive 1 power supply,
cooled with a LKB Multitemp II thermostatic circulator.
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2.9.1 Separation of yeast chromosomes
Whole YAC plugs were placed on the comb, and a 1% agarose gel poured around
them so that they were fully submerged. AB1380 plugs were used as a yeast
control. The chromosomes were separated using the following parameters:-
- 165vthroughout
- N/S 70 sec, E/W 70 sec for 21 hours followed by N/S 120 sec, E/W 120 sec for 21
hours
- running temperature 8°C
The gel was visualised by ethidium bromide staining and treated with 0.25 M HC1
for 15 minutes. The DNA was transferred to a Hybond-N+ filter using the alkali
blotting technique as above. Probes were used without purification of inserts
[CMM65 (D16S84), EKMDA (D16S83) and 218EP6 (D16S246)] and labelled with [a-
32p]-dCTP by random priming. Hybridisation was carried out exactly as for probing
of PCR products above. Filters were used to expose Kodak XAR-5 films in cassettes
with double intensifier screens overnight at -70°C.
2.9.2 Isolation of YACs
A 1% agarose gel was poured, the centre cut out, and YAC plugs were stacked 3
high against the comb and a 1% LMP agarose gel poured around them. The YACs
were separated from the larger yeast chromosomes and run into the LMP agarose
using the following programme:-
- 165vthroughout
- N/S 30 sec, E/W 30 sec for 24 hours
- running temperature 4°C
The gel was visualised by ethidium bromide staining, the YAC bands cut out using
a sterile scalpel blade and stored in TE8.
2.9.3 Separation of YAC digests and preliminary mapping
PMSF treated plugs were taken and 1 plug per Eppendorf tube was equilibrated
with 200 pi 1 x restriction enzyme buffer on ice for 30 minutes. The buffer was
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removed and replaced with 100 pi fresh buffer plus 3 pi restriction enzyme. Plugs
were digested overnight at the temperature appropriate to each enzyme. After
cooling on ice, plugs were cut in half and loaded on a 0.9% agarose gel. The
fragments were separated by PFGE using the following program:-
- 165v throughout
- N/S 2 sec, E/W 2 sec for 12 hours followed by N/S 5 sec, E/W 5 sec for 12 hours
- running temperature 8°C
The gel was visualised by ethidium bromide staining and treated with 0.25 M HC1
for 15 minutes. The DNA was transferred to a Hybond-N+ filter using the alkali
blotting technique, as above. The filter was probed with pBluescript as the YAC left
arm probe, stripped and re-probed with a 774 bp fragment of pBR322 as the YAC
right arm probe. The right arm probe was made by digesting pBR322 with Aual
followed by Sail, electrophoresing the products into a 1.5% agarose gel, excising the
774 bp fragment, treating with agarase, precipitating and resuspending the DNA.
Probes were labelled by random priming and hybridisation was carried out as per
the usual protocol. Filters were used to expose Kodak XAR-5 films in cassettes with
double intensifier screens for 3 days at -70°C.
2.10 ATTACHMENT OF CATCH-LINKERS
Blunt-end and cohesive-end catch-linkers, along with the complementary primer to
allow PCR amplification, were designed by Dr. J. Brown (MRC, HGU).
961L 5' GTC GAC GGT ACC GAA TTC 3'
963L 5' GAT CGT CGA CGG TAC CGA ATT CT 3'
962L 5' GTC AAG AAT TCG GTA CCG TCG AC 3'
961L is the blunt-end complement ofmaster primer 962L, and 963L is the Sau3A
compatible complement ofmaster primer 962L. The linkers are made by making a
solution of either 25 pM 961L/25 pM 962L (MF blunt-end linker) or 25 pM 963L/
25 pM 962L (963L Sau3A compatible linker), boiling for 10 minutes and annealing
by cooling slowly to room temperature. The stock solution is kept at -20°C.
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The YAC band was excised from LMP agarose after PFGE as described above
(approx. 200 pi of agarose) and equilibrated with 1 ml restriction enzyme buffer for
1 hour at room temperature. The buffer was then removed and replaced with 250 pi
buffer plus 2 pi restriction enzyme (8-10 units/pl), either BgllI or Rsal. BglII gives
Sau3A-compatible cohesive ends, and Rsal blunt ends. The plug was incubated at
37°C for 4 hours and then the enzyme inactivated and the plug melted by
incubation at 65°C for 10 minutes. 10 x Agarase buffer was added to a final
concentration of 1 x, along with 4 pi (3-agarase (1 unit/pl; New England Biolabs) and
the tube incubated at 40°C for 1 hour. The DNA was extracted with an equal
volume of phenol: chloroform:isoamyl alcohol (25:24:1 v/v), the aqueous layer
removed and extracted with an equal volume of chloroform:isoamyl alcohol (24:1
v/v). The aqueous layer was removed, 0.1 volumes 3 M sodium acetate (pH 6.0) was
added, the tube left on ice for 15 minutes and then spun in an Eppendorf centrifuge
at 12,000 rpm for 15 minutes at 4°C. The supernatant was removed. 2 volumes of
ethanol and 1 pi glycogen (20 mg/ml; Boehringer Mannheim) added and the DNA
precipitated overnight at -70°C. The DNA was collected by centrifugation for 30
minutes, the resulting pellet washed with 70% ethanol, air-dried and resuspended
in 10 pi TE8.
Ligation reactions were set up using 5 pi restricted YAC DNA, 3 pi linkers
(either 25 pM or 2.5 pM), 1 pi T4 DNA ligase (Boehringer Mannheim) and 1 pi 10 x
ligation buffer. DNA restricted with BgUl was ligated to the cohesive-end linker
962L/963L, and DNA restricted with Rsal was ligated to the blunt-end linker MF.
Cohesive-end ligations were allowed to proceed overnight at 12°C and blunt-end
ligations at room temperature. 90 pi of sterile distilled water was added to each
tube, and the reactions stopped by incubating at 65°C for 15 minutes.
2.11 FLUORESCENCE IN SITU HYBRIDISATION
This was carried out by Dr. M. Breen (YACs 71B2 and 71B4), Ms. S. Boyle (YAC
32A-A4) and Mrs. M. Harris(YAC C4-I12). Approximately 1 pg of amplified catch-
linkered YAC material was used for in situ hybridisation. Metaphase spreads were
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prepared from phytohaemagglutinin stimulated peripheral blood lymphocyte
cultures or lymphoblastoid cell cultures (BB33) by routine methods of colcemid,
potassium chloride hypotonic and methanol/acetic acid fixation treatments. Slide
preparations were air dried and stored under vacuum for up to two weeks. The PCR
amplified YAC fragments were labelled with biotin-16-dUTP (Boehringer Mannheim)
by a nick translation reaction (Rigby et al., 1977) in which the concentration of
DNAse I was adjusted to give fragment sizes averaging 200-500 bp. Labelled probe
was separated from the reaction by passing through a Nick™ column (Pharmacia)
equilibrated in 0.01 M Tris HC1 pH 8.0 / 0.2 M NaCl / 0.01 M EDTA. The level of
biotin incorporation was determined using an avidin alkaline phosphatase-
NBT/BCIP substrate assay (Vector laboratories).
For each slide, 50 ng of biotinylated amplimered YAC, 5 pg human Cotl DNA
(BRL) and 5 pg sonicated salmon sperm DNA were mixed and precipitated with
absolute ethanol. The DNA was pelleted by microcentrifugation and resuspended in
10 pi of a hybridisation mixture containing 50% formamide, 10% dextran sulphate,
2 x SSC (0.3 M NaCl; 0.03 M Tri-sodium citrate), 0.1% Tween-20. The DNA was
denatured at 75°C for ten minutes and then pre-annealed at 37°C for 30 minutes.
Immediately before use, slide preparations were passed through an ethanol series
(70%-90%-100%). Chromosomal DNA was denatured at 70°C in 70% v/v
formamide/2 x SSC for two minutes and then passed through a cold ethanol series
(70%-90%-100%). Hybridisation was performed under a sealed 22 x 22 mm
coverslip at 37°C for 16 hours. Post-hybridisation washing was carried out
according to Pinkel et al. (1986) except that cytochemical detection was as
described by Gosden et al (1991). Slides were mounted in antifade (1:1 glycerol:
Citifluor AF3) containing 3.75 pg/ml DAPI and 0.75 pg/ml propidium iodide. This
mixture of fluorochromes produces an R-banded pattern on the majority of
chromosome preparations treated as described above. Analysis of results was
carried out using a Leitz Ortholux II microscope fitted with a Ploemopak filter
system. Suitable chromosome preparations were scanned with a BioRad Lasersharp
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MRC 600 confocal scanner attached to the same microscope. Map positions were
determined by observation of the R-banding pattern.
2.12 END-CLONING TECHNIQUES
End-cloning of YACs 32A-A4 and C4-I12 was attempted using various techniques
detailed below.
2.12.1 End-cloning by asymmetric PCR
After Rosenthal et al. (1991). Vector primers 373 (left) and 556 (right) were taken
from Arveiler and Porteous (1991) and biotinylated as 496N (left) and 497N (right).
496N 5' Biotin-GCC AAGTTG GTTTAAGGC GC 3'
497N 5' Biotin-GCC CGA TCT CAA GAT TAC G 3'
20 pi PCR amplified catch-linkered YAC DNA was purified by Geneclean™ and
resuspended in 100 pi TE8. Asymmetric PCR was performed on 1 pi template with
90 sec at 95°C, 50 cycles of 30 sec at 95°C, 1 min at 55°C, 1 min at 72°C, finishing
with 3 min at 72°C. The biotin-labelled PCR products were isolated with
Dynabeads™ (Dynal) as in Rosenthal et al (1991), and the anchored DNA template
amplified with primers 962L and either 373 (left end) or 556 (right end), using the
same program as above with 35 cycles. Any product was re-amplified with the same
primers and subcloned into pBluescript.
2.12.2 End-cloning by Alu-vector PCR
1 pi YAC plug DNA was used as the template. Vector primer 373 or 556 was added
first and 5 cycles of asymmetric PCR performed before adding one of the Alu
primers. The PCR program was as for Alu-PCR. Any product was re-amplified with
the same primers and subcloned into pBluescript.
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2.13 cDNA LIBRARIES
2.13.1 Adult kidney cDNA library
An adult kidney cDNA library was purchased from Clontech Laboratories. Poly A+
RNA had been isolated from a young male whose kidney had been perfused for 24
hours. The libraiy was made by oligo (dT) priming and cloned into the lambda gtlO
(Agt 10) vector at the EcoRI cloning site. The average insert size is 0.9 kb (range 0.5-
3.2 kb). Titration was performed as recommended in the libraiy handbook, and the
titre found to be 2.35 x 10*® pfu/ml.
2.13.2 Foetal kidney cDNA library
This library was obtained from Dr. J. K. Cowell, ICRF. The library has an average
insert size of 1.0 kb and was made by oligo (dT) priming and cloned into the lambda
gtlO (/.gtlO) vector at the EcoRI cloning site. Titration was performed as for the
adult library and the titre found to be 1.25 x 10^ pfu/ml.
2.14 YAC-cDNA HYBRIDISATION
2 pi of the adult kidney cDNA library was diluted 1:10 (2 x 10® pfu/pl), and 10 pi
used per PCR reaction to achieve adequate representation. 2 pi of the foetal library
was also diluted 1:10 (1 x 10^ pfu/pl), and 10 pi used per PCR reaction. The diluted
cDNA libraries were subjected to two freeze/thaw cycles prior to use.
2.14.1 Primary amplification of cDNA
The cDNA libraries were amplified using the /.gtlO forward and reverse primers at a
concentration of 0.8 pM each. Ten PCR reactions were set up for each of the
libraries using 10 pi 1:10 diluted cDNA as template in a total volume of 50 pi. PCR
was carried out for 1 cycle with 3 min at 94°C, 1 min at 62°C and 3 min at 72°C; 20
cycles with 1 min at 93°C, 1 min at 62°C and 3 min at 72°C and 1 cycle with 1 min
at 93°C, 1 min at 62°C and 10 min at 72°C. The 10 reactions were then pooled, the
mineral oil removed by chloroform extraction and the DNA purified using
Geneclean™.
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2.14.2 Primary amplification of YAC DNA.
Ten PCR reactions were set up using 1 pi of Bgf(II-digested, catch-linkered YAC DNA.
The PCR program used was as before. As with the cDNA, the 10 reactions were
pooled, the mineral oil removed by chloroform extraction and the DNA purified
using Geneclean™.
2.14.3 Secondary amplification
1 pi of DNA from the primary amplification step was used as a template for further
PCR. Ten reactions were set up for both the cDNA and YAC DNA. The cDNA was
amplified as above, but the extension times were increased to 7 minutes per cycle.
The YAC DNA was amplified as above, but biotinylated 962L (C232) primers were
used. Amplification products were again pooled and purified.
2.14.4 Hybridisation and selection of enriched cDNAs
Biotinylated YAC DNA was pre-competed with human Cotl DNA (BRL) and an
excess of 962L primers (to prevent self-annealing of the C232 primers and
consequent hairpin formation). At the same time, amplified cDNA was pre-competed
with human Cotl DNA.
4 pi (600 ng) biotinylated YAC DNA, 5 pi 10 pM 962L and 20 pi 1 mg/ml
human Cotl DNA (BRL) were mixed together and the DNA precipitated with 2.9 pi
3 M sodium acetate pH 6.0 and 90 pi absolute ethanol at -70°C for 30 minutes. The
DNA was pelleted by centrifugation for 15 minutes at 4°C, washed with 70%
ethanol, dried, resuspended in 50 pi hybridisation buffer (6 x SSC, 0.1% SDS, 1 mM
EDTA, 10 mM Tris HC1 pH 7.5) in a PCR tube and covered with 30 pi mineral oil.
40 ql (10 pg) amplified cDNA was mixed with 20 pi Coil DNA. 6 pi sodium acetate
and 180 pi ethanol were added and the DNA precipitated as above, resuspended in
50 pi hybridisation buffer and covered with 30 pi mineral oil. Both tubes were
incubated at 100°C for 15 minutes, cooled to 68°C and incubated at 68°C for 2%
hours. The two tubes were mixed together giving a total volume of 50 pi and this
was incubated at 68°C for 20 hours to allow hybridisation to occur.
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50 pi Dynabeads™ (Dynal) were washed x 3 with binding/washing (B/W)
buffer (10 mM Tris HC1 pH 7.5, 1 mM EDTA, 2 M NaCl) then resuspended in 50 pi
B/W buffer + 30 pg denatured salmon sperm DNA. The beads were incubated at
room temperature for 15 minutes, washed with B/W buffer, resuspended in the
100 pi YAC/cDNA hybridisation mixture and incubated again at room temperature
for 15 minutes. The beads were then washed x 5 with 0.1% SDS, 0.1 M NaCl, 1 mM
EDTA at 68°C for 10 minutes per wash. After the final wash, the beads were
resuspended in 50 pi 2 x PCR buffer (Promega) and transferred to a 0.5 ml
Eppendorf tube for elution. The tube was heated to 75°C for 10 minutes, the
supernatant removed and kept and replaced by a further 50 pi 2 x PCR buffer. The
elution step was repeated at 85°C and 95°C, each time removing and keeping the
supernatant. 50 pi distilled water was added to each supernatant to produce 1 x
PCR buffer.
1 pi of this eluate was used as a template for PCR with the /.gtlO forward
and reverse primers as before. This amplified, enriched cDNA could then be taken
through further rounds of hybridisation. Once discrete bands were seen in the
enriched cDNA mixture, PCR of each band was performed by using a 23G needle to
pick up a piece of the band from the gel and inoculate the PCR reaction mix. The
bands were amplified with XgtlO primers for 20 cycles taking 5 pi of product into
fresh PCRmix (to 50 pi final volume) and re-amplifying for a further 15 cycles. 15 pi
of this product was again put into fresh PCR mix (to 50 pi final volume) and run
through a "clean-up" program in order to reduce the concentration of partially
extended and self-annealed products. This consisted of 1 cycle at 94°C for 4 min,
62°C for 2 min and 72°C for 10 min, followed by 2 cycles of 62°C for 2 min and 72°C
for 10 min.
2.15 COSMID SCREENING
An aliquot of a mouse cosmid library (Poustka et al., 1984) was kindly sent by Dr.
J. H. McVey (Haemostasis Research Group, CRC, Harrow). The titre was confirmed
to be 1 x 10^/ml after dilution plating. The mouse genome is 3 x 10^ base pairs,
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and therefore approximately 150,000 cosmid colonies are required to provide two
genome equivalents. 22 x 22 cm L-agar + 25 pg/ml kanamycin plates were prepared
and Hybond-N+ filters sterilised by autoclaving. 1 pi of the library (1 x 10® colonies)
was diluted with 5 pi L-broth, and 1 pi of this dilution added to 20 ml L-broth
(166,666 colonies). This was spread over the master filter using suction apparatus;
the filter was then placed on an agar plate and incubated overnight at 37°C. Replica
filters were made by removing the master filter onto sterile filter paper in a sterile
environment, placing a second filter on top and using a rolling pin to transfer the
colonies. The filters were orientated by a series of needle-stick holes, the filters were
peeled apart, placed colony side up on agar plates and incubated until the colonies
were 1 mm in size. A second replica filter was made in the same manner. The filters
were prepared for hybridisation by placing on 3MM Whatmann paper soaked in the
following solutions: 1.5 M NaCl/0.5 M NaOH for 7 minutes, 0.5 M Tris HC1 pH
7.4/1.5 M NaCl for 5 minutes and fresh 0.5 M Tris HC1 pH 7.4/1.5 M NaCl for 5
minutes. The filter was washed briefly in 2 x SSC and colony debris removed with a
gloved hand. DNA was fixed to the membrane by placing on 3MM Whatmann paper
soaked in 0.4 M NaOH for 20 minutes. Finally, the filter was rinsed briefly
(maximum 1 minute) in 5 x SSC and dried prior to hybridisation.
Filters were prehybridised in 20 ml hybridisation fluid and hybridised using
the above protocol. 100 ng amplified catch-linkered C4-I12 mouse YAC DNA was
labelled by random priming and unincorporated counts removed by gel filtration.
700 pi probe (1 x 10® cpm/ml hybridisation fluid) was added to 300 pi 20 x SSC
(5 x SSC final), 100 pi 1 pg/pl mouse Coil DNA (BRL) and 100 pi TE8, boiled for 10
minutes, placed on ice for 1 minute and allowed to pre-compete at 65°C for 2 hours.
600 pi of this probe mix was added to each filter, and hybridisation continued
overnight. Filters were used to expose Kodak XAR-5 films in cassettes with double
intensifier screens for 10 days at -70°C. Replicate signals were identified and
marked and the corresponding colonies on the master filter picked and
resuspended in 100 pi L-broth + kanamycin. Serial dilutions were made, the 1:100
and 1:1000 dilutions plated onto Hybond-N+ filters on L-agar + kanamycin plates,
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and incubated at 37°C overnight. Replicas were made of the 1:1000 filters
(approximately 100 colonies), and these were probed with C4-I12 as above.
2.16 CHEMICALS
Chemicals were purchased either from BDH Chemicals Ltd. or from Sigma Chemical





bacto-yeast extract 5 g
NaCl 10 g
(bacto-agar 20 g)
Add deionised water to 1 litre, and adjust pH to 7.0 with 5M NaOH. Sterilise by
autoclaving for 20 minutes at 15 lb/sq. in. on liquid cycle.
Terrific broth (TB)
bacto-tryptone 12 g
bacto-yeast extract 24 g
glycerol 4 ml
Add deionised water to 900 ml, and sterilise by autoclaving for 20 minutes at 15
lb/sq. in. on liquid cycle.
Allow the solution to cool to 60°C or less, and then add 100 ml of a sterile
solution of 0.17 M KH2PO4, 0.72 M K2HPO4. (This solution is made by dissolving
2.31 g of KH2PO4 and 12.54 g of K2HPO4 in 90 ml of deionised water, adjusting the
volume to 100 ml with deionised water and sterilising by autoclaving for 20 minutes
at 15 lb/sq. in. on liquid cycle.)
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Casamino broth/agar (-URA, -TRP)
yeast nitrogen base without amino acids 1.7 g
casamino acids 5 g
adenine hemisulphate 0.008 g
(bacto-agar 20 g)
Add deionised water to 1 litre and pH to 5.8. Sterilise by autoclaving for 20 minutes
at 15 lb/sq. in. on liquid cycle. After autoclaving, add 50 ml sterile 40% D-glucose.
YPD broth/agar
bacto-yeast extract 10 g
bacto-peptone 20 g
(bacto-agar 20 g)
Add deionised water to 1 litre, and pH to 5.8. Sterilise by autoclaving for 20




bacto-yeast extract 5 g
NaCl 0.5 g
Add the above to 950 ml deionised water and shake until dissolved. Add 10 ml 250
mM KC1, adjust the pH to 7.0 and the volume to 1 litre. Sterilise by autoclaving for
20 minutes at 15 lb/sq. in. on liquid cycle. After autoclaving, add 20 ml sterile 1 M
sterile glucose. Just before use add 5 ml sterile 2 M MgCl2.
2.18 BACTERIAL AND YEAST STRAINS
The genotype of the yeast host strain AB1380 is as follows:-
MATa \p + ura3 trpl ade2-l canl-100 lys2-l his5
The genotype of the host bacterial strain DH5a is as follows:-




3.1 LINKAGE ANALYSIS AND GENETIC HETEROGENEITY
Following the initial demonstration oflinkage between ADPKD and 3'HVR (D16S85)
(Reeders et al., 1985), many linkage studies have been performed on ADPKD
kindreds. Several of these studies have shown no evidence of linkage heterogeneity
(Reeders etcd., 1987; Lazarou etcd., 1987; Mandich etal., 1990; Turco etal, 1991)
despite reports of individual large families with typical ADPKD which do not
demonstrate linkage with chromosome 16p markers (Romeo et al., 1988; Kimberling
etal., 1988; Brissenden etal., 1989; Norby and Schwartz, 1990). The above data
would suggest that the number of PKD2 (unlinked) families is small in comparison
with the number of PKD1 (linked) families. In the provision of ante-natal and pre-
symptomatic diagnosis, and genetic counselling, it is important to establish the
extent of genetic heterogeneity in each population. Ten Scottish ADPKD kindreds
were included in the heterogeneity study by Reeders et al. (1987) which found no
evidence for a second ADPKD locus in kindreds from four different countries
(England, Scotland, Holland and Finland). The present study has extended the
Scottish sample to a total of 35 families, in order to clarify the extent of genetic
heterogeneity in this population, and to identify each family as either PKD1 or
PKD2.
In the absence of cytogenetic abnormalities that mark the position of the
disease gene, the correct identification of close flanking markers on either side of
the disease mutation is critical, since this is the only means of defining the physical
boundaries of the region containing the disease locus. Accurate localisation of the
PKD1 gene requires a genetically homogeneous sample and a large number of
kindreds. In order to facilitate accurate genetic mapping of PKD1, many markers
have been isolated from the short arm of chromosome 16. and these have been
ordered with respect to each other by a combination of linkage analysis, physical
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mapping to human-rodent hybrids, and long-range restriction mapping (Reeders et
al., 1988; Callen etaL, 1989; Breuning et al., 1990a; Germino etal., 1990; Harris et
al., 1990). Several human-rodent hybrids are available, each containing an aberrant
chromosome 16, deleted for various parts of 16p. They include CY13 (GM6227),
23HA (GM2324), N-OH1, and CY14 (Figure 3.1).
CY13 is a subclone of the 46,XX,t(l; 16)(q44;pl3.11) lymphoblastoid cell line
6227-1-C10. It contains the derivative chromosome 16qter-16pl3.11, and is
therefore deleted for the region 16pl3.1 l-16pter (Callen etal., 1986).
23HA contains the derl6 chromosome from GM2324, which is an EBV
transformed cell line from a reciprocal translocation carrier with the kaiyotype
46,XX,t(16;22)(pl3.3;ql2.2) (Germino etal., 1990).
N-OH1 is a somatic cell hybrid containing the abnormal chromosome 16
from a proband with a-thalassaemia, mental retardation and a subtelomeric
translocation. The proband has the karyotype 46.XY,-16,+der(16),t(l; 16)
(p36.3;pl3.3), and is trisomic for the tip of chromosome 1 and monosomic for the
tip of chromosome 16 (Lamb etal., 1989).
CY14 is a mouse/human hybrid containing the aberrant chromosome 16
from a cell line with an unbalanced translocation 46,XY,-16,+der(16)t(4;16)
(q31.1:pl3.3) (Breuning etal., 1987a; Callen etal., 1989). Detailed maps of
chromosome 16p have therefore been constructed, and a summary is shown in
Figure 3.2.
3.2 ANALYSIS OF FAMILIES
Thirty-five families were ascertained through patients with a diagnosis of ADPKD
attending the Medical Renal Unit, Royal Infirmary of Edinburgh, or the Renal Unit,
Western Infirmary, Glasgow, as described in Materials and Methods. The families
had previously been typed for 3'HVR (D16S85) and CMM65 (D16S84), and many
had been typed for VK5 (D16S94). Most of this work was carried out by Ms. P.M.
Pignatelli. Typing of the kindreds with VK5 (D16S94) was completed, and families
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3.2.1 Linkage and heterogeneity analysis
Five-point linkage analyses were carried out using LINKMAP, with probe data from
the 3'HVR (D16S85), CMM65 (D16S84). 26-6 (D16S125). and VK5 (D16S94) loci.
The program was run using different fixed ratios of recombination in males to
females, which identified a broad likelihood peak ratio in the region of 5 (0m:0t1-
This value was used in the final analysis. The resulting family lod scores were then
analysed for linkage heterogeneity using the HOMOG program. This analysis was
performed by P. Teague. Families found to be unlinked to chromosome 16p markers
as a result of the heterogeneity analysis (PKD2 families) were then removed from the
data set prior to further analysis.
3.2.2 Two-point linkage analysis
Two-point linkage analysis was performed between PKD1 and each of the five
marker loci in turn, i.e. 3'HVR (D16S85), CMM65 (D16S84), SM7 (D16S283), 26-6
(D16S125), and VK5 (D16S94). Recombination fractions were estimated at intervals
of 0.01 between 0 and 0.4. The MLINK subroutine was unable to support a fixed
ratio of recombination between the two sexes, and thus sex-averaged lod scores
were obtained. Two-point analysis was also performed for each of the pairs of
marker loci in turn. MLINK was used to obtain sex-averaged lod scores in the first
instance: analyses were then repeated using the ILINK subroutine, during which
the male recombination fraction was set for each calculation, and the iterative
process commenced at a female:male recombination ratio of 0.2, in order to identify
changes in this ratio.
3.2.3 Multipoint linkage analyses
Multipoint analyses were run using LINKMAP as above, and probe data from the
3'HVR (D16S85), CMM65 (D16S84), SM7 (D16S283), 26-6 (D16S125), and VK5
(D16S94) loci. The program was unable to run if data from the multi-allelic loci
3'HVR (D16S85) and SM7 (D16S283) were entered at the same time, regardless of
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using data from the PKD1, 3'HVR (D16S85), CMM65 (D16S84), and VK5 (D16S94)
loci, and this was followed by a second run using data from the PKD1, CMM65
(D16S84), SM7 (D16S283), 26-6 (D16S125), and VK5 (D16S94) loci, in order to
localise PKD1 more accurately.
3.2.4 Identification of recombinants
Haplotypes were drawn up for each pedigree, so as to allow the identification of
recombinants. Once these had been identified, they were further characterised in
collaboration with Dr. P. Harris (Oxford) and Ms. A. Snarey (London). Eight
additional markers were used to tiy and identify the point at which recombination
had taken place. Markers used were MS205, KG8, SM6 (2), CW4/cKLH9 (D16S291),
Nik2.9, Blu-24, CW3, CW2, and CW1/W5.2 (Figure 3.3).
3.3 RESULTS
3.3.1 Linkage heterogeneity
The results of the heterogeneity analysis using HOMOG are shown in Table 3.1. The
log (In) likelihood, on the assumption of a single ADPKD locus (linkage
homogeneity), was 55.22 compared with 63.05 (lod score 27.38) on the assumption
of one linked and one unlinked ADPKD locus (linkage heterogeneity). The likelihood
ratio is 2,514.9, which is statistically significant (chi-square 15.66; P< 0.001). The
maximum likelihood value of a, the proportion of families linked, was found to be
0.81 with approximate 95% confidence limits of 0.54-0.97, showing that at least 3%
of families are unlinked. The recombination fractions separating ADPKD from the
anchor locus 3'HVR (D16S85) were 0.049 (males) and 0.010 (females) under linkage
heterogeneity. Linkage heterogeneity is therefore present in this sample of families.
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Table 3.1 RESULTS OF HETEROGENEITY ANALYSES
Linkage heterogeneity Linkage homogeneity
a (proportion of
families linked 0.81 (0.54 - 0.97) 1.00
V 0.049 (0.025 - 0.059) 0.047
0f 0.010 (0.005 - 0.012) 0.009
Log (In) likelihood 63.05 55.22
P value < 0.0001
(chi-square = 15.66)
Likelihood ratio 2,514.9
Results of heterogeneity analyses in 35 ADPKD kindreds. Multipoint lod scores for
ADPKD, D16S85, D16S84, D16S125, and D16S94 were analysed with the HOMOG
program. The maximum likelihood values of the proportion of families linked, a,
and of the recombination fractions, measured proximally from D16S85, are shown
for males (9m) and females (0p) separately with approximate 95% confidence limits
(a, 0,) in parentheses.
3.3.2 Families that appear unlinked to PKD1
Only two small families out of 35 analysed show statistically significant evidence of
non-linkage to PKD1 (Table 3.2). with probabilities of 0.013 (PK52) and 0.007
(PK53) that they are linked to PKD1, conditional on the maximum likelihood values
of a (0.81) and 0m (0.049). Family PK53 (Figure 3.4) is informative with flanking
markers 3'HVR (D16S85) distally and 26-6 (D16S125) and VK5 (D16S94)
proximally, and would require either two or three double recombinants out of five
meioses to be consistent with a PKD1 locus. No exchange of flanking markers is
seen. This family, therefore, does appear unlinked from haplotype analysis. Family
PK52 (Figure 3.5a) is informative for 3'HVR (D16S85) and CMM65 (D16S84) distally
but with none of the proximal markers, so that only a single recombinant (with
3'HVR and CMM65 in II-2) out of three meioses needs to be invoked to be
consistent with a PKD1 locus. Further loci have been screened by P. Harris (Oxford)
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PK 1 0.784 PK 30 0.997
PK 2 1.000 PK 31 0.795
PK 3 0.995 PK 32 0.967
PK 4 1.000 PK 35 0.895
PK 5 0.932 PK 36 0.930
PK 6 0.999 PK 37 0.751
PK 7 1.000 PK 38 0.886
PK 8 0.747 PK39 0.780
PK 11 0.999 PK41 0.860
PK 17 0.999 PK 42 0.998
PK 18 0.999 PK 45 0.961
PK 19 0.871 PK 49 0.958
PK 24 0.881 PK 50 0.608
PK 25 0.460 PK 52 0.013
PK 26 0.895 PK 53 0.007
PK 27 0.574 PK 55 0.602
PK 28 0.982 PK 56 0.886
PK 29 0.289
Conditional probabilities of linkage to PKDI are shown for each of the 35 kindreds
studied. The results were obtained using the HOMOG program.
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Figure 3.4 PEDIGREE OF FAMILY PK53
51 1
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2 1 2 2 1 1 1 1 i 1 i ;; i 2 1 2
Haplotype analysis of family PK53 in which there are either two or three double
recombinants with ADPKD, depending on the linkage phase, on the assumption of
a PKD1 locus. There is no evidence of recombination between markers. The
unaffected individuals II-1, II-4 and II-5 are aged 39, 32 and 31 years respectively.
Possible haplotypes are shown for probes 3' HVR (D16S85), CMM65 (D16S84), 26-6
(D16S125) and VK5 (D16S94).
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Haplotype analysis of family PK52 in which a single recombination (in II-2) would
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Extended haplotype analysis of family PK52 demonstrating no exchange of flanking
markers 3'HVR (D16S85) and CRI-090 (D16S45). * = "recombinant" loci in II-2.
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in an attempt to find an informative proximal marker (Figure 3.5b). CA repeat
polymorphisms isolated from the SM6 (2). CW2, VK5 (D16S94) and CRI-090a
(D16S45) loci are informative, all of which were also recombinant in II-2, although
there is no exchange of flanking markers (e.g. 3'HVR (D16S85) and CRI-090a
(D16S45)). This would be consistent with non-linkage in this family also, since the
alternative explanations of either a double crossover between CW2 and VK5
(D16S94), which are located approximately 400 kb apart, or a location for PKD1
proximal to CRI-090 (D16S45) are both very unlikely. These two families were
therefore excluded from further analysis, and two-point and multipoint analyses
were performed on the remaining 33 families.
3.3.3 Two-point linkage analysis
The results of two-point linkage analyses between PKD1 and the marker loci are
shown in Table 3.3. Analyses were performed using MLINK so that sex-averaged
values were obtained. The maximum likelihood value of the recombination fraction
was found to be 0.07 at a lod score of 20.59 for PKDl-3'HVR (D16S85). The
corresponding values of the recombination fractions were 0.03 at a lod score of 8.37
for PKD1-CMM65 (D16S84), 0.03 at a lod score of 15.85 for PKD1-SM7 (D16S283),
0.00 at a lod score of 5.26 for PKD1-26-6 (D16S125), and 0.00 at a lod score of 8.67
for PKD1-VK5 (D16S94). All loci show close linkage to PKD1 and highly significant
lod scores. No recombination was found with the 26-6 (D16S125), and VK5
(D16S94) loci using MLINK, although three recombinants with 26-6 (D16S125)
were subsequently identified by haplotype analysis. A single definite recombinant
with CMM65 (D16S84) and a recombinant with SM7 (D16S283), which was later
shown to be in an unlinked family, were identified after haplotype analysis (see
below).
The results of two-point analyses between pairs ofmarker loci are shown in
Table 3.4. In general, highly significant lod scores are obtained with small values of
9, confirming close linkage of these markers with each other. Relatively large values
are obtained for 9niax between 3'HVR (D16S85) and 26-6 (D16S125) (0.16), SM7
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(D16S283) and 26-6 (D16S125) (0.17), and SM7 (D16S283) and VK5 (D16S94)
(0.11). In these cases, the lod scores are low, indicative of the small number of
informative meioses.
The two-point analyses between markers were repeated using ILINK with the
iterative process commenced at various fixed values of 0m (0.01 - 0.4), and a female:
male recombination ratio of 0.2 (not fixed). The results are shown in Table 3.5, with
the lod scores given for the corresponding 0m. The values obtained for the male
recombination fractions between markers correlate more closely with each other
than the sex-averaged values of 0 obtained with MLINK. However, during the course
of these calculations, surprising values for the 0f: 0m ratios were obtained and this
was therefore studied in further detail (see below).
3.3.4 Multipoint linkage analysis
The results of the four-point linkage analysis with PKD1, 3'HVR (D16S85), CMM65
(D16S84), and VK5 (D16S94) are shown in Figure 3.6. The maximum likelihood is
found to occur at the location D16S85-0.06-D16S84-0.02-(PKDl,D16S94)-cen
(order 1) at a peak lod score of 32.16. Since no recombination was observed
between PKD1 and D16S94, the order of these two loci cannot be determined. The
likelihood of the order D16S85-0.04-PKD1-0.02-D 16S84-0.02-D 16S94-cen (order 2)
is only 2.6 times lower than order 1, with PKD1 proximal to D16S84. However,
order 1 is at least 2.7 x 10^ times more likely than with PKD1 distal to D16S85. The
order D16S85-0.06-D16S84-0.02-(PKDl,D16S94)-cen is also consistent with the
recombinant haplotype in family PK19 (see below).
Given the most likely order, which places PKD1 proximal to CMM65
(D16S84), a five point linkage analysis was performed with PKD1, CMM65
(D16S84), 26-6 (D16S125), SM7 (D16S283), and VK5 (D16S94), so as to obtain a
more accurate localisation of PKD1. The results of the five-point analysis are shown
in Figure 3.7. The maximum likelihood is found to occur at the location D16S84-
0.004-PKDl-0.006-D16S283-0.005-D16S125-0.005-D16S94-cen at a peak lod
score of 21.64. The likelihood of this order is 279.25 times greater than the order
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Figure 3.6 RESULTS OF THE FOUR-POINT LINKAGE ANALYSIS
(J ! ! ! ' 1 ' ! ! 1 I 1 I I I I I I I 1 |
-45 -35 -25 -15 -5 0 5 15 25 35 45
Genetic location (cM)
Results ofmultipoint linkage analysis of ADPKD and the 3'HVR (D16S85), CMM65
(D16S84) and VK5 (D16S94) loci. The multipoint lod scores are plotted against
genetic location (based on recombination fractions in males) with reference to the
3'HVR (D16S85) locus at position 0. The location of the CMM65 (D16S84) and VK5
(D16S94) loci are also shown. Distances are given in centiMorgans (cM).
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Results ofmultipoint analysis of ADPKD and the CMM65 (D16S84), 26-6
(D16S125), SM7 (D16S283) and VK5 (D16S94) loci. The multipoint lod scores are
plotted against genetic location based on the recombination fraction in males.
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D16S84-0.01 -D16S283-0.001 -PKD1 -0.004-D 16S125-0.005-D 16S94-cen. The odds
ratios for the likelihood of the possible locations of PKD1 are given in Table 3.6.
Table 3.6 ODDS RATIO FOR THE LOCALISATION OF PKD1 BY MULTIPOINT
ANALYSIS
Order of Loci Lod Score (Zmax) Odds Ratio







0.003-PKD 1 -0.002-D 16S94-cen
16.853 60,673.63
Table showing the maximum lod scores obtained during five-point analysis by
LINKMAP of the CMM65 (D16S84), SM7 (D16S283), 26-6 (D16S125), VK5 (D16S94)
and PKD1 loci. The odds ratio for each of the three possible orders has been
calculated.
3.3.5 Analysis of PKD 1 recombinants
Fourteen individuals, from eleven different kindreds, were identified as having a
single recombination event between PKD1 and flanking markers.
In family PK1 (Figure 3.8) individual II-3 is affected and recombinant for
3'HVR (D16S85), presumed uninformative for CMM65 (D16S84) and non-
recombinant for SM7 (D16S283). Other recombinants for 3'HVR (D16S85), which
are also uninformative for CMM65 (D16S84) and non-recombinant for SM7
(D16S283), are seen in family PK3 (Figure 3.9, individual III-3), family PK11 (Figure
3.10, individual V-9), family PK25 (Figure 3.11, individual III-2) and family PK31
(Figure 3.12, individual II-5). All these individuals are affected with a clearly
positive ultrasound scan. Since the probe CMM65 (D16S84) is uninfonnative in all
these recombinants, probe MS205 (Figure 3.3) was used to type the families
84























3'HVR B 1 C C C 1 C A
CMM65 2 1 2 2 2 1 2 2
SM7 +6 1+8 +8 0 1+8 +6
26-6 2 1 2 1 2 1 2 2
VK5 2 1 1 2 1 1 1 2
III
IV
Haplotype analysis in family PK1 showing a single recombinant with 3'HVR
(D16S85) (II-3), which is presumed uninformative for CMM65 (D16S84) and non-
recombinant for SM7 (D16S283). Individual III-3 exhibits non-paternity on
haplotype analysis with at least one marker (SM7), or new mutation at the SM7
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Figure 3.10 PEDIGREE OF FAMILY PK11
D D A D A D B C ABAC C 1 D A B C 1 D A 1 D 3'HVR
1 1 2 1 2 12 2 2 2 2 2 1 1 2 2 1 1 2 2 1 2 CMM65
0 1 0 +6 +6 +2 +6 0 1 0 SM7
1 2 2 1 2 12 2 2 2 2 2 2 1 1 2 2 2 2 1 1 1 26-6
1 2 2 1 2 12 2 2 2 2 2 2 1 2 2 2 2 2 2 1 2 VK5
Haplotype analysis of family PK11 showing recombination in individual V-9. She is
recombinant for 3'HVR (D16S85), uninformative with CMM65 (D16S84) and VK5
(D16S94), and non-recombinant with SM7 (D16S283) and 26-6 (D16S125).
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Haplotype analysis of family PK25 showing a recombinant with 3'HVR (D16S85),
which is uninformative with CMM65 (D16S84), 26-6 (D16S125) and VK5 (D16S94),
and non-recombinant with SM7 (D16S283) (individual III-2).
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pat. v. o •
IE F IE B c : b 3'HVR
12 2 12 2 2 : 2 CMM65
10 +8 10 :-6 +6 6 SM7
i2 2 11 2 2 :2 26-6
2 12 2 2 : 1 VK5
Haplotype analysis of family PK31, showing a recombinant with 3'HVR (D16S85) in
individual II-5, which is then inherited by III-3. The typings of 1-1 and 1-51 are
inferred by haplotype as no DNA was available for analysis. II-5 is uninformative
with CMM65 (D16S84) and non-recombinant with SM7 (D16S283). Further typing
(see text) shows the crossover to be between 3'HVR (D16S85) and MS205, which is
located distal to CMM65 (D16S84), and therefore PKD1 is proximal to 3'HVR
(D16S85). Individual III-1 exhibits genetic evidence of non-paternity with at least
two markers. Ill-1 also shows a crossover in which PKD1 is non-recombinant with
SM7 (D16S283) but recombinant with 26-6 (D16S125). Ill-1 is unaffected on
ultrasound scan at the age of 31 years.
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(P. Harris, Oxford). MS205 detects an RFLP and maps close to EKMDA (D16S83)
which is proximal to CMM65 (D16S84). It was informative in all of the above
recombinants. All were non-recombinant for MS205, which localised the crossovers
to between 3'HVR (D16S85) and MS205, and the PKD1 gene to a position proximal
to 3'HVR (D16S85).
In family PK5 (Figure 3.13) II-2 is recombinant for 3'HVR (D16S85) and non-
recombinant for CMM65 (D16S84) and VK5 (D16S94). This individual is unaffected
with a negative ultrasound scan at the age of 37 years, and is therefore unlikely to
have a false negative diagnosis. In family PK7 (Figure 3.14) III-3 is also recombinant
for 3'HVR (D16S85) and, by inference from the haplotype, non-recombinant for
CMM65 (D16S84) and proximal markers. III-3 is affected with ADPKD. In family
PK28 (Figure 3.15) individual II-2 is recombinant for 3'HVR (D16S85) and non-
recombinant for CMM65 (D16S84) and other proximal markers. In these three
families, the crossovers have occurred between 3'HVR (D16S85) and CMM65
(D16S84), again placing the disease gene proximal to 3'HVR (D16S85).
In family PK27 (Figure 3.16), three recombinants have occurred, all in
affected individuals. II-4 is recombinant with 3'HVR (D16S85), uninformative with
SM7 (D16S283), and non-recombinant with 26-6 (D16S125). II-1 and II-3 are both
non-recombinant with 3'HVR (D16S85), uninformative with SM7 (D16S283), and
recombinant with 26-6 (D16S125). Typing with extra probes (Figure 3.3) (A. Snarey
and P. Harris) has helped in establishing the points of crossover. II-4 is non-
recombinant with KG8, which places the crossover between KG8 and 3'HVR
(D16S85) and the PKD1 locus proximal to 3'HVR (D16S85). II-1 and II-3 are both
non-recombinant with KG8, CW4/cKLH9 (D16S291) and CW2, uninformative for
SM6(2), CW3 and CW1, and recombinant for 26-6 (D16S125). This places both
crossovers between CW2 and 26-6 (D16S125), and the PKD1 locus distal to 26-6
(D16S125). The 26-6 (D16S125) typings were repeated and found to be consistent.
Confirmation of these recombinants with other proximal markers was not possible,
since 1-1 was uninformative for VK5. The probability that this family is linked to
PKD1 is only 0.57 based on the analysis shown in Table 3.2. However, exchange of
90











I B I C
I 1 I 1
I 0 I 0
I 2 I 2







C D 1 B D 1 B D
1 2 1 1 ; l 1 1 2
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2 2 1 2 • i 1 2 2
Haplotype analysis of family PK5 in which individual II-2 is recombinant for 3'HVR
(D16S85) and non-recombinant for CMM65 (D16S84), placing PKD1 proximal to
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Figure 3.15 PEDIGREE OF FAMILY PK28
II
u o51■ \J
; a D 1 B C 3'HVR
; l 2 1 2 2 CMM65
; o +2 1 0 -8 SM6(2)
; +2 -6 1 -4 -2 CW4
; o 0 1 0 0 CW3
;+2 0 1+2 +2 CW2
; +2 -6 1 0 0 SM7
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; 2 2 1 1 2 VK5
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Haplotype analysis of family PK28 showing a recombinant with 3 HVR (D16S85) in
individual II-2. This individual is unaffected with a negative ultrasound scan at age
33 years.
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Figure 3.16 PEDIGREE OF FAMILY PK27
A B 1 c c 3'hvr
3 -3 1 0 0 kg8
+2 +2 1+2 -6 sm6(2)
+2 -6 1 -6 +2 cw4
0 0 1 0 0 cw3
2 +2 1+2 +4 cw2
1 1 1 1 1 cw1
0 0 1 -2 0 SM7
2 1 1 2 1 26-6
0 0 1 +4 +2 vk5(ca)
1, C!>* 1k3 1v iv
b : c : a c b c a c B c
-3 : o : 3 0 -3 0 -3 0 -3 0
+2 : -s : +2 +2 +2 -6 +2 +2 +2 +2
-6 : +2 : +2 -6 -6 +2 -6 -6 -6 -6
0 : o : o 0 0 0 0 0 0 0






0 : o : o -2 0 0
1
0 0 -2
2 ; i : 2 2 2 1 1 2 1 2
0 ;+2 : o +4 0 +2 0 +4 0 +4
Haplotype analysis of family PK27 showing three recombinants, all in affected
individuals, II-1, II-3 and II-4. II-1 and II-3 are both non-recombinant with 3'HVR
(D16S85), KG8, CW4 (D16S291) and CW2, and recombinant with 26-6 (D16S125).
The other markers are uninformative. II-4 is recombinant with 3'HVR (D16S85) and
non-recombinant with KG8, CW4 (D16S291), CW2 and 26-6 (D16S125). The other
markers are uninformative.
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flanking markers has been shown to occur in all three recombinant meioses,
suggesting that it may be linked to PKD1. Individual III -1 in family PK31 (Figure
3.12) exhibits genetic evidence of non-paternity with at least two markers. Ill-1 also
shows a crossover in which PKD1 is non-recombinant with 3'HVR (D16S85), and
SM7 (D16S283) but recombinant with 26-6 (D16S125). Markers CMM65 (D16S84)
and VK5 (D16S94) were uninformative. The 26-6 (D16S125) typings were repeated
and again found to be consistent; no informative proximal markers were available to
confirm that recombination has occurred. This individual is unaffected at age 31
years with a negative ultrasound scan, and a false negative diagnosis is therefore
unlikely. This recombinant again places the location of PKD1 distal to 26-6
(D16S125).
Individual III-3 in family PK29 (Figure 3.17a) was found to be recombinant
with 3'HVR (D16S85) and SM7 (D16S283), and non-recombinant with 26-6
(D16S125) and VK5 (D16S94) after initial typing with these four markers. III-3 is
unaffected at age 42 years with a negative ultrasound scan. This would have placed
the location of PKD1 proximal to SM7 (D16S283). Further typing with other
markers (P. Harris and A. Snarey), however, suggests that this family is unlinked to
PKD1 (Figure 3.17b).
Individual III-5 in family PK19 (Figure 3.18) is recombinant for 3'HVR
(D16S85) and CMM65 (D16S84), uninformative for SM7 (D16S283) and 26-6
(D16S125), and non-recombinant for VK5 (D16S94). Further typing (A. Snarey and
P. Harris) shows III-5 to be uninformative for SM6(2) and CW4/cKLH9 (D16S291),
but non-recombinant with CW3 and CW2. This places the crossover between
CMM65 (D16S84) and CW3, and PKD1 proximal to CMM65 (D16S84). Ill-5 is,
however, unaffected with a negative ultrasound scan at age 23 years, and therefore
the possibility remains that he may develop the disease.
Taken together, the above results localise PKD1 distal to 26-6 (D16S125),
and proximal to CMM65 (D16S84).
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Haplotype analysis of family PK29, where initial typing with three markers
suggested a recombinant with 3'HVR (D16S85) and SM7 (D16S283) in individual
III-3 (Figure 3.17a). This individual was non-recombinant with 26-6 (D16S125) and
VK5 (D16S94), which would have placed the location of PKD1 proximal to SM7
(D16S283). Further typing, however, suggests that this family is unlinked to PKD1
(Figure 3.17b). In individual III-3 recombination between SM7 (D16S283) and 26-6
(D16S125) has occurred, and in individual III-4 recombination between 26-6
(D16S125) and VK5 (D16S94) has occurred.
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A E B 1 D B 1 D A 1 D A . F'
- 1 1 2 1 1 2 2 1 2 2 : 1
- 1 0 1 0 0 1 0 0 :0
- 1 -6 1 -2 -6 1 1 -6 :+2
- 1 +4 1+10 +2 1 + 10 +4: +2
- - 1 - 2 I +2 +2 1 +2 -2 : +2
- 0 1 0 0 1 0 0 1 0 0 :0
2 1 2 1 1 2 1 1 2 11 2 :2
- - 1 1 1 1 1 1 2 1 1 1 : 1
Haplotype analysis of family PK19 in which individual III-5 is recombinant for
3'HVR (D16S85) and CMM65 (D16S84), and non-recombinant with CW3, CW2 and
VK5 (D16S94). The other markers are uninformative. III-5 is unaffected with a
negative ultrasound scan at age 23 years.
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3.3.6 Identification of new mutations
Following haplotype analysis, two individuals who had apparently inherited a new
mutation were identified. These were in families PK8 and PK54. In family PK8
(Figure 3.19), both parents are unaffected as far as can be determined from death
certificates. Individual II-1 appears to be a new mutation, with the affected
chromosome being inherited by both III-1 and III-2. Individual II-4 has the same
'affected' chromosome, but is unaffected with a normal ultrasound scan at age 53
years. The possibility exists, however, that the family is unlinked to chromosome 16
(PKD2). Family PK54 (Figure 3.20) was excluded from linkage analysis in view of the
fact that there was only one affected individual and no clear linkage to chromosome
16. 1-1 is assumed to be unaffected, and 1-51 is clearly so with a negative
ultrasound scan at age 84 years. II-1 has now moved to Oxford where the two
children have been typed by Dr. P. Harris. The children of II-1 are both affected and
have inherited the same paternal chromosome from II-1. This chromosome
originated from 1-51 and has also been inherited by II-2 and II-6. Both of these
siblings are unaffected. II-2 has a negative ultrasound scan at age 52 years.
3.3.7 Female : male recombination ratios in the PKDI region
Twenty-nine single crossover events were identified in the region flanked by 3'HVR
(D16S85) and VK5 (D16S94). Of these, ten occurred in female meioses, eighteen in
male meioses, and one was unknown. Twelve recombinants occurred in the interval
between 3'HVR (D16S85) and PKDI, and all of these were in male meioses. Nine
recombinants occurred in the interval between PKDI and VK5 (D16S94), three in
male meioses and six in female meioses. Seven recombinants occurred in the
overlapping region between CMM65 (D16S84) and 26-6 (D16S125), four in female
meioses and three in male meioses. Although the total number of crossovers is
small, there does seem to be a change from a clear excess of recombinants in males
distally, to a female excess nearer VK5 (D16S94).
In the course of performing the two-point lod score analyses between
markers using ILINK and a starting value of 0.2 for 0f: 0m (female/male ratio),
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Haplotype analysis of family PK8. The haplotypes of 1-1 and 1-51 are inferred.
Individual II-1 appears to be a new mutation, with the affected chromosome being
inherited by both III-1 and III-2. Individual II-4 has the same 'affected' chromosome,
but without the mutation, and is unaffected with a normal ultrasound scan at age
53 years.
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(1 1) 1 1 CMM65
(-10 0) 0 +2 SM6{2)
(-2 -6) -6 -2 CW4
(0 +2) +2 0 CW3
(-14 -2) +2 0 CW2
(+2 +8) +2 0 SM7
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5" i'
A E A E C E * B C * C E A B
1 1 1 1 1 1 1 1 1 1 1 1
0 0 0 0 +2 -10 -10 0 +2 0 0 -10
-6 -6 -6 -6 -2 -2 -2 -6 -2 -6 -6 -2
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+2 +8 +2 +8 0 0 +2 0 0 +8 * 0 +2
2 1 2 1 1 2 2 1 1 1 1 2
Haplotype analysis of family PK54 showing a new PKD1 mutation in II-1. 1-1 is
assumed to be unaffected having died at age 74 years of a cerebrovascular accident
and prostatic carcinoma. His blood urea, electrolytes and creatinine were all
normal. 1-51 is unaffected with a normal ultrasound scan at age 84 years. II-1 has
now married (family in Oxford; typed by Dr. P. Harris) and both his children have
inherited the affected chromosome and are affected. The mutation has occurred on
the maternal chromosome. Individuals II-3 and II-4 are recombinant for 3'HVR
(D16S85), and individual II-6 is recombinant for SM7 (D16S283) and VK5
(D16S94).
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surprising values were obtained at the end of the iterative process. The analysis was
performed in two runs, one for families PK1-PK19 and one for families PK24-PK56.
Figure 3.21 is a graphical representation of the maximum likelihood 0f : 0m ratio
obtained at the various starting values of 0m. For some of the pairs ofmarkers
[3'HVR (D16S85)-CMM65 (D16S84); CMM65 (D16S84)-SM7 (D16S283)] widely
differing ratios were obtained in the two data sets, whereas for other pairs [SM7
(D16S283J-26-6 (D16S125); 26-6 (D16S125)-VK5 (D16S94)] the ratios are of the
same order. This can at least partly be explained by the fact that in the distal region
[3'HVR (D16S85)-SM7 (D16S283)] twice as many of the recombinants in males
occurred in the first group of families (PK1-PK19) than in the second group ( PK24-
PK56), whereas in the proximal region [SM7 (D16S283)-VK5 (D16S94)]the
recombinants are more evenly distributed between the two groups. In order to
establish whether or not this was an artefact, further calculations were performed.
Firstly, the ILINK program available was able to run with a maximum of 30
pedigrees, and therefore the first 30 pedigrees (PK1-PK45) were used. Runs were set
up between pairs of markers, commencing the iterative process at the expected
male recombination fraction for that interval. Each run was repeated using nine
different set values, between 0.1 and 30.0, for the 0f : 0m ratio, and the maximum
likelihood value identified. The results are shown in Table 3.7.
Table 3.7 FEMALE : MALE RECOMBINATION RATIOS (ILINK)
Loci Starting
value of 0m




D16S84 0.06 0.074 0.016 0.2 10.97
D16S84 -
DI6S283 0.01 0.007 0.126 20.0 4.69
D16S283 -
D16S125 0.005 0.042 0.465 30.0 2.84
D16S125 -
D16S94 0.005 0.075 0.016 0.2 4.68
Results of two-point linkage analysis in families PK1-PK45 (n = 30) using ILINK
showing male (0m) and female (0f) recombination fractions, and the ratio 0f: 0m. at
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Starting value of 0m
Graphical representation of the maximum likelihood 0f: 0m ratio obtained at
various starting values of 0m. The data were obtained using the ILINK program with
families PK1-PK19 and then families PK24-PK56.
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The female/male ratio, 9f: 9m, obtained at the maximum lod score for each marker-
marker pair is 0.2 for the interval 3'HVR (D16S85)-CMM65 (D16S84), rising to 20.0
for CMM65 (D16S84)-SM7 (D16S283), 30.0 for SM7 (D16S283)-26-6 (D16S125).
and falling again to 0.2 for the interval 26-6 (D16S125)-VK5 (D16S94).
Secondly, three-point analyses were run on all the families (PK1-PK56)
using the LINKMAP program as follows: (1) CMM65 (D16S84) was used as a test
locus at five positions between 3'HVR (D16S85) and SM7 (D16S283) which were
fixed apart at a value of 9m = 0.07; (2) SM7 (D16S283) was used as a test locus at
five locations between CMM65 (D16S84) and 26-6 (D16S125) which were fixed
apart at a value of 9m = 0.015; (3) 26-6 (D16S125) was used as a test locus at five
locations between SM7 (D16S283) and VK5 (D16S94) which were fixed apart at a
value of 9m = 0.01; and (4) VK5 (D16S94) was used as a test locus at five locations
for the outside interval with SM7 (D16S283) and 26-6 (D16S125) fixed apart at a
value of 0.005. The results are shown in Table 3.8.
Table 3.8 FEMALE : MALE RECOMBINATION RATIOS (LINKMAP)
Locus order and 9m 9f : 9m ratio Zmax
D16S85-0.056-D16S84-0.016-D16S283 0.2 32.02
D16S84-0.003-D16S283-0.012-D16S125 35.0 10.72
D16S283-0.008-D16S125-0.002-D 16S94 40.0 7.82
D16S283-0.005-D16S125-0.1-D16S94 2.0 7.31
Results of three-point analyses in all PKD1 families using LINKMAP showing the
0f : 9m ratio obtained at Zmax for each of the four intervals studied
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The female/male (0f : 0m) ratio obtained for the interval 3'HVR (D16S85)-SM7
(D16S283) is 0.2 at a maximum lod score of 32.02, with CMM65 (D16S84) most
likely to be located as follows: -
3'HVR (D16S85)-0.056-CMM65 (D16S84)-0.016-SM7 (D16S283).
Once more, the 0f: 0m ratio rises markedly in the next two intervals being 35.0 at a
maximum lod score of 10.72 for CMM65 (D16S84)-0.003-SM7 (D16S283)-0.012-26-
6 (D16S125), and 40.0 at a maximum lod score of 7.82 for SM7 (D16S283)-0.008-
26-6 (D16S125)-0.002-VK5 (D16S94). The 0f: 0m ratio then falls again to 2.0 at a




In this study, 35 families with ADPKD have been analysed with five polymorphic
markers on chromosome 16. The data were used to calculate a, the proportion of
PKD1-linked families versus unlinked families with a mutation elsewhere in the
genome. The likelihood of two loci is 2,514.9 times greater than for a single locus,
with two small families providing statistical evidence of non-linkage to PKD1,
confirmed on haplotype analysis. A third unlinked family, PK29, was identified only
after extended haplotype analysis. The maximum likelihood value of a is 0.81. with
95% confidence limits of 0.54 - 0.97, showing that at least 3% of families are
unlinked. Several attempts have been made to estimate a in different populations.
At first, no evidence for heterogeneity was found in a set of 28 families from
northern Europe, since the maximum likelihood value of a was 1.00 (Reeders et al,
1987). All of the families studied by Lazarou et al (1987) and Turco et al (1991)
demonstrated evidence of linkage to chromosome 16p. Mandich etal (1990) found
no significant evidence for genetic heterogeneity after examining twenty-nine Italian
families, although the maximum likelihood value of a was 0.92. Two unlinked
families of Italian origin had been described earlier (Kimberling et al, 1988: Romeo
et al, 1988), so it seems that heterogeneity is present in this population, albeit at a
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low level. A value of a = 0.95 was obtained after analysis of 12 French families
together with the 28 families analysed by Reeders et al. (1987), but this was not
statistically different from a = 1.00 (Bachner et al., 1990). A similar value (a = 0.96)
was observed by Pieke et al. (1989), after analysis of 42 families from the USA, but
again statistically significant heterogeneity was not present.
The value of a = 0.81 obtained in this study is lower than the above
estimates, but similar to a value of 0.86 obtained by Peters and Sandkuijl (1992)
who analysed a large set of 328 families from all over Europe, including the 35
described here. As in the present study, the 95% confidence limits were wide (0.79 -
0.91), reflecting the relatively large number of small families where the lod score
was close to zero. This heterogeneity analysis, and those of Reeders et al. (1987),
Bachner et al. (1990), and Mandich et al. (1990), were performed on two-point
linkage data, and Pieke et al. (1989) used three point data. In the present study,
however, the more powerful technique ofmult ipoint linkage analysis followed by
heterogeneity analysis is employed.
Phenotypic differences between PKD1 and PKD2 families have been
described (Bear et al., 1989; Parfrey et al., 1990; Ravine et al., 1992) where PKD2
families have a milder phenotype with delayed appearance of cysts, and a lower risk
of developing hypertension or progressing to renal failure. It is therefore possible
that proportionately fewer PKD2 families attend renal clinics and are consequently
under-represented in genetic studies. Such selection bias, if present, would under¬
estimate the true number of unlinked families. Alternatively, the milder phenotype
may represent allelic differences confined to the limited number of PKD2 families
analysed. The value of a obtained in this study of families ascertained at renal
clinics may, if anything, under-estimate the proportion of PKD2 families. The
phenotype in family PK53 (Figure 3.4) is consistent with a milder form of the
disease, with the mother (I-1) having normal renal function and only borderline
hypertension at age 59 years. However, this is not uniformly so within the family,
since the two affected sons (II-2 and II-3) required renal dialysis at the ages of 33
years and 27 years respectively. Family PK52 (Figure 3.5) shows the typical PKD1
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phenotype: the father (1-1) received a renal transplant at age 64 years, and the
affected daughters (II-1 and II-2) are hypertensive with normal renal function at age
43 years and 39 years respectively. In family PK29 (Figure 3.17) II-1 required
dialysis at the age of 51 years and was transplanted the following year. II-2 has
been lost to follow up. All three families are of Scottish ancestry. The three unlinked
families seen in this study are similar to those first described by Romeo et al. (1988)
and Kimberling et al. (1988) in that they demonstrate the typical PKD1 phenotype.
This result has implications for pre-symptomatic diagnosis of ADPKD. The
available evidence suggests that there is little indication for this under the age of 18
years (Watson etal., 1990), but in early adulthood pre-symptomatic diagnosis has
the advantage of allowing close follow-up of individuals at risk. The level of
heterogeneity observed will have an effect on the accuracy of genetic diagnosis, and
will be most serious in small families which generate limited or no information for
or against linkage. In this study 3 out of 35 families are unlinked, and therefore the
risk of error for a small family with phase-known flanking markers is approximately
10%. In families large enough to show clear linkage to 16p, the accuracy of
diagnosis is 99% using flanking markers (Breuning et al., 1990b). In families that
are clearly unlinked to PKD1, the risk for any individual is identical to the
statistical risk following a negative ultrasound at any given age. Caution should be
exercised if recombination is observed in a family in the absence of flanking marker
exchange.
The presence of genetic heterogeneity in ADPKD also has clear implications
for molecular studies. A genetically homogeneous population must be identified in
order to accurately localise PKD1, and to screen for mutations in any candidate
genes. In order to identify the chromosomal site of the PKD2 locus large unlinked
families are required, although the three unlinked families identified in this study
(PK29, PK52, PK53) will still be of value in confirming linkage and in phenotype-
genotype studies.
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3.4.2 Two-point linkage analysis
The lod scores between PKD1 and the marker loci are all highly significant,
confirming the close linkage of PKD1 to this region. A sex-averaged recombination
fraction of 0.07 for PKD1-3'HVR is consistent with previously published results
(Reeders etal., 1985; Breuning etal., 1990a). Comparison of the recombination
fraction between all pairs of loci should, in theory, allow the order to be determined.
In practice, however, for loci separated by less than 10% recombination, too few
crossovers are available for precise estimation even when large numbers of meioses
are analysed. Multipoint analysis, in which information from multiple loci is
considered simultaneously, is therefore used to determine the order of loci (Lathrop
etal., 1984).
Two-point analyses were performed between pairs ofmarker loci. In general,
the results are as expected, showing that the markers are closely linked with each
other. Four pairs ofloci give higher than expected values for ©max [3'HVR (D16S85)
and 26-6 (D16S125) (0 = 0.16), 3'HVR (D16S85) and VK5 (D16S94) (0 = 0.11), SM7
(D16S283) and 26-6 (D16S125) (0 = 0.17). and SM7 (D16S283) and VK5 (D16S94)
(0 = 0.11)], although the confidence limits (Zmax ± 1) are wide and the sample sizes
small. Also, the lod score values are low and no conclusions regarding the order of
the markers, or the likely physical distance between them, can be made from these
data.
3.4.3 Multipoint linkage analysis
Breuning et al. (1987b) established flanking markers for PKD1, namely 3'HVR
(D16S85) on the distal side and 24-1 (D16S80) proximally. Both markers are
separated from PKD1 by a recombination fraction of approximately 0.05. Previous
multipoint analyses of the PKD1 region have been described by Reeders et al.
(1988), Breuning et al. (1990a), and Germino et al. (1990). From these studies it is
clear that PKD1 lies proximal to 3'HVR (D16S85) and 2BP5 (D16S21), and distal to
24-1 (D16S80), CRI-0327 (D16S63), and CRI-090 (D16S45). Further refinement of
the map of this region has come from the combined use of linkage analysis and
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human-rodent hybrid cell lines. All the probes used by Reeders et al. (1988) are
distal to the CY13 breakpoint and thus lie in the region 16pl3.1 l-16pter. Within
this region, four subregions have been distinguished by means of the 23HA,
N-OH1, and CY14 breakpoints. The most important polymorphic loci are thus
separated into the following four groups, extending distally: (1) CRI-090 (D16S45),
CRI-0327 (D16S63) and 24-1 (D16S80) proximal to 23HA, (2) VK5 (D16S94), 26-6
(D16S125) and SM7 (D16S283) proximal to N-OH1, distal to 23HA, (3) CMM65
(D16S84) and GGG1 (D16S259) proximal to CY14, distal to N-OH1, and (4) EKMDA
(D16S83), 2BP5/Fr3-42/cos2B/HMJ 1 (all D16S21), and 3'HVR (D16S85) distal to
CY14 (Figure 3.1).
Although PKD1 clearly lies proximal to the markers in group 4 and distal to
those in group 1, its genetic relationship to the loci within groups 2 and 3 remains
less clear. Most of these loci show few, if any, recombinations with PKD1, which on
the one hand supports the view that they lie closer to the gene than those in groups
1 and 4, but on the other hand makes ordering difficult. In addition, several pitfalls
exist which can result in a misleading genetic assignment, so that it is important to
accumulate as much genetic evidence as possible. Firstly, false positive and false
negative diagnoses can lead to misinterpretation of results. It is generally accepted
that false positive diagnosis by ultrasound scanning is rare, but it has been
reported (Reeders et al., 1988). The probability of a false negative diagnosis
following an ultrasound scan is age dependent, but veiy unlikely after the age of 30
years (Parfrey etal, 1990; Coto etal, 1992). Secondly, double recombinants,
although veiy rare in such small genetic distances, can occur and may be mimicked
by gene conversion events. Thirdly, mistyping can occur, so that it is important that
each apparent recombinant is checked, preferably by an independent laboratory or
by typing with other markers. Finally, non-paternity can arise and lead to
erroneous interpretation of results, so that this should be checked if possible by
genetic fingerprinting.
The results of this study confirm the tight genetic linkage of CMM65
(D16S84) in region 3 which shows only a single recombinant with PKD1 (0max =
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0.03; Zmax = 8.37); similarly with VK5 (D16S94) in region 2 which shows no
definite recombination with PKD1 (0max = 0.0; Zmax = 8.67). Multipoint analysis
shows the most likely order to be D16S84-0.004-PKD1-0.006-D16S283-0.005-
D16S125-0.005-D16S94-cen, which gives a multipoint lod score of 21.64.
3.4.4 Recombinants with PKD1
A meiosis showing a single recombination event between the closest informative
flanking markers contains information that is useful in ordering markers that lie
close to PKD1. In this set of 32 PKD1 families (excluding PK29, PK52 and PK53), 13
single recombinants were identified between PKD1 and the flanking markers. Nine
of these recombinants place PKD1 proximal to 3'HVR (D16S85), which is in keeping
with the results of the multipoint analysis in this study, and with previous studies
(Breuning etal.. 1987b and 1990a; Reeders etal., 1988; Germino etal, 1990).
Three recombinants place PKD1 distal to 26-6 (D16S125): these are individuals II-1
and II-3 from family PK27, both of whom are clearly affected in a kindred with
typical clinical features of ADPKD, and individual III-1 from family PK31 who is
unaffected at age 31 years. The presence of recombinants with 26-6 (D16S125) in
two families that are not unequivocally PKD1 raises some doubts as to their
validity, although in each case exchange of flanking markers has occurred (Figure
3.12; Figure 3.16). Confirmation of these recombinants with another proximal
marker has so far not been possible. The final recombination event in individual III-
4 of family PK19 places PKD1 proximal to CMM65 (D16S84). This kindred also
shows typical features ofADPKD, but III-4 is unaffected with a clearly negative
ultrasound scan at age 23 years. At this age, the probability of detecting cysts in a
gene carrier by ultrasound scanning is 0.92 (Bear et al., 1992). The possibility
therefore exists that he may yet develop ADPKD, but it is more likely that he will
remain unaffected. These four recombinants (II-1 and II-3 from PK27; III-1 from
PK31; III-4 from PK19) therefore localise the PKD1 gene to the interval between
CMM65 (D16S84) distally and 26-6 (D16S125) proximally.
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Somlo etal. (1992b) identified eleven single recombinant meiotic events in
eight linked families, out of over 200 families originally studied. Of these eleven
recombinants, three placed PKD1 proximal to GGG1 (D16S259) and two placed
PKD1 distal to 26-6 (D16S125). Since GGG1(D16S259) is located approximately 10
kb distal to CMM65 (D16S84) (Germino etal., 1990), the recombinants identified in
this study place PKD1 in exactly the same interval as that obtained by Somlo et al.
(1992b). This interval is known to span approximately 750 kb of DNA (Germino et
at, 1992), and within this interval there is some doubt regarding the localisation of
PKD1 as defined by recombinants. Somlo et al. (1992b) found that the two
recombinants locating PKD1 distal to 26-6 (D16S125) also placed the disease distal
to the marker 92.6SH1.0, but they also identified a recombinant which located
PKD1 proximal to 92.6SH1.0. This individual is unaffected at the age of 33 years,
which leaves open the possibility that he may yet develop renal cysts. This seems
unlikely given that two studies have shown that all renal cysts in gene carriers are
detectable by ultrasound by the age of 30 years (Parfrey et al., 1990; Coto et al.,
1992). However, the brother of this individual, who should be affected according to
flanking markers, remains unaffected at the age of 40 years, and it may be that this
family has a late-onset form of the disease due to allelic variation. Various
possibilities exist to explain this apparent anomaly. The family may be unlinked,
and this would be consistent with a later than expected onset of the disease. There
may have been a gene conversion event, the PKD1 gene may straddle the 92.6SH1.0
locus, there may be more than one gene in the region, or the individual may have a
false negative diagnosis. If the gene does straddle the 92.6SH1.0 locus, the three
recombinants would be intragenic, suggesting a recombinational hot spot. There
are no recombinants in the families analysed in this study which throw any further
light on this problem.
3.4.5 New mutations
Dalgaard (1957) calculated the rate of new mutations in ADPKD to be between 6.5 x
10-5 ancj 12 x 10"5 per gene per generation, one of the highest mutation rates in
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genetic disease. This is likely to be an over-estimate since many patients with
ADPKD are asymptomatic with normal renal function, but can be diagnosed on
ultrasound scan. Since this technology was not available in 1957, it is likely that
many parents have been given a false-negative diagnosis, thereby increasing the
apparent mutation rate. As discussed in the following chapter, a high mutation rate
is inconsistent with the presence of linkage disequilibrium, which has been
detected in this population (see Chapter 4). Only two new mutations have been
seen in the 36 families studied, consistent with a low mutation rate and a high
reproductive fitness in ADPKD (Milutinovic et al., 1983). Direct determination of the
mutation rate from this data is difficult, however, because (i) the size of the
population from which the 36 families were ascertained is uncertain because of
incomplete ascertainment ; (ii) other families with only a single affected member
were excluded from the study.
3.4.6 Recombination ratios
In the heterogeneity analysis, LINKMAP was run with probe data from the 3'HVR
(D16S85), CMM65 (D16S84), 26-6 (D16S125) and VK5 (D16S94) loci using different
fixed ratios of 9m : 0f. A broad likelihood peak at a ratio of 5 was obtained, which is
consistent with 0m : 0f = 6 between 3'HVR (D16S85) and PKD1 (Reeders et al.,
1987) and a 0m : 0f of 14 between 3'HVR (D16S85) and CRI-090 (D16S63) (Keith et
al., 1990). Breuning et al. (1990a) also noted a striking excess of 0m over 9f across
the distal part of their map (3'HVR (D16S85) to CRI-0133 (D16S58). Harris et al.
(1990) estimated the physical distance between 3'HVR (D16S85) and CMM65
(D16S84) and found that the elevated 0m :0 f ratio was due to an increased level of
male recombination, which was at least four times greater than that expected in the
genome as a whole.
In the present study, 29 single recombinant events were identified in the
PKD1 region, with an overall male to female ratio of 2:1. The results, however,
suggested a reversal of the ratio from a clear male excess distally to a female excess
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towards VK5 (D16S94). In addition, during checking of the MLINK two-point
analyses between markers using the ILINK program, a surprising difference in the
9m ;9 f ratio was obtained for the different intervals. A ratio of 5.0 was obtained for
the interval 3'HVR (D16S85)-CMM65 (D16S84), a finding entirely in keeping with
the above published data. In the intervals CMM65 (D16S84)-SM7 (D16S283) and
SM7 (D16S283)-26-6 (D16S125) however, there was a marked reversal of the ratio
with 0f : 0m being 20.0 and 30.0 respectively. The ratio then fell again to 0f : 0m =
0.2 in the final interval between 26-6 (D16S125) and VK5 (D16S94). Similar results
were obtained with three-point analyses using LINKMAP, although in this case the
excess of female over male recombination extends to beyond VK5 (D16S94), where
it was again found to be falling. The corresponding likelihood lod scores are highly
significant (ranging from 7.31 to 32.02 in the LINKMAP calculations, and 2.84 to
10.97 in the ILINK calculations: see Tables 3.7 and 3.8).
In this study, the number of meioses during which recombination has
occurred is very small, and the results therefore have to be treated with caution.
Nevertheless there is a consistent trend towards reversal of the ratio from a male
excess in recombination distally to a female excess proximal to CMM65 (D16S84).
This trend is seen both in the linkage programs, ILINK and LINKMAP, and in
analysis of the recombinants themselves. 16pl3.3 is located within an R band on
Giemsa staining, and falls into the type of R band known as a T band (Holmquist,
1992). T bands contain the highest number of CpG islands, are very GC-rich and
have a high gene density (Holmquist. 1992; Craig and Bickmore, 1993). Meiotic
chiasmata are the cytological manifestation of crossing over, and these occur very
frequently in T bands (Holmquist, 1992). Since R band regions contain less densely
packed chromatin (Craig and Bickmore, 1993) they may be more open for
recombination to occur.
The overall length of the female map of chromosome 16 exceeds that of the
male by 78 cM (Keith et al., 1990), consistent with the fact that the genetic maps of
female autosomes are approximately 90% longer than those of the male (Donis-
Keller et al., 1987). There are, however, certain chromosomal regions within which
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males exhibit higher recombination rates than females, and these appear to be
preferentially located in distal chromosomal regions (Keith et ai, 1990). All the
published data summarised above have analysed regions extending considerably
outside the PKD1 region itself, and there is little data available for the
recombination ratios in each interval. Indeed, Gerrnino et al. (1990) comment that,
in their study of 201 meioses, too few recombination events were seen either to
make an estimation of 0m : 0f for smaller intervals meaningful or to allow
comparison of 0m : 0f for adjacent intervals within the array. Although this may also
be true for this study, the observation of a change in the 0m : 0f ratio may be of
interest, and may be associated, for example, with the presence of differential male
or female gamete-specific expression of genes within the region.
Conclusions
In summary, the results presented in this chapter confirm the presence of genetic
heterogeneity in ADPKD, and estimate the proportion oflinked families (PKD1) to be
81% in this Scottish population. Two-point analyses between PKD1 and marker loci
confirm the close linkage of PKD1 to the region of chromosome 16p flanked by the
3'HVR (D16S85) and VK5 (D16S94) loci, and multipoint analysis shows the most
likely order to be D16S84-0.004-PKD1-0.006-D16S283-0.005-D16S125-0.005-
D16S94-cen. Four recombinants have been identified which are consistent with a
localisation of PKD1 to the interval CMM65 (D16S84)-26-6 (D16S125). Marked
variability of the female : male recombination ratios in the different intervals






If the alleles at two loci are associated at random in a population (linkage
equilibrium), then the frequency of the combination of any two alleles will equal the
product of the individual allele frequencies. Thus, at equilibrium, if the frequency of
allele A at one locus is 0.5 and the frequency of allele B at a second locus is 0.3,
then the frequency of the gametes carrying both A and B would be 0.15 (Lewontin,
1988).
Linkage disequilibrium, or non-random association, refers to the situation
where alleles at two loci may be found together more or less often than would be
predicted from their frequency in the general population. Genetic recombination is
a major factor acting to randomise the alleles at different linked loci, and thus
linkage disequilibrium may reflect the rarity of crossing over in meiosis between the
two loci, and therefore the long period of time required to reach genetic equilibrium
for veiy closely linked loci. Factors acting to produce non-random association of loci
include natural selection, migration, mixing of genetically dissimilar populations
(population stratification), genetic drift, small population size and non-random
mating (such as inbreeding and assortative mating).
For linkage disequilibrium to be detected between two loci, such as a genetic
marker and a disease mutation, the markers are usually closely linked and have
low mutation rates. If two loci are separated by more than 10^ base pairs, the
effects of recombination in producing random association render the effects of
mutation negligible, and for loci located more closely together the effects of
mutation and recombination are likely to be comparable and of less importance
than other factors such as those mentioned above (Carothers and Wright, 1992).
Assuming that mutation rates do not exceed 10"^ per gamete per generation, these
considerations would exclude mutation as a general explanation for anomalous
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situations where linkage disequilibrium exists between two linked loci, such as Z
and A, but not between Z and B, where B is a third locus known to be closely linked
to A (Carothers and Wright, 1992), Huntington's Disease is such a situation
(MacDonald etai, 1991).
The presence of linkage disequilibrium, as a genetic mapping tool, has been
of value in the search for two recently cloned genes, namely those responsible for
cystic fibrosis and Huntington's disease (Estivill etal, 1987; Snell etal, 1989). In
cystic fibrosis, strong linkage disequilibrium was noted for closely linked DNA
markers with little or none detected for the more distant markers, which thus
provided genetic confirmation of the location of the gene. These studies also
provided information on the origin and homogeneity of the cystic fibrosis (CF)
defect, with the unusually high degree of linkage disequilibrium suggesting that a
substantial proportion of CF mutant genes in the population are descended from a
single mutation (Estivill et al., 1987). In Huntington's disease, a complex pattern of
linkage disequilibrium was obtained, perhaps suggesting that multiple mutations
had occurred (MacDonald et al, 1991). Nevertheless, the finding of strong linkage
disequilibrium between the disease and DNA markers was able to support a
localisation of the gene close to these markers. The alternat ive method of genetic
fine mapping is by haplotype analysis of individuals recombinant for the disease
(see Chapter 3). Although recombinational events can be useful in providing
evidence in favour of a certain locus order they can be misinterpreted due to
misdiagnosis, gene conversion or the assumption of a single recombinant as the
simplest explanation of a haplotype. The advantage of disequilibrium mapping over
the single crossover approach, as one gets closer to the gene, is that it enables data
from all families to be used, rather than relying on a decreasing number of
informative recombinational events. The potential disadvantage is that a "plateau"
of linkage disequilibrium may be reached covering several hundred kilobases of
DNA, within which further refinement of the localisation is impossible (Kerem et al,
1989).
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4.2 ASSESSMENT OF LINKAGE DISEQUILIBRIUM
As described in Materials and Methods, ADPKD families were ascertained and their
members typed for the markers 3'HVR (D16S85), CMM65 (D16S84), SM7 (D16S283)
26-6 (D16S125), and VK5 (D16S94). Three families found to be unlinked to
chromosome 16 in the heterogeneity analysis were excluded (PK29, PK52, PK53).
The results were transferred to the pedigrees and haplotypes constructed. In
twenty-nine families the haplotypes could be determined unambiguously, and in
the remaining four, the haplotypes were determined by minimising the number of
crossovers. The affected chromosome in each family was established in this way
and allele frequencies or marker to marker haplotype frequencies calculated. The
normal chromosomes used to establish control frequencies were derived from the
unaffected spouses of family members. Because of the distance of alpha-globin from
PKD1, the 3'HVR results were used to help establish haplotypes but were not
analysed for the presence or absence of linkage disequilibrium.
4.3 RESULTS
4.3.1 Haplotypes
The haplotypes of affected (PKD1) and normal chromosomes for each family are
displayed in Tables 4.1 and 4.2.
4.3.2 PKD1 - marker linkage disequilibrium studies
The presence or absence of allelic association was determined by establishing the
frequency ofmarker alleles in haplotypes of PKD1 chromosomes compared with the
control population and applying a chi-squared test. In the case of the multi-allelic
microsatellite marker, SM7 (D16S283), all cells with values less than 5 were pooled
prior to analysis, values were derived using Yates' correction. The results of the
analysis are shown in Tables 4.3 to 4.6.
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Table 4.1 HAPLOTYPES OF PKD1 CHROMOSOMES
Family CMM65 SM7 26-6 VK5
PK 1 2 +6 2 2
PK 2 1 0 1 2
PK 3 1 +2 2 2
PK 4 2 0 2 2
PK 5 2 0 1 2
PK 6 1 0 2 2
PK 7 2 -2 2 2
PK 8 1 0 2 2
PK 11 2 +6 2 2
PK 17 1 +4 2 1
PK 18 1 0 1 2
PK 19 2 0 2 2
PK 24 1 0 - 2
PK 25 2 -2 2 1
PK 26 1 0 2 1
PK 27 - 0 2 -
PK 28 2 -6 2 2
PK 30 2 +4 - 2
PK 31 2 +6 2 2
PK 32 - -2 1 2
PK 35 1 0 1 1
PK 36 2 0 1 2
PK 37 - -12 1 -
PK 38 1 0 - 2
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Table 4.1 Continued
Family CMM65 SM7 26-6 VK5
PK 39 1 0 - 2
PK 41 1 -2 1 2
PK 42 - +4 1 2
PK 45 2 0 2 1
PK 49 2 0 2 1
PK 50 1 - - 2
PK 55 2 +6 - -
PK 56 1 -2 2 -
Table 4.2 HAPLOTYPES OF NORMAL CHROMOSOMES
Family CMM65 SM7 26-6 VK5
PK 1 2 +8 1 2
2 0 2 1
PK 2 2 +2 2 1
2 + 10 2 1
1 - 2 2
2 - 1 2
2 - 2 1
2 - 2 1
PK 3 1 -4 2 2
1 0 1 2
1 - 2 1
2 - 1 1
PK 4 1 0 2 2
1 +2 1 1
1 - 2 2
1 - 1 1
PK 5 1 0 2 2
1 0 2 1
PK 6 2 -4 1 2
1 0 2 1
PK 7 2 0 1 2
2 0 2 2
1 0 2 1
1 0 2 1
2 0 2 1
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Table 4.2 Continued
Family CMM65 SM7 26-6 VK5
PK 7 1 0 2 2
1 - 2 2
2 - 2 2
PK 8 1 0 2 1
2 0 2 2
PK 11 2 - 2 2
2 - 2 2
1 +6 2 2
1 0 2 2
2 0 1 2
1 +2 2 1
PK 17 1 0 2 1
2 0 1 2
PK 18 2 0 2 1
2 0 2 2
1 +6 2 -
2 +2 2 -
PK 19 2 0 1 1
1 0 2 1
PK 24 1 0 - 2
1 +2 - 2
PK 25 2 0 1 1
2 0 2 1
PK 26 1 0 2 1
1 0 2 1
Table 4.2 Continued
Family CMM65 SM7 26-6 VK5
PK 27 - 0 - 1
- -8 - 2
PK 28 2 0 1 1
2 0 2 2
PK 29 - 0 1 2
- +2 2 2
- 0 1 1
- 0 1 2
PK 30 1 -2 - 2
2 0 - 1
2 - - 1
2 - - 1
PK 31 2 -6 2 1
2 0 1
PK 32 - -2 2 1
- +4 2 1
PK 35 1 0 2 1
1 +8 2
PK 36 2 +6 2 1
2 +4 2 1
PK 37 - 0 2 -
- 0 2 -
- . 1 2
- - 2 2
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Table 4.2 Continued
Family CMM65 SM7 26-6 VK5
PK 38 1 0 - 1
2 +2 - 2
PK 41 1 - 2 1
2 - 2 1
PK 42 - 0 2 2
- -6 2 2
PK 45 2 -6 - -
2 +6 - -
PK 49 2 0 2 -
2 0 2 -
2 -2 2 1
2 0 2 2
PK 50 1 - - 2
2 - - 2
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Table 4.3 CMM65 (D16S84)
Affected Control Total X2 P
Allele 1 14 32 46
Allele 2 14 42 56
28 74 102 0.151 n.s.
Table 4.4a SM7 (D16S283)
Affected Control Total
Allele 1 (+10) 0 1 1
Allele 2 (+8) 0 2 2
Allele 3 (+6) 4 4 8
Allele 4 (+4) 3 2 5
Allele 5 (+2) 2 7 9
Allele 6 (0) 15 43 58
Allele 7 (-2) 5 3 8
Allele 8 (-4) 0 2 2
Allele 9 (-6) 1 3 4
Allele 10 (-8) 0 1 1
Allele 11 (-12) 1 0 1
31 68 99
Table 4.4b SM7 (Contracted)
Affected Control Total X2 P
Alleles 1-5 9 16 25
Allele 6 15 43 58
Alleles 7-11 7 9 16
31 68 99 1.116 n.s.
Table 4.5 26-6 (D16S125)
Affected Control Total X2 P
Allele 1 9 18 27
Allele 2 17 56 73
26 74 100 0.578 n.s.
Table 4.6 VK5 (D16S94)
Affected Control Total X2 P
Allele 1 6 40 46
Allele 2 22 40 62
28 80 108 5.814 < 0.02
No evidence of linkage disequilibrium was found between PKD1 and markers
CMM65 (D16S84), 26-6 (D16S125) and SM7 (D16S283), all ofwhich show close
genetic linkage to PKD1 (Breuning etal., 1990a; Harris etal., 1991). In the case of
VK5 (D16S94), also closely linked (Hyland etal., 1990), there is evidence of linkage
disequilibrium: the affected haplotypes in 6 kindreds showing the 1.6 kb allele
(allele 1) and in 22 kindreds the 1.3 kb allele (allele 2), compared with the control
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population who showed 40 1.6 kb alleles and 40 1.3 kb alleles. This result is
significant at the 2% level (Yates' corrected - 5.814). The allele frequencies in the
control population are in good agreement with those published previously
(Breuning etal., 1990a; Harris etai, 1991).
4.3.3 Marker - marker disequilibrium studies
In order to assess whether or not there was any disequilibrium between DNA
markers, the allele frequencies for markers on the normal chromosomes were first
established. Pairs ofmarkers were then compared using Fisher's exact test (two-
tailed). For pairs ofmarkers where all the cells contained five or more, the chi-
squared test using Yates' correction was also performed, and the results from the
two tests compared. The results are shown in Tables 4.7 to 4.12.
Table 4.7 CMM65 (D16S84) - SM7 (D16S283)
CMM65
SM7





Allele 0 17 19 36
Other alleles 8 12 20
Total 25 31 56 0.05 n.s. p = 0.78
Table 4.8 CMM65 (D16S84) - 26-6 (D16S125)
CMM65
26-6





Allele 1 3 11 14
Allele 2 24 24 48
Total 27 35 62 - - p = 0.07
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Table 4.9 CMM65 (D16S84) - VK5 (D16S94)
CMM65
VK5





Allele 1 16 20 36
Allele 2 15 17 32
Total 31 37 68 0.002 n.s. p = 1.00
Table 4.10 SM7 (D16S283) - 26-6 (D16S125)
26-6
SM7





Allele 0 11 28 39
Other alleles 3 16 19
Total 14 44 58 n.s. p = 0.35
Table 4.11 SM7 (D16S283) - VK5 (D16S94)
VK5
SM7





Allele 0 21 18 39
Other alleles 10 11 21
Total 31 29 60 0.036 n.s. p = 0.79
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Table 4.12 26-6 (D16S125) - VK5 (D16S94)
VK5
26-6





Allele 1 7 11 18
Allele 2 28 22 50
Total 35 33 68 0.937 n.s. p = 0.28
No evidence of statistically significant linkage disequilibrium was detected between
markers using this method of analysis. Haplotypes obtained for the affected
chromosomes were then compared with those for the control chromosomes, using
the chi-squared test. Once more, cells containing numbers less than 5 were pooled,
and values were obtained using Yates' correction. The results are shown in Tables
4.13 to 4.18.
Table 4.13 CMM65 (D16S84) - SM7 (D16S283)
Affected Control Total X2 P
Haplotype 1/0 8 17 25
Haplotype 2/0 6 19 25
All other
haplotypes 12 20 32
26 56 82 2.603 n.s.
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Table 4.14 CMM65 (D16S84) - 26-6 (D16S125)
Affected Control Total X2 P
Haplotype 1/1
+ 2/1 5 13 18
Haplotype 1/2 5 25 30
Haplotype 2/2 10 24 34
20 62 82 0.838 n.s.
Table 4.15 CMM65 (D16S84) - VK5 (D16S94)
Affected Control Total X2 P
Haplotype 1/1
+ 2/1 6 35 41
Haplotype 1/2 11 15 26
Haplotype 2/2 9 16 25
26 66 92 5.26 < 0.1
Table 4.16 SM7 (D16S283) - 26-6 (D16S125)
Affected Control Total X2 P
Haplotype 0/2 9 28 37
All other
haplotypes 18 30 48
27 58 85 1.118 n.s.
Table 4.17 SM7 (D16S283) - VK5 (D16S94)
Affected Control Total X2 P
Haplotype 0/2 12 18 30
All other
haplotypes 16 43 59
27 61 89 0.988 n.s.
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Table 4.18 26-6 (D16S125) - VK5 (D16S94)
Affected Control Total X2 P
Haplotype 1/1
+ 1/2 7 18 25
Haplotype 2/1 5 27 32
Haplotype 2/2 11 21 32
23 66 89 2.06 n.s.
4.3.4 Assessment of linkage disequilibrium with other markers
In view of the finding of linkage disequilibrium with VK5 (D16S94), and the
potential implications of this finding for the genetic localisation of PKD1, it was
decided to look for evidence of linkage disequilibrium with a series of other markers.
Aliquots of DNA from each family were sent to Dr. Peter Harris (Oxford) who typed
them for four new microsatellite markers in the region, namely SM6 (2), CW4
(D16S291), CW3, and CW2 (Figure 3.3). The results of the analysis are shown in
Tables 4.13 and 4.14. There is evidence of linkage disequilibrium with marker CW4
(D16S291). but not with any of the other three markers.
Aliquots of DNA were also sent to Angela Snarey (London) who typed them
for ten markers in the region, five of which had not been previously used to type
these families. Both cKLH9, which is the same as CW4 (D16S291), and a new
marker, W5.2 (CW1), showed statistically significant linkage disequilibrium with
PKD1: the other eight markers were not in linkage disequilibrium with PKD1. Both
cKLH9/CW4 (D16S291) and W5.2 (CW1) are located at least 300 kb proximal to
CMM65 (D16S84) (see Figure 3.3).
Attempts to construct extended haplotypes using data from all the typed
markers in this set of families has failed to identify a single founder chromosome (A.
Snarey, personal communication; manuscript submitted). This suggests the
presence ofmore than one independent mutations within the Scottish PKD1
families.
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+ 16 1 .8 0 0 + 16 1 0.8 0 0
+ 14 3 2.3 2 7.7 + 10 1 0.8 0 0
+ 12 CO to CO 0 0 + 8 0 0 1 4.8
+ 6 5 4.0 0 0
+ 4 2 1.6 1 3.8 + 4 12 9.6 4 15.4
+ 2 28 22.7 6 23.0 + 2 46 36.8 11 42.3
0 54 41.9 9 34.6 0 32 25.6 4 15.4
- 2 1 0.8 0 0 - 2 14 11.2 0 0
- 4 1 0.8 1 3.8 - 4 1 0.8 0 0
- 6 16 12.4 4 15.4 - 6 1 0.8 0 0
- 8 7 5.4 2 7.7 - 8 1 0.8 0 0
- 10 8 6.2 0 0 - 12 2 2.0 0 0
- 14 1 0.8 0 0 - 14 o00or—4 6 23.1
- 30 1 0.8 0 0
- 32 3 2.3 1 3.8
Allele frequencies for PKD1 and normal chromosomes in the Scottish population.
Families typed for markers SM6 (2) and CW2 by P. Harris (Oxford).
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+ 6 2 2.2 1 4.8 + 10 0 0.8 0 0
+ 4 2 2.2 5 *23.8 + 6 3 2.4 1 3.8
+ 2 35 38.5 3 *14.3 + 4 31 25.2 6 23.0
0 16 17.6 2 9.5 + 2 19 15.4 4 15.3
- 2 15 16.5 3 14.3 0 68 55.3 12 46.2
- 4 4 4.4 1 4.8 - 2 0 0 2 7.7
- 6 17 18.7 5 23.8 - 4 1 0.8 0 0
*
p = <0.05
Allele frequencies for PKD1 and normal chromosomes in the Scottish population.
Families typed for markers CW4 and CW3 by P. Harris (Oxford).
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4.4 DISCUSSION
These results suggest the presence of linkage disequilibrium between PKD1 and
VK5 (D16S94) in a Central Scottish collection of 32 ADPKD families. Any initial
disequilibrium occurring when a disease mutation arises is dissipated at the rate of
(l-r)n in n generations, where r is the recombination fraction separating marker and
disease locus. If r is veiy small, the rate of approach to equilibrium is slow.
Similarly, a recent mutation will take a finite time to reach equilibrium with
adjacent markers, even when r is significant. Since the recombination fraction
between PKD1 and VK5 is expected to be very small, (0max = 0.00 on two-point
linkage analysis in this population - see Chapter 3), any mutation arising is likely
to be in disequilibrium for some considerable time. As discussed in the previous
chapter, the identification ofmeiotic crossover points by haplotype analysis has led
to the proposal that PKD1 lies between CMM65 (D16S84) and 26-6 (D16S125), a
region shown by pulsed field gel electrophoresis to contain less than 750 kb of DNA
and predicted to contain a large number of genes (Germino et al, 1992). The more
proximally located marker VK5 (D16S94) lies just outside this area. The suggestion
of linkage disequilibrium between VK5 (D16S94) and PKD1 has implications for the
genetic localisation of PKD 1 and, if confirmed by other groups with ethnically
homogeneous patient populations, it would argue for a detailed physical mapping
effort in the proximal part of the CMM65 (D16S84) - 26-6 (D16S125) interval and
extending towards VK5 (D16S94). There has been one report describing failure to
find linkage disequilibrium between VK5 (D16S94) and PKD1 (Elles, 1992) in 38
families from the North West of England. In this population, the allele frequencies
observed for 26-6 (D16S125) and VK5 (D16S94) were significantly different from
those seen in the Scottish and Dutch populations (this study; Breuning et al,
1990a). Linkage disequilibrium may be obscured in other populations by allelic
heterogeneity at PKD1: either Ihe mutation may have arisen in another population
associated with a common marker haplotype or different mutations in the PKD 1
gene may be present in the same population. Linkage disequilibrium may be
present but remain undetected due to small sample size (Thompson et al., 1988). It
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is possible that the finding oflinkage disequilibrium in the Scottish population is a
chance occurrence associated with a small sample of affected chromosomes,
although this is made less likely by the finding of linkage disequilibrium between
PKD1 and other markers in the region (see below).
Since the two-point linkage analysis between PKD1 and 26-6 (D16S125)
also gave a 0max of 0.00, the failure to find linkage disequilibrium between PKD1
and 26-6 (D16S125) is perhaps surprising. This could be because a common PKD1
mutation arose in association with the more frequent 26-6 allele (allele 2), making it
more difficult to detect disequilibrium, or because the polymorphism is itself
subject to significant mutational change. Microsatellite markers, such as SM7
(D16S283), are thought to have relatively high mutation rates compared with RFLP
markers. Weissenbach etal. (1992) estimated that the mutation rate of
microsatellites was close to 1 x 10"^ per locus per gamete, and more recent data
suggest that it may be as high as 1 x 10"^ per locus per gamete (J. Weissenbach,
personal communication). As discussed above, a high mutation rate would serve to
mask the presence of any linkage disequilibrium between loci. Despite this
possibility, linkage disequilibrium has been demonstrated between two highly
polymorphic microsatellite markers on chromosome 5 separated by 7 kb
(Sherrington et al, 1991), suggesting that microsatellites may be sufficiently stable
to allow this finding to be detected. Again, the most likely explanation for the
absence oflinkage disequilibrium is that the PKD1 mutation is associated with the
most frequent SM7 (D16S283) allele.
In order to investigate further the finding oflinkage disequilibrium between
PKD1 and VK5 (D16S94), aliquots of DNA from the Scottish families were sent to
Dr. Peter Harris in Oxford where they were typed for four markers (SM6 (2), CW4
(D16S291), CW3, and CW2). They found evidence oflinkage disequilibrium between
PKD1 and CW4 (D16S291) but not with any of the other markers. CW4 lies
approximately half-way between CMM65 (D16S84) and 26-6 (D16S125), as can be
seen in Figure 3.3. The same aliquots were typed by Ms. A. Snarey for probes KG8,
KM 17, Blu-2, Nik2.9 and W5.2. Linkage disequilibrium was demonstrated between
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PKD1 and W5.2 in the Scottish population, and also confirmed between cKLH9/
CW4 (D16S291) and PKD1. Thus, evidence of linkage disequilibrium has been
found between PKD1 and each of the markers CW4/cKLH9 (D16S291), W5.2 and
VK5 (D16S94), but not with any of the other markers in the same region [CMM65
(D16S84), KG8, SM6 (2), KM17, Blu-2, Nik2.9, CW3, CW2, SM7 (D16S283) and 26-
6 (D16S125)]. The fact that linkage disequilibrium has not been detected between
PKD1 and all the markers tested may be due to sample size, to the varying abilities
of individual loci to detect linkage disequilibrium as a result of allele frequencies, to
mutation at individual loci or to the presence ofmultiple mutations.
In Huntington's disease (HD), linkage disequilibrium was initially detected
between HD and both the D4S95 and D4S98 loci (Snell et al., 1989; Theilmann el
al., 1989). More extensive studies showed that the pattern oflinkage disequilibrium
was extremely complicated (MacDonald et al., 1991), and a convincing peak of
linkage disequilibrium was never detected. The use ofmulti-allele systems to
construct haplotypes of HD chromosomes showed a wide diversity of haplotypes,
but also suggested that a common segment was shared between D4S182 and
D4S180 on these chromosomes, a distance of approximately 500 kb (MacDonald et
al, 1992). The identification of a gene containing a trinucleotide repeat that is
expanded and unstable on HD chromosomes proved to be consistent with this
localisation (The Huntington's Disease Collaborative Research Group, 1993).
Alternatively, a plateau oflinkage disequilibrium can define an area on either side
of a gene, as was seen in cystic fibrosis (Kerem et al., 1989). In this case, however,
although the association coefficients appeared to be rather constant over a 300 kb
interval, fluctuations were detected with several markers not showing linkage
disequilibrium within the plateau (Kerem et al., 1989). As in HD, the location of the
gene proved to be consistent with this localisation by linkage disequilibrium.
It is therefore possible that a plateau oflinkage disequilibrium between
CW4/cKLH9 (D16S291) and VK5 (D16S94) may be present in PKD1, with the
picture being obscured by various factors such as allelic heterogeneity at PKD1, the
varying ability of each marker locus to detect linkage disequilibrium due to allelic
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variation and mutation of the microsatellite marker loci. In Huntington's Disease,
recombinant mapping led to conflicting predictions with one recombination event
suggesting that the most terminal markers flank the disease gene, and two others
favouring a telomeric location for the defect (MacDonald et al., 1989). Linkage
disequilibrium data was proved to be accurate by the isolation of the gene. Errors in
localisation by recombination mapping can occur because there are only a small
number of events and several opportunities for error such as mistyping,
misinterpretation (e.g. gene conversion, double crossovers) and misdiagnosis. The
finding of linkage disequilibrium in PKD1 may therefore be important in the
localisation of the gene.
The markers analysed in this study do not show any marker-marker
disequilibrium. This is, perhaps, surprising given that SM7 (D16S283), 26-6
(D16S125) and VK5 (D16S94) are separated from each other by only approximately
100 kb (Breuning et al., 1990a; Harris et al., 1991). However, if the marker alleles
have low mutation rates and arose a long time ago, there will have been sufficient
time for them to reach linkage equilibrium. CMM65 (D16S84) is located 750 kb
distal to 26-6 (D16S125) (Germino et al., 1992), so failure to find linkage
disequilibrium is less surprising. Previous studies also demonstrate that there is no
simple relationship between marker-marker distance and the presence or absence
of linkage disequilibrium. Lift and Jorde (1986) found no consistent relationship
between the amount of linkage disequilibrium and the physical distance between
pairs of loci within a highly polymorphic region of chromosome 2q spanning 20 kb.
They suggest that since recombination events are very rare between sites that are
only several kilobases apart, other factors, such as mutation, admixture, and drift,
may disturb the expected relationship between distance and linkage disequilibrium.
Hegele et al. (1990) similarly found that five physically close pairs ofmarkers at the
low-density lipoprotein (LDL) receptor locus were in significant linkage
disequilibrium, but that other physically close markers were in linkage equilibrium
with each other. These markers were separated from each other by a maximum of
20 kb. At the p-globin locus, two clusters of linkage disequilibrium, separated by
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9.1 kb of DNA, were found to be in equilibrium with each other due to a "hot spot"
of recombination between the two clusters (Chakravarti et al., 1984). Finally it has
been suggested that all physically close markers may be in linkage disequilibrium
that is undetectable because of the sample size and the magnitude of allele
frequencies (Thompson et al., 1988). The absence of marker-marker disequilibrium
in this study, therefore, may be due to a variety of factors.
The population prevalence ofADPKD is high (1 in 1000), and approximately
80% of cases are the result ofmutations in the PKD1 gene (Wright et al., 1993).
This might be consistent with a high mutation rate for PKD1, although it should be
noted that the reproductive fitness of ADPKD patients is high (Dalgaard, 1957;
Milutinovic et al., 1983). The higher the reproductive fitness, the lower the mutation
rate required to maintain a prevalence of this magnitude. Linkage disequilibrium is
not expected to occur if the mutation rate at PKD1 is high since each new mutation
is likely to occur on a different chromosomal background, and equilibrium is
reached more rapidly. The results described in these ADPKD families would
therefore suggest that the high prevalence is maintained by a high reproductive
fitness or other factors, such as reproductive compensation or previous selective
advantage, in the presence of an intermediate or a low mutation rate.
In conclusion, linkage disequilibrium mapping suggests that the search for
PKD1 should be in the region between cKLH9/CW4, W5.2 and VK5 (D16S94). As in
Huntington's Disease, there are multiple haplotypes, presumably associated with
different PKD1 mutations. Linkage disequilibrium may therefore be seen with some





5.1 YEAST ARTIFICIAL CHROMOSOMES
The yeast artificial chromosome (YAC) vector pYAC4 (Figure 5.1) is constructed from
a pBR322 backbone, and retains much of the plasmid sequence including the
bacterial origin of replication (ori) and the ampicillin resistance gene [Amp1). The
vector also has all the essential yeast chromosomal elements to enable replication
and segregation in a yeast host: a yeast centromere (CEN4) and autonomous
replication sequence (ARS), and two Tetrahymena telomere sequences (TEL), one for
each vector arm. The two vector 'arms' are derived by restriction endonuclease
cleavage of the YAC plasmid vector, and large fragments of restricted DNA are
ligated between the arms to form a linear YAC. In addition, the vector arms carry
selectable markers (TRP1 on the left arm and URA3 on the right arm) to enable
positive selection. pYAC4 is one of the most commonly used cloning vectors and
has a single cloning site in the middle of the ochre suppresser (SUP4) gene, whose
interruption by inserted DNA results in red recombinant clones in the presence of
the ade2-l mutation in the yeast host (Burke et ai, 1987). AB1380 is a strain of
Sacchcuomyces cerevisiae containing a non-Mendelian genetic determinant \|/+ that
enhances the expression of ochre suppresser tRNAs and causes extremely slow
growth in SUP* strains. It is commonly used as a transformation host for YACs.
5.1.1 YAC libraries
Three total genomic YAC libraries, two human and one mouse, were used during
this project and are discussed below.
ICI (Imperial Chemical Industries) YAC library (Anand et cd.. 1990)
A YAC library of 35,000 clones was constructed from human lymphoblastoid








HIS 3 I TEL
Bam HI
Yeast artificial chromosome cloning vector pYAC4. The pBR322 sequences are shown
as a thin line, and include the ampicillin-resistance gene (Amp7) and bacterial origin
of replication (On). SUP4, TRPI, HIS3 and URA3 are yeast genes: SUP4 is an ochre-
supressing allele of a tyrosine tRNA gene that is interrupted when exogenous DNA is
cloned into the vector; TRPI and URA3 are present in the artificial chromosomes and
allow selection for molecules that have acquired both chromosome arms from the
vector; HIS3 is discarded during the cloning process. ARSI and CEN4 are sequences
that are naturally adjacent to TRPI on yeast chromosome IV; ARSI is an
autonomous-replication sequence and CEN4 provides centromere function. The TEL
sequences are derived from the termini of the Tetrahymena macronuclear ribosomal
DNA molecules.
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PFGE prior to ligation to the pYAC4 vector, and transformation was perfonned
using the S. cerevisiae host strain AB1380. Characterisation of the library shows
the average insert size to be 350 kb, giving a 3.5 genome equivalent library. The
authors used 14 single copy probes to screen the library by colony hybridisation as
well as the polymerase chain reaction (PCR), and isolated between one and five YAC
clones per probe. They therefore concluded that there was good overall
representation of the human genome in the library.
CEPH (Centre d'Etude du Polvmorphisme Humainl YAC library (Albertsen el al.
1990)
This YAC library was constructed from large fragments of DNA from a human
lymphoblastoid (46.XY) cell line. Once again, DNA was size-fractionated prior to
ligation to the pYAC4 vector, and S. cerevisiae AB 1380 was used as the yeast host.
The library has 50.000 clones with a mean insert size of 430 kb, and contains the
equivalent of seven haploid human genomes.
St. Mary's Hospital Medical School mouse YAC library (Chartier el al. 1992)
A mouse YAC library was constructed from female C57BL/10 mice in a
recombination-deficient strain of S. cerevisiae (3a) carrying a mutation in the
RAD52 gene. Size-fractionated DNA was ligated to the pYAC4 vector, and following
transformation of the yeast host a library of 41,568 clones was obtained with an
average insert size of 240 kb. This represents more than a threefold coverage of the
mouse genome.
5.1.2 Screening of YAC libraries
In order to utilise YAC libraries as a source of cloned DNA, large numbers of clones
require to be screened in order to detect those containing specific DNA sequences.
Colony hybridisation is effective as a screening technique (Brownstein et al., 1989),
but it is cumbersome and time-consuming. PCR can be used to assay DNA from
pools of YAC clones for the presence of specific sequences (Green and Olson, 1990):
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the number of clones in each pool decreases with each round of screening. Several
YAC clones may be identified using a single probe. These YACs will have
overlapping inserts, all containing the probed locus, and initial alignment of the
clones can be done using inter-Alu PCR fingerprinting (Nelson et al, 1989). In order
to build up a YAC contig containing cloned DNA from a large region, libraries can
either be screened with many probes from the area in the hope that the resultant
clones will overlap, or YAC walking can be employed whereby sequence information
or DNA probes from the end of a YAC are used to re-screen the libraiy for an
overlapping clone.
5.2 PHYSICAL MAPPING AROUND PKD1
PCR primers complementary to DNA sequences flanking the PKD1 gene were used
to screen YAC libraries in order to obtain cloned DNA from the region. In view of the
finding of linkage disequilibrium between PKD1 and VK5 (D16S94), most of the
primers used to screen the YAC libraries were in the proximal half of the CMM65
(D16S84)-VK5 (D16S94) interval. PCR primers to the GGG1 (D16S259), SM33p22
and 26-6 (D16S125) loci were made available by Dr. M. H. Breuning (Leiden). In
order to improve proximal coverage, it was decided to design primers to the 3'
untranslated region of the sequence for AJ1 cDNA, an ATPase-like vacuolar proton
channel gene (ATPL) which is located approximately 50 kb distal to 26-6DIS
(D16S125) (Gillespie et al, 1991), and to subclone and sequence part of VK5
(D16S94), so that primers could be designed to this locus. The positions of these
loci in relation to PKD1 are shown in Figure 5.2.
The aim was to obtain as many YACs as possible from this region, to
characterise these YACs, and then use them to screen cDNA libraries in order to
identify cDNAs with sequence homology to the cloned DNA. Biotinylated cosmid
DNA has been used to enrich PCR-amplified cDNA libraries by hybridisation
followed by selection of hybrids using a biotin-streptavidin reaction (Korn et al.,
1992). A similar technique using YACs as the source of DNA was thought to be




























HY - human YAC
MY - mouse YAC
Location of probes GGG1 (D16S259), ATPL, SM33p22, 26-6 (D16S125) and VK5
(D16S94), which were used in screening the YAC libraries. The four YACs (three
human and one mouse) obtained are indicated with their approximate positions.
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chromosomes by PFGE, digested with a restriction enzyme and the fragments
ligated to catch-linkers. This material was then amplified using the 962L primer
(complementary to the catch-linker) and re-amplified with the biotinylated 962L
primer (C232). cDNA inserts were amplified from the cDNA library by PCR using the
Agt 10 forward and reverse primers. After pre-competingwith Cotl DNA, the cDNA
inserts and biotinylated YAC DNA were allowed to hybridise and the specific
hybrids selected by binding to streptavidin-coated magnetic beads. Non-specific
hybrids were removed by washing and the specific hybrids eluted from the beads at
various temperatures and amplified using >,gtlO primers. This selection process
could be repeated as necessary until the hybrids were pure enough to be cloned
and sequenced.
The mouse YAC was also used to screen a cosmid library by hybridisation;
the identified cosmids could then be used to screen the cDNA libraries directly by
filter hybridisation.
5.3 RESULTS
5.3.1 Subcloning and sequencing of VK5 (D16S94) using Mspl
Probe VK5 (Hyland et aL. 1990) is a 7 kb EcoRI-BamHI fragment in pBR322. The
plasmid was digested with EcoRI and BamHI to release the insert, which was then
excised from a 0.8% TAE agarose gel and purified by Geneclean™. Digestion of the
insert with Mspl yielded 11 bands, the largest ofwhich was 1.3 kb in size. Since
Mspl has a recognition sequence of CCGG, VK5 must be highly CG-rich. Digestion
of pBR322 DNA with Mspl gives 26 fragments, the largest of which is 622 bp.
pBR322 containing the VK5 insert was digested with Mspl, and several bands were
obtained, the largest of which was 1.3 kb. This band was excised from agarose,
purified and subcloned into pBluescript that had been digested with Clal to give
compatible cohesive ends. This DNA was transformed into DH5a cells, which were
then plated onto L-agar containing ampicillin, X-gal and IPTG. White recombinant
clones were picked, DNA minipreps prepared and the subclone digested with EcoRI.
The 1.3 kb fragment was cloned in both orientations, and two EcoRI sites were
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present in each clone (Figure 5.3). Since there are no EcoRI sites in VK5, the 1.3 kb
fragment must be spanning the pBR322 EcoRI cloning site, the other EcoRI site
being present in the cloning vector. The ends of the 1.3 kb Mspl subclone were
sequenced using M13 universal and reverse primers, and the ends of the 7 kb VK5
insert were sequenced using primers close to the EcoRI and BamHI sites in pBR322.
The sequence data obtained are detailed in Appendix 1. One end of the Mspl
subclone was confirmed as being pBR322 sequence and the other end is unique
sequence from VK5. The VK5 sequence adjacent to the pBR322 BamHI cloning site,
and the unique VK5 sequence obtained from the Mspl subclone, were found to be
very GC-rich, with GC contents of 62% and 63% respectively.
5.3.2 VK5/MspIPCR
The internal VK5 sequence together with VK5 end sequence from the EcoRI cloning
site inwards was used to design forward (VF1) and reverse (VR1) PCR primers using
the PRIMER (Version 0.5) program package (Whitehead Institute for Biomedical
Research). The primer sequences are as follows:-
VF1 5' GGC CGC GTG TTT TGC TTT TG 3' (Tm = 67.9°C)
VR1 5' AGA AGG CAA CGA GGG CTG GC 3' (Tm = 68.2°C)
In view of the melting temperatures (Tm) of the primers, an annealing temperature
of 63°C was used, and PCR was carried out as described in Materials and Methods.
The expected product of approximately 1.3 kb was obtained. The optimal MgCl2
concentration was found to be 1.0 mM; multiple bands were obtained at higher
concentrations.
5.3.3 Subcloning and sequencing of VK5 (D16S94) using Kpnl
The above subcloning experiment was repeated using KpnI. Digestion of the VK5
plasmid with Kpnl gives three bands, approximately 7 kb, 3.5 kb and 1.4 kb in size.
Since there are no Kpnl sites in pBR322, the 3.5 kb and 1.4 kb fragments must be
within the VK5 insert. This was confirmed by digestion of the insert itself with the
same enzyme, giving four fragments of approximately 3.5 kb, 2.0 kb, 1.4 kb and
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Figure 5.3
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EcoRI digests of ten randomly-picked VK5/MspI clones. Clones 1, 2, and 6 do not
contain inserts. Clones 3, 4, 5 and 10 contain the VK5/MspI insert in the opposite
orientation from clones 7. 8 and 9. Two EcoRI sites are present in all the clones
containing inserts. The cloning vector is pBluescript.
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<0.1 kb in size. The 1.4 kb fragment was subcloned into pBluescript KS, which had
also been digested with Kpnl, by the same method as before, and the ends
sequenced (Appendix 1). The ends of this fragment were also found to be veiy GC-
rich, with a GC content of 62-64%. A 28 bp repeat, separated by 25 bp, was seen
very close to one end of the fragment.
Primers were designed to the Kpnl fragment forward and reverse sequence,
avoiding the repeat sequence at the forward end. This was done using the PRIMER
(Version 0.5) program. The forward (C719) and reverse (C718) primer sequences are
as follows:-
C719 5' CCA GGC CTC AGC ATC CCA AG 3' (Tm = 67.5°C)
C718 5' CAC TGC TGC CCA CTG GGT CA 3' (Tm = 68.2°C)
PCR was initially carried out using the same program as for the VK5/MspI PCR,
except that an annealing temperature of 62°C was used in view of the slightly lower
Tm of one of the primers (C719). The expected product of approximately 1.3 kb was
obtained when the VK5 plasmid was used as a template, but multiple non-specific
bands were obtained using genomic DNA. Since the VK5/MspI primers were
working well, the VK5/Kpril primers were not tested further.
5.3.4 PCR of ATPL
The sequence of the 3' untranslated region of the ATPL locus (Gillespie et al, 1991)
is shown in Appendix 1 with its complementaiy strand. This was used in the
PRIMER (Version 0.5) program to design forward and reverse primers: these are
shown on the sequence in Appendix 1. No amplification product was obtained with
the first set of primers tested (B928 and B927), but the pairs C18 (forward) and C19
(reverse) proved successful. The primer sequences are as follows:-
C18 5' CCC GCC CCC AGT AGT TGG TC 3' (Tm = 68.1°C)
C19 5' AAC AGG AAC CCA CAA GGC GAC A 3' (Tm = 68.2°C)
These primers should give a product 295 bp in length, which contains a unique
BgUl site. An annealing temperature of 63°C was used, and PCR was carried out as
described in Materials and Methods. Using the above conditions, an amplification
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product of approximately 300 bp containing a Bglll site at the expected position was
obtained. The optimal MgCl2 concentration was found to be 1.5 mM,
5.3.5 YAC library screening
CEPH YAC library
The CEPH YAC library was screened with primers to the GGG1 (D16S259), ATPL
and VK5 (D16S94) loci. Screening was performed by PCR, and the product
visualised on agarose gels by ethidium bromide staining. The results are as
follows: -
1. GGG1 (D16S259) - PCR screening of the 113 master pools yielded a single
positive product of the correct size (1 kb) in pool 18 (Figure 5.4). The corresponding
96-well plates (69, 70. 71, and 72) were sent from CEPH and screened by colony
hybridisation. Two clearly positive colonies were seen in replicate, corresponding to
clones 71B2 and 71B4.
2. ATPL - PCR screening of the master pools revealed a single positive in pool 94
(Figure 5.5). Subpools, consisting of rows x columns, were obtained but no positive
YAC clone could be identified after secondary screening. Secondary screening was
carried out by PCR, followed by Southern transfer and probing of the filter with
labelled PCR product from human genomic DNA.
3. VK5 (D16S94) - no positive master pools were identified using the primers VF1
and VR1.
ICI YAC library
The ICI YAC library was screened with primers to the GGG1 (D16S259), 26-6
(D16S125), SM33p22, ATPL and VK5 (D16S94) loci. Screening with primers to the
GGG1 (D16S259) and 26-6 (D16S125) loci was initially performed by PCR alone,
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Figure 5.4


































Screening of the CEPH YAC library with primers to the GGG1 (D16S259) locus
yielded a product from master pool 18. This product was the same size as the
control product obtained from genomic DNA. Clones 71B2 and 71B4 were isolated
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Screening of the CEPH YAC library with primers to the ATPL locus yielded a faint
product from master pool 94 (Figure 5.5a). Re-screening of this pool confinned that
it was positive with the ATPL primers (Figure 5.5b). The product was the same size
as the control product obtained from genomic DNA. No positive YAC clone was
identified after secondary screening.
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visualising any product on the gel by ethidium bromide staining. No positive pools
were obtained, however, so the sensitivity was increased by Southern blotting the
gels and probing the resultant filters. The results are as follows:-
1. GGG1 (D16S2591 - no positive pools were obtained on screening by PCR with
visualisation of the product by ethidium bromide staining.
2. 26-6 (D16S125) - three positive pools (M14, M26 and M32) were obtained on
screening the master pools. The Ml4, M26 and M32 subpools were therefore
screened, and a single positive subpool, 32A, was identified. Tertiary screening of
the 32A rows x columns revealed a clear amplification product of the correct size
(430 bp) in tubes 1 and 12, corresponding to YAC clone 32A-A4 (Figure 5.6).
3. SM33p22 - master pool M14 was positive with primers to this locus, and
screening of the subpools revealed 14C to be positive. Despite many attempts,
however, no YAC clone could be isolated from the 14C rows x columns.
4. ATPL - three positive master pools (M25, M31 and M34) were obtained after
primary screening. Secondary screening of the M25, M31 and M34 subpools found
only subpool 31A to be positive (Figure 5.7). Tertiary screening of the 31A rows x
columns revealed a weakly positive band in tube 8 and a strongly positive band in
tube 18. corresponding to YAC clone 31A-H10.
5. VK5 (D16S94) - three positive pools (M9, M15 and M32) were obtained on
screening the master pools. Screening of the M9, Ml 5 and M32 subpools revealed a
single positive subpool, 32A. Tertiary screening of the 32A rows x columns revealed
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Autoradiograph showing tertiary screening of the ICI YAC library subpool 32A. The
32A rows x columns were screened using primers to the 26-6 (D16S125) locus. A
clear product was seen in samples 1 and 12, which was of the same size obtained
from genomic DNA. This isolates 32A-A4 as the positive clone.
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Figure 5.7
Autoradiograph showing secondaiy screening of the ICI YAC library M31 subpools
with the C18/C19 primers to the ATPL locus. A clear product of the correct size was
seen in subpool 31A.
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Figure 5.8
Row/Column A BCDEFGH 1 2 c -£
Samples 1 23 4 567 8 9 10 5 o
Column 3 4 567 8 9 10 11 12 § H
Samples 11 12 13 14 15 16 17 18 19 20 15 o
Autoradiograph showing tertiary screening of the 32A rows x columns with primers
to the VK5 locus. Clear products of the correct size were obtained in samples 1 and
12, corresponding to YAC clone 32A-A4
152
St. Mary's Hospital Medical School mouse YAC library
Screening was performed by PCR followed by Southern blotting and probing. The
annealing temperature of the PCR programme was reduced, initially by 3°C, to
allow for species differences in sequence, and the primers tested on mouse (ThyBl)
DNA. Once the correct product was obtained, the primers were used to screen the
mouse YAC library. No product could be obtained from ThyBl using the GGG1
(D16S259) primers, despite reducing the annealing temperature to 55°C (from 68°C)
and increasing the MgCl2 concentration to 2.5 mM (from 1.5 mM). A product was
obtained using the ATPL primers by decreasing the annealing temperature to 57°C
(from 63°C): the product was clearly visible on ethidium bromide staining and was
of similar size as the product obtained from human genomic DNA, but without the





Ethidium bromide-stained gel showing the PCR product obtained from mouse
(ThyBl) DNA using the C18/C19 primers to the ATPL locus. There is no change in
size of the product after incubation with Bglll, indicating that the Bglll site present
in human genomic DNA is absent in ThyBl DNA.
A product was obtained using the SM33p22, 26-6 (D16S125) and VK5 (D16S94)
primers by decreasing the annealing temperature to 60°C (from 66°C, 65°C and
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63°C respectively). In the case of VK5 (D16S94), the MgCl2 concentration was
increased to 1.5 mM from 1.0 mM. For all three loci, the products obtained were not
visible by ethidium bromide staining alone, but were clearly seen if the DNA was
transferred to a filter and probed with labelled product from human genomic DNA.
The mouse YAC library was therefore screened with primers to the ATPL,
VK5 (D16S94), SM33p22 and 26-6 (D16S125) loci. The results are as follows:-
1, ATPL - screening of the complex pools revealed a clear product in pool C (Figure
5.10a), and screening of the simple pools revealed C4 to be positive (Figure 5.10b).
Rows x columns were prepared from the corresponding 96-well plates, and tertiary
screening identified C4-I12 as the positive YAC clone.
2. VK5 (D16S94) - complex pools B, C and E were found to be positive on primary
screening, and simple pools B5 and E9 on secondary screening. Rows x columns
were prepared from the corresponding microtitre plates, but no reproducible
positives were identified on tertiary screening.
3. SM33p22 - complex pools E and F were found to be clearly positive on primary
screening (Figure 5.11), but no clearly positive pools could be identified on
secondary screening.
4, 26-6 (D16S125) - as with the above locus, complex pools E and F were found to
be weakly positive on primary screening but, again, no clearly positive simple pools
could then be identified.
Screening of the three libraries therefore yielded a total of five positive clones: 71B2
and 71B4 from the CEPH library positive for the GGG1 (D16S259) locus; 32A-A4
and 31A-H10 from the ICI library positive for the 26-6 (D16S125)/VK5 (D16S94)
and ATPL loci respectively: and C4-I12 from the St. Mary's mouse library positive


















Autoradiograph showing the results of primary screening of the St. Mary's Hospital
mouse YAC library with primers to the SM3p22 locus. Complex pools E and F were
found to be positive, with a product of the correct size demonstrated. Screening of
the corresponding simple pools was unrewarding.
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5.3.6 Characterisation of the YAC clones
71B2 and 71B4 (GGGl-positive human YAC)
The clones were plated out onto Casamino agar, and plugs made from cultures of
single colonies. Plug DNA was used as a template for PCR with primers to the
GGG1 (D16S259), 26-6 (D16S125) and SM33p22 loci, and to the Alu primers TC-65
and 517 (Nelson et al., 1989). A clear product of the correct size was obtained with
both 71B2 and 71B4 using the GGG1 (D16S259) primers (Figure 5.12a), but no
amplification product was obtained for either YAC using primers to 26-6 (D16S125)
or SM33p22. PCR with the Alu primers gave the same band pattern for both YACs
(Figure 5.12b) suggesting that they may be the same.
The yeast chromosomes were separated by pulsed field gel electrophoresis
(PFGE), but no YAC band could be seen separate from the host yeast chromosomes
on ethidium bromide staining (Figure 5.13). Following Southern blotting and
probing of the filter with CMM65 (D16S84), which is located approximately 10 kb
proximal to GGG1 (D16S259), a clear band was obtained for both 71B2 and 71B4
overlying the second smallest host yeast chromosome. 71B2 and 71B4 therefore
both contain a YAC, 280 kb in size, with insert DNA from chromosome 16p positive
for the GGG1 (D16S259) and CMM65 (D16S84) loci, but negative for the EKMDA
(D16S83), 26-6 (D16S125) and SM33p22 loci.
For each clone, the YAC band and its co-migrating host chromosome were
cut out from LMP agarose, digested with Bglll or Rsal and ligated to catch-linkers.
This material was amplified with 962L primers, labelled with biotin by nick
translation and used for fluorescence in situ hybridisation. The in situ hybridisation
was carried out by Dr. M. Breen. Both 71B2 and 71B4 gave a weak signal on 16p,
but signals were also seen on six other chromosomes, suggesting either that both
the clones were chimaeric, containing DNA from several different chromosomal
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a) PCR of 71B2 and 71B4 YAC plugs with primers to the GGG1 (D16S259) locus. As
expected, a clear amplification product was seen in all the samples, indicating the
presence of the GGG1 (D16S259) locus on both YACs.
b) PCR of 71B2 and 71B4 YAC plugs with the Alu primers TC-65 and 517. An
identical band pattern was seen for both YACs, suggesting that they contain

























Ethidium bromide-stained pulsed field gel, showing separation of the yeast
chromosomes in AB1380 and DNA from CEPH YAC clones 71B2 and 71B4.
Separation was achieved using a pulse time of 70 sec for 21 hours, followed by a
pulse time of 120 sec for 21 hours. The YACs cannot be clearly distinguished from
the host yeast chromosomes. Probing of this gel with labelled GGG1 PCR product
from genomic DNA indicated that the YAC was in a position overlying the second
smallest yeast chromosome in both cases.
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In conclusion, therefore, clones 71B2 and 71B4 contain the same potentially
chimaeric YAC, with what may only be a small proportion of the insert DNA from
16p around the GGG1 (D16S259) locus.
32A-A4 (26-6/VK5-positive human YAC)
32A-A4 was grown up on Casamino agar and plugs made from cultures of single
colonies. Plug DNA was used as a template for PCRwith primers to the VK5
(D16S94), 26-6 (D16S125), ATPL and SM33p22 loci, and for inter-AluPCR with
primers TC-65, 517, 153, 154, 450 and 451. Clear amplification was seen following
PCR with primers to VK5 (D16S94) and 26-6 (D16S125), but not with primers to
ATPL or SM33p22. No bands were seen after PCR with TC-65, but all the other Alu
primers amplified multiple bands (Figure 5.14).
Figure 5.14
PCR of 32A-A4 YAC plugs with Alu primers TC-65, 517, 450, 451, 153 and 154. No
product was obtained using primer TC-65, but all the other primers gave multiple
bands. This indicates that the 32A-A4 YAC contains several repeats of the Alu
consensus sequence.
160
The yeast chromosomes were separated by PFGE and a YAC band was
visible below the smallest host chromosome on ethidium bromide staining,
approximately 230 kb in size (Figure 5.15). The DNA was transferred to a Hybond-
N+ filter by alkali blotting, and the position of the YAC confirmed by hybridisation
with the probe 26-6 (D16S125). The filter was then stripped and probed with
218EP6 (D16S246) which is located proximal to VK5 (D16S94) (Figure 1.3). The
YAC did not hybridise with this probe.
The YAC was cut out from LMP agarose (Figure 5.15b), digested with Bglll or
JRsal, ligated to catch-linkers and amplified with 962L primers. The amplified
material was labelled with biotin by nick translation and used for fluorescence in
situ hybridisation. This in situ hybridisation was carried out by Ms. S. Boyle, and
the YAC material was clearly shown to hybridise to 16p only. 32A-A4 is therefore a
non-chimaeric 230 kb YAC with the VK5 (D16S94) and 26-6 PROX and/or DIS
(D16S125) loci present. The YAC does not extend to include either the SM33p22 or
218EP6 (D16S246) loci.
Preliminaiy pulsed field mapping of the YAC was performed by digesting
YAC plugs with the following rare cutter enzymes: Notl, BssHW, Eagl, Kspl, SalI, S/il,
Nrul, and Mlul. Half of each of the digested plugs were separated by PFGE, the DNA
transferred to a filter and the filter probed sequentially with left and right arm
vector probes. The restriction map showing the two ends of the YAC is shown in
Figure 5.16, and shows the presence of at least two CpG-rich clusters which could
represent CpG islands within the insert DNA.
31A-H10 (ATPL-positive human YAC)
The clones were plated out onto Casamino agar, and plugs made from cultures of
single colonies. Plug DNA was used as a template for PCR with primers to the ATPL
and VK5 (D16S94) loci, and the Alu primers 517, 153, 154, 450 and 451. No
amplification was obtained with the C18/C19 ATPL primer pair that had been used
to pull out the YAC, or with the VK5 (D16S94) primers, but bands were obtained
with the Alu primers suggesting the presence of human DNA in the YAC.
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Figure 5.15a
Ethidium bromide-stained pulsed field gel, showing separation of the yeast
chromosomes in AB1380, DNA from ICI YAC clone 32A-A4 and DNA from control
YAC clones. Separation was achieved using a pulse time of 70 sec for 21 hours,
followed by a pulse time of 120 sec for 21 hours. The YAC can be clearly














































Ethidium bromide-stained LMP pulsed field gel, showing separation of the yeast
chromosomes in AB1380 and DNA from ICI YAC clone 32A-A4. The YAC band is
seen below the smallest yeast chromosome. The YAC DNA was excised, digested
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The yeast chromosomes were separated by PFGE, and a YAC band could be
seen on ethidium bromide staining which was separate from, and smaller than, the
host yeast chromosomes, approximately 180 kb in size. Following Southern
transfer, the filter was probed with labelled ATPL PCR product, and a weak signal
was obtained in a position consistent with the band previously seen. The filter was
stripped and re-probed using pBR322 DNA, and a strongly positive band was seen
in the same position confirming the presence of YAC vector sequence.
PCR was then performed on material taken directly from half each of nine
YAC colonies, and amplification was obtained using the ATPL primers. Cultures
were grown using -URA.-TRP selection from the other halves of the colonies and
DNA plugs made. However, multiple attempts at PCR amplification of these plugs
with the ATPL primers failed.
It therefore seems that clone 31A-H10 contains a YAC with a human DNA
insert which is positive for the ATPL primer sequences when amplified from a
colony, but if the clone is grown up and made into plugs this sequence is lost. This
unstable YAC could not be isolated from a pulsed field gel with any degree of
confidence, and was therefore not analysed further.
C4-I12 (ATPL-positive mouse YAC)
Clone C4-I12 was picked from the microtitre plate, grown up on Casamino agar and
plugs made from cultures of single colonies. Plug DNA was used as a template for
PCR with primers to the ATPL, 26-6 (D16S125) and VK5 (D16S94) loci. Clear
amplification was seen with the ATPL primers, but not with primers to the other two
loci. The yeast chromosomes were separated by PFGE and a possible YAC band was
visible well below the smallest host chromosome on ethidium bromide staining
(Figure 5.17a). The DNA was transferred to a Hybond-N+ filter by alkali blotting,
and the filter probed with the ATPL PCR product from murine genomic DNA
template. A strongly positive band was seen at the base of the gel (Figure 5.17b),
corresponding to a YAC of approximately 160 kb in size. Confirmation of the
165
Figure 5.17
Figure 5.17a shows an ethidium bromide-stained pulsed field gel ofYAC clone C4-
112 with a diffuse YAC band at the bottom of the gel, smaller than the smallest host
yeast chromosome. Figure 5.17b is the autoradiograph of the filter corresponding to
the gel in Figure 5.17a which has been probed with labelled pBR322. pBR322
recognises the vector sequence in the YAC, and confirms the position of the C4-I12
















Figure 5.17c is the ethidium bromide-stained LMP pulsed-field gel from which the
diffuse C4-I12 YAC band was excised. Figure 5.17d shows the PCR products from
the C4-I12 plug and the excised YAC band using the ATPL primers. This confirms
the presence of the ATPL sequence on the excised band.
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presence of a YAC was obtained by stripping the filter and re-probing with pBR322,
which again gave a strongly positive band in the same position.
The YAC was excised from LMP agarose (Figure 5.17c), and this material was
used as a template for PCR using the ATPL primers. Good amplification was
obtained, confirming the presence of the ATPL sequence in the excised YAC band
(Figure 5.17d). The YAC DNA was then digested and ligated to catch-linkers. This
material was PCR amplified using the 962L primers, labelled with biotin by nick
translation and attempts made at fluorescence in situ hybridisation. This in situ
hybridisation was carried out by Mrs. M. Harris. A clear signal was obtained on a
single mouse chromosome using this material, but it was not possible to identify
the chromosome.
Preliminary pulsed field mapping of the YAC was performed by digesting
YAC plugs with the following rare cutter enzymes: Notl, Eagl. Kspl, Sail, SfU, Nrul,
and Mlid. Half of each of the digested plugs were separated by PFGE, the DNA was
transferred to a filter and the filter probed sequentially with left and right ann
vector probes. The restriction map showing the two ends of the YAC is shown in













Diagram showing the position of restriction sites at each end of YAC C4-I12. The
map is not to scale. This preliminary restriction map was constructed from
complete digests of C4-I12 YAC plugs separated on a pulsed field gel and probed
sequentially with left and right arm vector probes. A single CpG-rich cluster is seen,
close to the left arm.
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5.3.7 YAC-cDNA hybridisation
The details of the method used are described in Materials and Methods.
Biotin-streptavidin binding
A trial run was performed in order to ensure that the Geneclean™ procedure, used
to remove unused biotinylated primers from the PCR reaction, did not affect binding
of the biotinylated product to the Dynabeads™. 1 pi of a plasmid containing a
catch-linkered insert was used as the template for PCR. Samples were set up using
either 962L or C232 (biotinylated 962L) as the primer and PCR was carried out.
100 pi of each product was then either extracted with chloroform and using the
Geneclean procedure, or extracted only with chloroform. 25 pi Dynabeads was
added to each tube and treated as in the protocol. Both the Geneclean-ed and the
non-Geneclean-ed biotinylated C232 products bound to the Dynabeads, with no
detectable DNA remaining in the supernatant (Figure 5.19). The Geneclean
procedure had no effect on the binding to Dynabeads.
Titration of cDNA libraries
An adult and a foetal kidney cDNA library were available for screening. The titre of
the adult library was found to be 2.35 x 10^ pfu/ml. The titre of the foetal library
was found to be 1.25 x 101 * pfu/ml.
Amplification of cDNA
Primary PCR amplification of the cDNA library was carried out using the A,gtlO
primers. Amplification of a good size range of inserts was obtained for both libraries
with an extension time of three minutes (Figure 5.20a). Further amplification of this
material using the same PCR programme led to a significant reduction in the size of







DNA was PCR amplified using either the 962L (non-biotinylated) primer or the C232
(biotinylated) primer. In samples 962LA and C232A, the PCR product was extracted
with chloroform and purified using the Geneclean procedure. In samples 962LB and
C232B, the PCR product was extracted with chloroform and not further purified.
Each of the four samples was incubated with Dynabeads as described in Materials
and Methods. The samples on the gel are as follows:-
1. 962LA added to Dynabeads and the supernatant removed immediately
after incubation
2. 962LA prior to the addition of Dynabeads
3. 962LB added to Dynabeads and the supernatant removed immediately
after incubation
4. 962LB prior to the addition of Dynabeads
5. C232A added to Dynabeads and the supernatant removed immediately
after incubation
6. C232A prior to the addition of Dynabeads
7. C232B added to Dynabeads and the supernatant removed immediately
after incubation
8. C232B prior to the addition of Dynabeads
DNA is therefore present in all samples prior to the addition of Dynabeads. Samples
962A and 962B are non-biotinylated, and there was no/little binding of the sample
to the Dynabeads with a significant amount present in the supernatant. Samples
C232A and C232B are biotinylated, and there was complete binding of both samples
to the Dynabeads with none being present in the supernatant. Purification with










Q 32A-A4 Bgl II
32A-A4 Bgl II
32A- A4 Rsa I
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1 Marker III
a) Ethidium bromide-stained gel showing PCR amplification of adult and foetal
kidney cDNA libraries using the ^.gtlO forward and reverse primers,
b) Ethidium bromide-stained gel showing PCR amplification of YAC 32A-A4 that
has been digested with either BgM or Rsal and ligated to catch-linkers as described
in Materials and Methods. PCR was performed using the biotinylated C232 primers
and either lpl of catch-linkered material (upper 4 lanes) or 1 pi 1:10 diluted
material (lower 4 lanes).
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Amplification of 32A-A4 YAC DNA
The 32A-A4 YAC DNA was amplified using biotinylated 962L primers (C232). Good
amplification was obtained using the same PCR programme as for the non-
biotinylated primers (Figure 5.20b).
YAC-cDNA hybridisation
Hybridisation of biotinylated YAC DNA and cDNA inserts, both ofwhich had been
competed with Cod DNA, was performed as described in Materials and Methods.
1 pi of material eluted from Dynabeads at 75°C, 85°C and 95°C after the first round
of hybridisation was amplified with the Xgt 10 primers, using an extension time of 7
min for 25 cycles. A good yield was obtained with the adult library, and a lower but
visible yield for the foetal library. Within the background smear, however, clear
bands could be seen. The adult cDNA material eluted at 95°C, and the foetal cDNA
material eluted at 85°C and 95°C, were therefore amplified in sufficient quantity to
allow a second round of hybridisation to be performed. 1 pi ofmaterial eluted at
95°C from the second round of hybridisation was amplified with the XgtlO primers,
using an extension time of 7 min for 20 cycles; 5 pi of product was then placed in
fresh PCR mix and taken through a further 10 cycles of PCR. Multiple clear bands
were seen, especially in the adult library (Figure 5.21a). Each band or "fraction" was
then amplified from a needle stab of the gel. Clear bands were obtained for the
smaller fractions, but the larger fractions failed to amplify despite increasing the
extension time to 10 minutes per cycle (Figure 5.21b).
Two of these fractions (A7 and A8 from the adult library) were selected at
random, re-amplified by PCR, and the blunt-ended fragments subcloned into
pBluescript. DNA was directly amplified from recombinant colonies, using M13
primers, and inserts of differing sizes were obtained (Figure 5.22a). 25 pi of product
from the A7 colonies were digested with EcoRI, and 4 different sizes or orientations
of inserts were seen (Figure 5.22b). As expected, therefore, the fraction consists of a
number of different hybrid products within a very narrow size range. Since a
























a) 1 |o.l ofmaterial eluted at 95°C from the second round of YAC-cDNA hybridisation
was amplified with the ^.gtlO primers as described in the text. Better yields were
obtained for the adult library than the foetal library, but multiple bands could be
seen in each sample. The samples in the lower two lanes have been through the
'clean-up' programme,
b) A needle stab was taken from each band of the above gel and PCR amplification
performed using the XgtlO primers. Good amplification of the smaller bands was
obtained, but the larger bands have failed to amplify.
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Figure 5.22a
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Fractions AKA7 and AKA8 were cloned into pBluescript and DNA was directly
amplified from randomly picked recombinant colonies using the M13 forward and
reverse primers. Colonies A7-3, A7-4, A7-5, A7-10, A8-1, A8-2, A8-10 and A8-16
contain no insert. Within each fraction (AKA7 and AKA8) inserts of differing sizes
have been cloned, and each fraction therefore consists of a number of different
hybrid products within a very narrow size range.
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Figure 5.22b
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25 |il of PCR products from the AKA7 colonies were digested with EcoRI. The
samples are run on the gel both uncut (A7-la - A713a) and after digestion with
EcoRI (A7-lb - A7-13b). Four different sizes or orientation of insert are seen: clones
1, 4 and 6; clones 2, 9, and 12; clones 3 and 8; and clone 13. Clones 10 and 11
behave as empty vector and clone 5 has not amplified.
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experiments were carried out in order to try and reduce the number of fractions to
be more closely characterised.
Assessment of fractions
1. Dot blot filters of the cDNA-YAC hybrid fractions were prepared and
hybridised with labelled YAC DNA or with a labelled 2 kb Alu fragment (not
including vector). All the fractions hybridised to both the YAC and the Alu sequence
(Figures 5.23a and 5.23b). Both filters were washed to high stringency (0.1 x
SSC/0.1% SDS/65°C). This would suggest that the cDNA hybrids do have sequence
homology with the YAC used in their selection, but that these sequences also
contain a high proportion of Alu repetitive sequences.
2. Agarose plugs containing AB1380, CHI-16 (a chromosome 16-only hybrid
cell line), 32A-A4 or C4-I12 were digested with Hindlll and electrophoresed in a
0.8% TBE agarose gel. The DNA was transferred to Hybond-N+ filters and probed
with labelled 26-6 (D16S125). This probe hybridised clearly to a single fragment of
the digested YAC 32A-A4, but not to AB1380, CHI-16 or C4-I12, confirming that
this sequence is present in single copy in the 32A-A4 YAC. The filter was then
stripped and re-probed; first with the YAC-cDNA hybrid fraction AKA7 after Cotl
competition, and then with the labelled Alu fragment. Both the YAC-cDNA hybrid
and the Alu probe hybridised to several discrete bands within the Hindlll digested
YAC, but at least one band hybridised only with the cDNA and not with the Alu
probe.
Since the Alu probe hybridised to several fragments in the digested YAC, the
YAC must contain at least several Alu repetitive sequences. This is in keeping with
the finding that PCR of 32A-A4 YAC DNA using the Alu primers led to the
amplification ofmultiple bands. The AKA7 fraction also hybridised to several
fragments in the digested YAC, nearly all of which were the same fragments as
those hybridising to the Alu probe. This would suggest that AKA7 contains a high





Autoradiographs of dot blots prepared with adult and foetal kidney cDNA-32A-A4
YAC hybrid fractions and hybridised with either labelled 32A-A4 total YAC DNA
(Figure 5.23a) or with labelled Alu fragment (Figure 5.23b). All the fragments




32A-A4 (26-6/VK5-positive human YAC)
Attempts were made to clone the ends of 32A-A4 by both the asymmetric PCR and
the AZu-vector PCR methods. 32A-A4 was digested with Bglll and ligated to catch-
linkers, or digested with Rsol and ligated to catch-linkers. Both were amplified by
PCR with 962L primers and used as starting material for the asymmetric PCR. No
consistent product was obtained using this method. AZu-vector PCR was performed
using vector primers 373 and 556 with each of the Alu primers in turn. Most of the
pairs of primers produced multiple bands, but pairs 373/451. 373/154 and
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Gel photograph showing the PCR products obtained from AZu-vector PCR of YAC
32A-A4 with different sets of primers. Each of the six Alu primers (TC-65, 517, 450,
451. 153 and 154) were combined in turn with either the left arm vector primer 373
or the right arm vector primer 556. Pairs 373/451, 373/154 and 556/517 gave
single bands. Pair 373/TC-65 yielded no PCR product, and all the other pairs gave
multiple bands.
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These three bands were re-amplified by PCR of a needle stab of DNA from the
agarose gel, and pairs 373/154 and 556/517 again gave single bands. Both
fragments were isolated from a 0.8% TAE agarose gel, purified using Geneclean and
probed against a filter from a pulsed field gel containing 32A-A4 and control YACs.
Fragment 373/154 hybridised strongly to 32A-A4 in a position consistent with the
YAC band, and also hybridised weakly to the control clones, again over the site of
the YAC bands (Figure 5.25). This cross hybridisation is likely to be due to the
presence of a small amount of vector sequence present in the end-fragment.
Fragment 556/517 gave a similar picture. Both fragments were subcloned into
pBluescript ready for sequencing.
C4-I12 (ATPL-positive mouse YAC)
Attempts were made to clone the ends of C4-I12 by the asymmetric PCR method.
C4-I12 digested with Bglll and ligated to catch-linkers, and C4-I12 digested with
Rsal and ligated to catch-linkers, were both amplified by PCR with 962L primers
and used as starting material for the asymmetric PCR. No consistent product was
obtained using this method.
5.3.9 Screening of a mouse cosmid library
A mouse cosmid library was obtained from Dr. J. H. McVey and was screened with
YAC C4-I12, using amplified catch-linkered DNA as a probe and mouse Cotl DNA as
competitor. Four positive colonies (A, B, C, and D) were identified on screening the
master filters, and these were picked and re-plated. Secondary screening was
performed on the 1:1000 dilutions of the above colonies using the same protocol.
The filters from colonies A and C were covered with positive signals corresponding
to the colonies, and plates B and D showed a few positive colonies. Positive colonies
from each plate were grown up and DNA prepared using the rapid boiling miniprep
technique. The DNA was digested with EcoRI, electrophoresed in a 0.8% agarose gel
(Figure 5.26) and transferred to a filter.
179
Figure 5.25
Autoradiograph showing hybridisation of the 32A-A4 end clone 373/154 to various
YACs. Clone 373/154 hybridises strongly to 32A-A4 in a position consistent with
the YAC band, and also hybridises weakly to the control clones, again over the site
of the YAC bands.
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Figure 5.26
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EcoRI digests of cosmid clones, obtained by screening a mouse cosmid library
directly with mouse YAC C4-I12 which is positive for the ATPL locus. Clones Dl,
D2, and D3 appear to be the same and are therefore more likely to be genuine.
The digests suggest that several different cosmids have been obtained, some of
which appear to be the same. Probing of the filter with labelled C4-I12 gives a
strong positive signal in all lanes. The cosmids now need to be probed back to the
YAC to ensure that they contain sequence from C4-I12, and they will then be a
useful resource for screening cDNA libraries and for repeating attempts at








Identification of cDNAs and candidate genes requires cloned DNA from the region of
search. The region around the PKD1 gene on chromosome 16, from GGG1
(D16S259) to 26-6PROX (D16S125). has been almost entirely cloned in a cosmid
contig. although two 'unclonable' gaps of <20 kb and 60 kb remain (Germino et al.,
1992). Since YACs are able to accommodate up to 1 Megabase of insert DNA, it is
potentially much quicker to build up a YAC contig of an area than a cosmid contig.
In addition, segments of the human genome that have been cloned into YACs are
generally stable, and nearly all DNA appears to be clonable (Abidi et al, 1990). It
was therefore decided to make use of YAC technology in order to obtain cloned DNA
from the PKD1 region. As discussed in Chapter 4, the finding of linkage
disequilibrium between PKD1 and VK5 (D16S94), argued that the search for PKD1
should be concentrated in the proximal half of the 750 kb region between GGG1
(D16S259) and 26-6 (D16S125), and extended proximally towards VK5 (D16S94).
Primers to the GGG1 (D16S259), 26-6 (D16S125) and SM33p22 loci were already
available as part of a European Concerted Action programme (Dr. M. H. Breuning).
In view of the disequilibrium findings, primers were designed to the VK5 (D16S94)
and ATPL loci, so that four proximal loci and one distal locus were used to screen
the YAC libraries.
5.4.1 GC content of VK5
In order to design primers to the VK5 (D16S94) locus, the VK5 insert (in pBR322)
was subcloned and sequenced. The DNA surrounding the a-globin complex is
known to be GC-rich (Fischel-Ghodsian et al., 1987), and Harris et al. (1990) found
that this GC-rich region extended for more than 2 Megabases proximally. A large
number of CpG clusters have been mapped to the interval GGG1 (D16S259) - 26-6
(D16S125) suggesting that the PKD1 region will be gene-rich (Germino et al, 1992).
Mammalian genomes have an average G + C content of 41%. In subcloning and
sequencing VK5, five small fragments of approximately 200 bp were sequenced. One
of the ends of the complete insert, adjacent to the pBR322 EcoRI site, has a slightly
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higher than average GC content at 49%, but the other end of the insert (adjacent to
the pBR322 BamHI site) and the ends of the subclones have a very high GC content
of between 62 and 64%. This therefore indicates that the GC-rich region, and
probably the gene-rich region, extends beyond 26-6 (D16S125) at least to VK5
(D16S94).
5.4.2 Screening of YAC libraries
There are two basic methods of screening YAC libraries for the presence of single
copy sequences. Hybridisation with radioactively labelled probes (Brownstein et al,
1989) requires that the individual YAC clones have been transferred to filters.
Screening by this method can yield false positives by cross-hybridisation, especially
since probes may contain repeat sequences found in a number of YACs. As an
alternative, a PCR-based method has been developed (Green and Olson, 1990) in
which initial screening was by PCR of pools of YAC DNA, and the individual YAC
clone(s) identified by a final hybridisation step. This method of screening requires
that eveiy probe be sequenced and primer pairs synthesised. The generation of
inappropriate PCR products has been observed with several PCR assays,
presumably generated from sequences that match the PCR primers imperfectly
(Green and Olson, 1990). Green and Olson (1990) compared screening by colony
hybridisation with that by PCR, and detected the same positive clones for 8 different
genes. Screening by colony hybridisation, however, also yielded numerous false
positives.
Since both the CEPH and ICI YAC libraries were available as pools of YAC
DNA, and since some PCR primers were already available, it was decided to use PCR
screening as the method of choice in this project. Rows x columns are now also
available, enabling the final round of screening to be performed by PCR also.
In a library of approximately 23,000 clones with an average insert size of 250
kb, single-copy sequences are expected, on average, to be represented twice (Green
and Olson, 1990). Similarly, a complexity of 3-4 genome equivalents should give a
95% chance of finding a given sequence, increasing to 98-99% with 6-10 genome
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equivalents (Riley et al., 1992). The ICI YAC library consists of 35,000 clones with
an average insert size of 350 kb, and the CEPH YAC library has 50,000 clones with
a mean insert size of 430 kb. The complexity of these two libraries is 3.5 and 7
genome equivalents respectively. Screening of these libraries with a single-copy
probe would therefore be expected to yield several positive YAC clones in 95-98% of
cases. In this project, the CEPH YAC library was screened with primers to three loci
[GGG1 (D16S259), ATPL and VK5 D16S94)], and only one YAC clone was obtained.
The ICI YAC library was screened with primers to five loci [GGG1 (D16S259), ATPL,
SM33p22, 26-6 (D16S125) and VK5 D16S94)] and only two YAC clones were
obtained. This is a far lower return than would be expected from the above data. In
order to ensure that positive clones had not been missed, the sensitivity of
screening was increased by Southern blotting the PCR reaction products and by
probing the filters with labelled PCR product from human genomic DNA. Green and
Olson (1990) noted complete inhibition of PCR in the presence ofmore than 60-80
ng of purified yeast DNA/pl, the optimal concentration for PCR being 20 ng/gl. Care
was therefore taken not to exceed this concentration.
M. H. Breuning and P. Harris (personal communication) have since also
reported little success in isolating YACs using probes from the same region. It
therefore appears that 16pl3.3 is under-represented in these two libraries, perhaps
because YAC clones from this region are inherently unstable. It is of interest that
one of the three YACs isolated was potentially chimaeric, and another was
apparently unstable on growing up in culture, or contained sequences harmful to
the host.
5.4.3 Co-cloning
Chimaeric YACs contain insert fragments from non-contiguous regions of the
genome. This co-cloning may potentially occur as a result of co-ligation of two
fragments of insert DNA. or where co-transformation ofmore than one ligated DNA
recombinant in the same cell is followed by homologous recombination between
repetitive sequences (such as Alu sequences) in the two molecules (Green et al,
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1991). In order to detect the presence of chimaerism in a YAC, Green et al. (1991)
developed sequence tagged sites (STSs) from the ends of the YAC inserts, and the
assigned these STSs to particular human chromosomes by PCR analysis of DNA
from a panel of human-hamster hybrid cell lines. This was then confirmed using X
subclones containing the ends of the YAC inserts as probes in fluorescence in situ
hybridisation (FISH) assays of human metaphase chromosomes. In this project, the
whole YAC was labelled by digestion, attachment of catch-linkers, amplification and
biotinylation, and this material was used for FISH analysis of human metaphase
chromosomes. Co-cloning has been measured in the range of 50% for contigs in the
CF (Green and Olson, 1990) and HLA (Bronson et al., 1991) regions using YACs
from a library of total human DNA. The assembly of contigs is usually unaffected
providing that a sufficient number of non-chimaeric clones are available to span the
gap. YAC libraries made from human-rodent hybrid cells seem to show a lower level
(20%) of co-cloning (Little et al., 1992). The potentially chimaeric YAC 71B2/71B4
obtained from the CEPH library in this project appears unusual in that DNA
segments from six different chromosomes are present: an alternative explanation
might be that it contains a low copy repetitive element.
5.4.4 Clone under-representation/instability
Different reports have emphasised both the stability and instability of human YACs.
Abidi et al. (1990) found that the recovery of Xq sequences was consistent with
random cloning, i.e. that all or nearly all sequences were equally clonable in YACs.
Brownstein et al. (1989) evaluated the stability of YAC clones during prolonged
propagation in yeast, and found that there was no detectable change through 60
generations. The human Y chromosome is rich in tandem repeats, and Neil et al.
(1990) found that structural instability could be detected in all YAC clones
examined. Albertsen et al. (1990) estimated the frequency of stable induced
rearrangements to be no more than 5%, and Anand et al. (1990) mapped 15 YACs
from five different loci and found one to be rearranged. Colonies from an unstable
YAC usually show multiple bands that hybridise to an insert probe. Alter growth in
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yeast, sequences contributing to the instability may be lost, and a stable deletion
derivative seen. Very unstable sequences may be deleted at an early stage and are
therefore essentially unclonable.
Certain YACs may also appear stable, but the structure does not correspond
to that of genomic DNA. Many of the examples of instability have been found in
YACs containing human repetitive DNA sequences (Neil et al., 1990). The cause of
most of the instability appears to be recombination carried out within the yeast cell,
with the structures of rearranged YACs being those expected to result from
homologous recombination events. Neil et al., (1990) re-transformed YAC clones
containing tandemly repeated elements into strains carrying mutations in the RAD1
and RAD52 genes. They demonstrated an increased stability of some of the
unstable YAC clones when they were transformed into a host strain carrying a
rad52 mutation. The sequences most easily stabilised were those with short
subunit repeats.
YACs containing subtle internal rearrangements such as inversions have
also been identified (M. Dixon, personal communication). Since there is only a
single yeast ARS in pYAC4, large human inserts, especially GC-rich inserts, may
show delayed replication in a growing yeast culture with consequent inadvertent
selection for deleted or rearranged clones which replicate faster. This could be
relevant to the GC-rich region around PKD1.
It is therefore possible that chromosome 16p is a region that is inherently
unstable in YACs. There have certainly been report s of repetitive sequences, with
two probes known to hybridise to more than one locus on chromosome 16 (Germino
etal, 1992). 26-6 (D16S125) recognises two loci, 26-6PROX and 26-6DIS, less than
150 kb apart (Gillespie et al., 1990), and some individuals have a third copy of the
repeat sequence (P. Harris, personal communication). There is also a 40 kb
segment, beginning approximately 10 kb telomeric to the Noll clone N54, that is
present in several copies on chromosome 16 (Germino et al., 1992). One of the ends
of the Kpnl subclone ofVK5 sequenced in this project also shows a repeat sequence
of 28 bp. If this is the case, it may be that a YAC library transformed into a
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recombination-deficient host would be more productive when screened with the
same probes.
The St. Mary's Hospital Medical School mouse YAC library has been
constructed in the S cerevisiae strain 3a, which is a rad.52 strain. This library has a
complexity of 3.5 genome equivalents and therefore should yield a number of clones
for each probe. There is known to be linkage conservation between human
chromosome 16p and mouse chromosome 17, with many markers from between
GGG1 (D16S259) and 26-6 (D16S125) mapped to this chromosome in the mouse
(Himmelbauer et al., 1992). This mouse YAC library was therefore screened with
primers to the ATPL, VK5 (D16S94), SM33p22 and 26-6 (D16S125) loci. Despite the
presence of the rad.52 host, only one YAC was successfully identified from this
library.
5.4.5 Screening of cDNA libraries for transcribed sequences within YACs
Several methods have been described by which YACs can be used to screen for
expressed sequences either within cDNA or YAC-derived genomic libraries. These
include using the complete YAC as a hybridisation probe, enrichment by "direct
selection" and exon amplification. Generally speaking, YACs are too large to be used
in their entirety to screen cDNA libraries, but small YACs of 160-180 kb have been
successfully used in this manner (Elvin et al., 1991; Chen et al., 1992). Lovett et al.
(1991) describe a direct selection scheme based on the hybridisation of an entire
cDNA library to a YAC clone immobilised on a filter. Non-specific hybrids are then
eliminated and specific hybrids eluted. These molecules are then amplified and
either cloned or taken through further selection/amplification cycles. Exon
amplification (Buckler et al., 1991) is a method for isolating exon sequences by
virtue of selection for functional 5' and 3' splice sites. Fragments of cloned genomic
DNA are inserted into an intron present within a mammalian expression vector and,
after transfection of COS cells, cytoplasmic mRNA is screened by PCR amplification
for the acquisition of an exon from the genomic fragment. The amplified exon is
derived from the pairing of unrelated vector and genomic splice signals.
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Another method for the selection of transcribed sequences has been
described by Korn et al. (1992), based on the hybridisation of cDNA inserts, which
had been amplified by PCR from cDNA libraries, to biotinylated DNA from cosmids.
Non-specific hybrids were then removed and the selected cDNAs eluted and re-
amplified by PCR. It was felt that this method could easily be modified so that
catch-linkered YAC material was used rather than cosmids for screening the cDNA
libraries. Korn et al. (1992) sheared the cosmid DNA to an average size of 500-800
bp and biotinylated this material. PCR amplification of YAC DNA digested with Bglll
and ligated to catch-linkers gives fragments of 300-600 bp in size, and biotinylation
was achieved by the use of biotinylated primers in the PCR amplification. In a
similar method to protocol B (Korn et al.. 1992), 600 ng biotinylated YAC DNA was
pre-competed with 20 pg human Cotl DNA for 2'A hours. 10 pg of amplified cDNA
was also pre-competed with 20 pg human Cotl DNA for 21/2 hours, and the two were
hybridised together for 20 hours. The streptavidin-coated magnetic beads were
added at this stage, rather than to the biotinylated YAC. cDNAs were eluted at
increasing temperatures of 75°C, 85°C and 95°C in order to try and increase
specificity. Two rounds of enrichment were performed and several YAC-cDNA
hybrids were obtained. Assessment of these fractions indicates that they contain a
high proportion ofAlu repetitive sequences, although at least the one fraction so far
tested (AKA7) does hybridise with one band in a Hindlll digest of the YAC that is not
recognised by the Alu sequence. This, however, could still represent a diverged or
low copy repetitive element on the cDNA. Only subcloning and sequencing of the
fraction will demonstrate how much of it is unique, and how much repetitive,
sequence. Given that several PCR products were obtained using Alu primers on
32A-A4, it seems likely that the insert DNA is Alu-rich. In order to try and compete
out these sequences more effectively, the hybridisation could be repeated using Alu
repetitive sequences as well as Coll DNA in the pre-competition step. The enriched
library could also be plated out and probed with yeast, ribosomal or mitochondrial
clones, or a combination of these, and the negative clones picked for further study.
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Although full restriction mapping using partial digests of the 32A-A4 YAC
has not been completed, preliminary mapping of total digests with rare-cutting
enzymes indicates that the human DNA insert is GC-rich, and may contain at least
two CpG islands. Continued use of this YAC to identify cDNA sequences is therefore
likely to be of value.
5.4.6 End-cloning
Construction of a YAC contig can be achieved either by using several probes from a
region to pull out overlapping YACs, or by cloning the ends of the YAC and
designing primers for further screening. It had been hoped that several overlapping
clones would be identified using the primers available, but this did not prove to be
the case. A number ofmethods have been developed to isolate YAC ends. The amp1"
gene and bacterial origin of replication in the left arm of pYAC4 can be used to
rescue an insert fragment attached to it, following digestion and circularisation of
the total YAC DNA and transformation of the products into E. coli. The right ami of
pYAC4 does not have the bacterial sequences necessary for plasmid rescue, but
they can be inserted by retrofitting the appropriate bacterial sequences prior to
plasmid rescue. Several alternatives to this cloning approach have been described.
These include inverse PCR (Arveiler and Porteous, 1991), vectorette PCR (Riley et
al., 1991), Alu PCR which has been adapted for use in end-recovery by including
Ala primers and a vector specific primer (Nelson et al, 1991) and a combination of
an oligo-cassette with a biotinylated primer from a known locus (e.g. the vector) in
conjunction with the biotin-streptavidin separation system (Rosenthal etal, 1991).
Since the 32A-A4 YAC had already been digested and ligated to catch-
linkers, it was decided to attempt both Alu-vector PCR and the biotin-streptavidin
methods in order to isolate end clones. No consistent product could be obtained
using the modified method of Rosenthal et al. (1991), most probably because the
catch-linker was less specific than the oligo-cassette, and because no nested
primers were available. End fragments were, however, obtained using the Aiu-vector
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PCR method, and these are available for subcloning, sequencing, and designing of
PCR primers.
Since the YAC libraries were screened with primers to the SM33p22 and
ATPL loci, both of which are located close to the distal end of YAC 32A-A4, and no
clones were identified, it seems unlikely that screening the libraries with primers to
the end clones would yield an overlapping distal clone.
5.4.7 YAC C4-I12
Having obtained a mouse YAC positive for the ATPL primers, it was of particular
interest to obtain a chromosomal localisation for this YAC. After many attempts at
fluorescence in situ hybridisation using biotinylated YAC material, a consistent
signal was obtained but the mouse chromosome could not be identified. A mouse
cosmid library was also screened with labelled C4-I12, and several cosmids were
identified. If these are confirmed as being present on the YAC, repeat attempts at in
situ hybridisation can be made using this cosmid material. The cosmids could also
be used to screen a mouse cDNA library in order to try and identify the mouse
homologue of ATPL, and any other genes present in the area.
5.5 CONCLUSION
Three YAC libraries were screened with primers to several loci surrounding PKD1,
and only two stable, non-chimaeric YACs (one human and one mouse) could be
identified. The human YAC has been confirmed as being located on chromosome





ADPKD is one of the most common genetic diseases in man with an incidence of 1
in 1000. End-stage renal disease requiring dialysis or transplantation occurs in at
least 50% of patients by the age of 70 years (Churchill et al., 1984; Parfrey et al.,
1990), despite treatment for hypertension. Isolation of the genes responsible for
ADPKD would make a significant contribution to the understanding of the
pathophysiology of the disease, would allow accurate diagnosis, and would point to
possible treatment options.
Linkage was first demonstrated between ADPKD and 3'HVR (D16S85) in
1985 (Reeders et al., 1985) but, despite intensive effort since then, the PKD1 gene
has yet to be cloned. This is likely to be due to several factors. Firstly, the
biochemical defect is unknown and therefore a positional cloning approach is
required. Secondly, there are no known cytogenetic abnormalities in PKD1 patients
to aid chromosomal localisation of the gene. Thirdly, genetic heterogeneity has been
shown to be present, and care therefore has to be taken in order to distinguish
families linked to chromosome 16 (PKD1) from those which are unlinked (PKD2).
Recently, PKD2 has been shown to be linked to chromosome 4 markers (Peters et
al., 1993). Fourthly, genetic mapping techniques, such as linkage analysis,
identification of recombinants and assessment of linkage disequilibrium, all provide
guides to the chromosomal location, but can be misleading, as was the case in
Huntington's Disease. Finally, the area is very GC-rich (Harris et al., 1990) and
therefore likely to contain several genes (Germino etal., 1992), all ofwhich require
to be screened for mutations.
The aim of this project was initially to establish the presence or absence of
genetic heterogeneity, and to verify the chromosomal location of PKD1 in the
Scottish population by means of linkage analysis, recombinant mapping, and
linkage disequilibrium mapping. Once this was achieved, it was anticipated that
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yeast artificial chromosome (YAC) technology would allow rapid identification of
cloned DNA from the region which could then be used to screen cDNA libraries and
identify candidate genes.
The presence of genetic heterogeneity was confirmed in the Scottish
population with the maximum likelihood value of a being 0.81 (81% of families
linked to chromosome 16p), and 3 out of 35 families (8.6%) identified as being
unlinked after haplotype analysis. The presence of genetic heterogeneity is
important since the accurate localisation of PKD1 requires a genetically
homogeneous population, and it is important that mutation screening is performed
using individuals from families that are clearly linked to 16p.
Multipoint linkage analysis of our set of families identified the most likely
location of PKD 1 as:-
D16S84-0.004-PKD 1 -0.006-D 16S283-0.005-D 16S 125-0.005-D 16S94-cen
This localisation is entirely in keeping with previous multipoint studies (Reeders et
al., 1988; Breuning etal., 1990a; Germino etal., 1990). Identification of
recombinants, one between PKD1 and CMM65 (D16S84) and three between PKD1
and 26-6 (D16S125), localised the position of PKD1 to between CMM65 (D16S84)
and 26-6 (D16S125). This is again consistent with the majority of previous
recombinant data (Somlo etal., 1992b), although it should be noted that one
recombinant in a 33 year old unaffected individual is at variance with the rest of the
data. Conflicting localisations by recombinant mapping also occurred in
Huntington's Disease (MacDonald et al., 1989). In this case, attempts were made to
sort out the anomaly using linkage disequilibrium mapping. The picture of linkage
disequilibrium seen in Huntington's Disease was extremely complicated, but a
common segment could be identified by haplotype analysis (MacDonald et al.,
1992). This segment was later shown to contain the gene (The Huntington's Disease
Collaborative Research Group, 1993) and linkage disequilibrium mapping therefore
proved useful in this situation.
In this study, linkage disequilibrium was first detected between PKD 1 and
VK5 (D16S94). VK5 (D16S94) is located on the proximal side of the CMM65
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(D16S84)-26-6 (D16S125) segment thought to contain the gene by the majority of
recombinant mapping data. Further markers were therefore studied, and linkage
disequilibrium was detected between PKD1 and CW4/cKLH9 (D16S291), and
between PKD1 and W5.2. This would be compatible with a plateau of linkage
disequilibrium covering the proximal half of the CMM65 (D16S84)-26-6 (D16S125)
interval and extending at least to VK5 (D16S94). Such a plateau of linkage
disequilibrium, within which not all markers demonstrate disequilibrium, has also
been seen in cystic fibrosis (Kerem et aL, 1989). This finding would argue that the
search for PKD1 should be concentrated in the proximal half of the CMM65
(D16S84)-26-6 (D16S125) region, and perhaps should be extended as far as VK5
(D16S94) or beyond. Another possible explanation for the above findings is that
PKD1 may be a large gene spanning both 26-6 (D16S125) and VK5 (D16S94), the
26-6 (D16S125) recombinants being intragenic.
It is of interest that a very promising candidate gene, AJ1, has been
excluded on the grounds of recombinant mapping data and the absence of a
mutation in one affected individual (Gillespie etcd., 1991). It is assumed that the
screened DNA is from an individual with a PKD 1 mutation, although no data is
provided on the linkage analysis of this family. Should the screened individual be
from an unlinked family, however, then AJ1 remains a strong candidate gene
despite the recombinant mapping data, particularly in view of the linkage
disequilibrium data presented here.
Further genetic mapping is unlikely to narrow the localisation of PKD 1
further, and attempts were therefore made to obtain cloned DNA from 16pl3.3 by
screening of yeast artificial chromosome (YAC) libraries. These attempts were largely
unsuccessful with only four YACs being isolated from three YAC libraries (two
human and one mouse). Only two of these four YACs were able to be used, since
one was unstable and one either highly chimaeric or containing low-copy repetitive
sequences. The human YAC 32A-A4, positive for both 26-6 (D16S125) and VK5
(D16S94), was from the area localised by genetic mapping as being likely to contain
the PKD1 gene, and it also contained at least two CpG clusters suggesting that
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genes were present on the YAC. Initial attempts to isolate cDNA from a human and
a foetal kidney cDNA library using a YAC-cDNA hybridisation technique were
unsuccessful. 16pl3.3 is thought to lie in a T band which is both Alu-rich and GC-
rich (Holmquist, 1992). Certainly, the sequence data obtained in this project
confirms that the area around VK5 is very GC rich and one problem with the YAC-
cDNA hybridisation technique was the presence of a high number of Alu repeat
sequences. The technique could be modified for future use by increasing the
competition, especially for Alu repeat sequences. It would also be worthwhile using
the whole YAC as a probe against the cDNA libraries
The region of 16p surrounding PKD1 is very GC-rich and likely to contain a
large number of genes. Several cDNAs have already been isolated (Somlo et al.,
1992a) and screening for mutations therefore presents a formidable task. Once a
candidate gene has been isolated, the knowledge of its function will prove useful in
solving the mystery surrounding cyst formation. Many experiments on the
pathophysiology of the disease have been performed, and it seems clear that a
combination of abnormal cell proliferation and abnormal fluid transport is required
for cyst formation. Epithelial proliferation can be the result of alteration of
extracellular matrix composition, altered susceptibility to, or synthesis of, peptide
growth factors, or abnormal expression of growth-related genes including proto-
oncogenes. Abnormal fluid transport could be the result of alterations in ion
pumping, or reflect changes in polarity of cell structure or function. Since some of
the structural proteins involved in the extracellular matrix, e.g. E-cadherin and N-
cell adhesion molecule, seem to be involved in the polarisation of renal epithelial
cells, it is possible that a defect in a structural protein may account for both
epithelial cell proliferation and abnormal ion and fluid transport. Such a defect
could also account for the extrarenal manifestations of polycystic kidney disease.
One of the striking features of ADPKD is the absence of a detectable
abnormality in most of the nephrons. Reeders (1992) has postulated that the
explanation for this may involve either a two-hit model, as in retinoblastoma, or a
heritable unstable repeat with somatic mosaicism of the trinucleotide repeat
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number. There is, as yet, no evidence for either of these hypotheses: undoubtedly
the answer will only become clear once the gene has been isolated.
In conclusion, therefore, this project has provided evidence of genetic
heterogeneity of ADPKD in the Scottish population, and suggested a localisation for
PKD1 on linkage analysis and recombinant mapping which is consistent with other
published data. The finding of linkage disequilibrium has not been previously
noted, and would argue for concentration of the search for PKD1 more proximally. A
human YAC containing both the 26-6 (D16S125) and VK5 (D16S94) loci was
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APPENDIX ONE
Forward sequence of VK5/MspI subclone
5 TGG TAC CGG GCC CCC CCT CGA GGT CGA CGG TAT CG:G CGT CAA CAC
GGG ATA ATA CCG CGC CAC ATA GCA GAA CTT TAA AAG TGC TCA TCA TTG
GAA AAC GTT CTT CGG GGC GAA AAC TCT CAA GGA TCT TAC CGC TGT TGA
GAT CCA GTT CGA TGT AAC CCA CTC GTG CAC CCA ACT GAT CTT CAG CAT CTT
TTA CTT TCA CCA GCG TTT CTG GGT GAG CAA AAA CAG GAA GGC AAA ATG
CCG CAA AAA AGG GAA TAA GGG CGA CAC GGA AAT 3'
Sequence obtained using the M13 universal primer with the VK5/MspI subclone.
The pBluescript SK vector sequence is shown in bold type. The insert sequence
shows 100% homology with pBR322 sequence, bases 3905-4142. The GC content
of the sequence is 48%.
Reverse sequence ofVK5/MspI subclone
5 GGC AAC AAA AGC TGG TAC CGG GCC CCC CCT CGA GGT CGA CGG TAT
CG:G TCA GAG GCC ATG CTC ACG TGT CCT GAG GTC CCC GAT GAC AAG CCA
CAA TGC CAT GGC ACA GTG GCC CAT GCA GCA CTC AGG TGG CTT CCG TGG
AAG CTG CTG AAG AAG GCA TGC CCT GCA CAG ACC CAT CAG ACC CCA CCC
GCC GCA GCT TGC CAA AAC CAG AGA GAA GGC AAC GAG GGC TGG CAG CAC
CTT CCA GCA TGG GCG GGA AGG GGA GGC 3'
Sequence obtained using the M13 reverse primer with the VK5/MspI subclone. The
pBluescript SK vector sequence is shown in bold type. The VK5 sequence has a GC
content of 63%. The VR1 primer sequence is underlined.
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VK5 sequence from the pBR322 EcoRI site
5' GGA CGC TCT CGT GTC GTC ATG TCG AGC CAC AGG TGC TCT TGG GAT TTC
AGG AAC ATG ACT CAT TTT ATT TTG GAA CTT AGA AAT AGA ATA TTT GGA GGC
GAA CGA GGA AGC AGA AAA CAG CAG CTG TTC GGG CCG CGT GTT TTG CTT
TTG TGG ATG TGC TCA GGA TTG CTT TGG GCC TCG TGC 3'
VK5 sequence obtained using a 15 mer pBR322 EcoRI site clockwise primer
(5' GTA TCA CGA GGC CCT 3'). The primer was very close to the cloning site and
no vector sequence was obtained. The GC content of the sequence is 49%. The VF1
primer sequence is underlined.
VK5 sequence from the pBR322 BamHI site
5' GCC CCT CGG CCC CCT GCC CTC CCC ACC CTC CAA TCT CCT CAA AAC TCT
TCC TCA AGG TAC CCT CCC CAC TTC CCT CAC CAG TGT CCA GGA ACC CCC
TGA GGC CAC CCC CAA GTC GGC CTG GGC TCC CCT AGG ACA GGC TCA GGC
GCT GGC AAT GCT GCT GAG GTG AAC TCC AAA ATG AGC ATG GCA GCT CAG
AGA CCA GG 3'
VK5 sequence obtained using a 16 mer pBR322 BamHI site counter-clockwise
primer (5' ATG CGT CCG GCG TAG A 3'). The primer was very close to the
cloning site, and no vector sequence was obtained. The GC content of the sequence
is 62%.
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Forward sequence of VK5/KpnI subclone
5 CAC CGC GGT GGC GGC CGC TCT AGA ACT AGT GGA TCC CCC GGG CTG
CAG GAA TTC GAT ATC AAG CTT ATC GAT ACC GTC GAC CTC GAG GGG GGG
CCC GGT AC:C CAC CCC TGC ACT CAG GGA TOG CCC AGA CCC CCA CCA CGA
CAA CTG GAC CCC CAT GTC CCT GCA CTC AGG GAT GGC CCA GAC CCC TAT
GAC AGC CAG GCC TCA GCA TCC CAA GTC CTC ACT CAC ACA GCA GAG GCT
GGG CCC GGG GAA CAG AGG ACC CTG GGT CCC TGA GAC ACA GCC CTC AGT
GGC ATT CCT AAG AGC ATG GCC CT 3'
Sequence obtained using the M13 universal primer with the VK5/KpnI subclone.
The pBluescript KS vector sequence is shown in bold type. A 28 bp repeat sequence
is underlined. The GC content of the sequence is 64%.
Reverse sequence of VK5/KpnI subclone
5' AAA GGG AAC AAA AGC TGG GTA C:CC TTA GCT GCT TGG GCC CAT GCC
GGC ACC CCT GTG GCC GCC TCA CTG GGC TGG GTC CAC TGC TGC CCA CTG
GGT CAG CCG CCA GCT ATA CAG GAG CAG CAG GTA GCT GGG GCT GCT CTC
CCG GCC GTT GGT CCA ACT GCC CAG GTC TTA GAG AGG CCA AAG TGT GAG
CCT CGT CCA GCT GCT TTT TGG CTT GGT CAT CTG CTG CTG TCA TGC TTA TTG
TGA TTT GCG 3'
Sequence obtained using the M13 reverse primer with the VK5/KpnI subclone. The
pBluescript KS vector sequence is shown in bold type. The GC content of the
sequence is 62%.
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Sequence of AJ1 cDNA from which the ATPL primers were designed
CACAGAATAT TATGTAAAGA CCACCCCTCC TCATTCCAGA ACGAACAGCC
TGACACATCT GCAGCGCCGC CCGCCCCCAG TAGTTGGTCT TGTACATGCG
B928 C18
CAGTATCCTA GTGCCCATCG TCTGTTTCCC CGCCTTGCCC CCGCCCGCCC
CGTGCCGTGG ACATCTGGGC CCACTCATCG CCCCTCCAGG CCCCCGGCGC
CCCACCCCCT AAAGTGCTCT AGTATGCGGA TGATTTAGAA TTGTCATTTC
I BglII
TCTTTACTGG ATGTTTATTA TTAAAGATCT CGCCTGTTCC TGCGTCTGCG
GAGCCGCCCT TGTCTCCCAG CTATCTATAA CCTTAGCTTG TGTGTCGCCT
ACAGCGGA
TGTGGGTTCC TGTTGCTGAG ACTTTTCCTG GATGGAGCCG CCCTCACCGC
ACACCCAAGG ACAA
C19
GCCCGTGGCC CTGCGCGGAG CTGTGTCCAA TAAAGTTCTT GCT
CGCGCCTC GACACAGGTT ATT
B927
Sequence of the 3' untranslated region of AJ1 (ATPL) cDNA, with the nucleotides
shown 5' to 3'. The four primer sequences tested are underlined and the position of
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Abstract A genetic heterogeneity analysis of 35 kindreds
with adult-onset polycystic kidney disease (ADPKD) was
carried out using the D16S85, D16S84, D16SI25 and
D16S94 loci that are closely linked to the PKD1 locus on
chromosome 16. The results show that the likelihood of two
ADPKD loci is 2,514.9 times greater than for a single locus
(P < 0.0001). The maximum likelihood lod score is 27.38 un¬
der heterogeneity with PKD1 lying 4.9 cM proximal to
D16S85 (in males). At least 3% of kindreds are unlinked to
PKD1, since the 95% confidence limits of alpha, the propor¬
tion of families linked to PKD1, are 0.54-0.97. Only 2 out of
35 kindreds (5.7%) show statistically significant evidence of
non-linkage to PKD1, with conditional probabilities of 0.987
and 0.993 that the disease locus is unlinked. This confirms
the existence of a small subgroup of ADPKD kindreds that
are unlinked to PKD1 and provides a firm basis for genetic
counselling of this population on the basis ofDNA probes.
Introduction
The first study of genetic heterogeneity in adult-onset poly¬
cystic kidney disease (ADPKD) was reported by Rceders et
al. (1987) who found no evidence to support heterogeneity in
a sample of 27 northern European families from four coun¬
tries. Subsequently, two reports have been published describ¬
ing families that appear unlinked to this region of chromo¬
some 16 (Romeo et al. 1988; Kimberling et al. 1988). We
have extended our initial heterogeneity study of 10 ADPKD
families, included in the report of Reeders et al. (1987) to a
total of 35 families from central Scotland to clarify the extent
of genetic heterogeneity in this population.
Materials and methods
Ascertainment and diagnosis offamily members
Families were ascertained through the Medical Renal Unit,
Royal Infirmary of Edinburgh and the Renal Unit, Western
Infirmary, Glasgow. In all, 343 members of 35 ADPKD fam¬
ilies were admitted to the study. Diagnostic criteria included
Correspondence to: A.Wright
the presence of two or more cysts greater than 0.5 cm in di¬
ameter in one kidney and at least one such cyst in the other
kidney, together with a family history of ADPKD. Ultra¬
sound examinations were carried out by experienced sonolo¬
gists, one in each centre, as described previously (Watson et
al. 1987; Pignatelli et al. 1992). Pedigrees were drawn up
on the basis of interviews with patients and relatives and
checked by consultation with the centralised Register for
Births,Marriages and Deaths for Scotland. Afterobtaining in¬
formed consent, as approved by the local ethical committee.
30-50ml EDTA anticoagulated blood was removed from fam¬
ily members and frozen at -70*C prior to extraction of DNA.
DNA extraction and analysis
DNA was extracted and analysed formarkers as described by
Pignatelli et al. (1992) except that in addition to D16S85,
D16S84 and D16S94, the D16S125 (26-6) locus (Breuning el
al. 1990) was analysed.
Linkage and heterogeneity analysis .
Five-point linkage analyses were carried out using th<
LINKMAP subroutine of the LINKAGE program package
version 5.03 (Lathrop et al. 1984). Recombination fraction:
were estimated at intervals of 0.01 between 0 and 0.4. Muta
tion rates were set at 2 x 10-6 per ADPKD locus per gamete
for both sexes and the ADPKD gene frequency at 0.0005
The program was run using different fixed ratios of recombi
nation in males to females, which identified a broad likeli
hood peak ratio in the region of 5 (6m : 60- This value wa
therefore used for the final analysis. The resulting family lo<
scores were then analysed using the HOMOG program pack
age (Ott 1985) for linkage heterogeneity. The probability o
detecting a PKD1 gene carrier by ultrasound analysis wa
taken to be 0.64, 0.92 and 1.00 for ages 0-10 years, 10-3'
years and over 30 years respectively (Bear et al. 1991).
, Results
Multipoint heterogeneity analysis
Multipoint linkage analysis was carried out using probe dal
from the D16S85, D16S84, D16S125 and DI6S94 loci. Th
>/0
D16S84 locus is more closely linked to PKDi than is
D16S85 and both are thought to be distal to PKDI, whereas
DI6S125 and DI6S94 are probably proximal (Gillespie et al.
1991). The five-point lod scores were analysed for linkage
heterogeneity using the HOMOG program package. The re¬
sults are shown in Table I.
The log (In) likelihood on the assumption of a single
ADPKD (linkage homogeneity) was 55.22 compared with
63.05 (lod score 27.38) on the assumption of one linked and
one unlinked ADPKD locus (linkage heterogeneity). The
likelihood ratio is 2,514.9, which is statistically significant
(chi-square 15.66; P< 0.0001). The maximum likelihood
value of a, the proportion of families linked, was found to be
Table 1. Results of heterogeneity analyses in 35 adult-onset polycystic
kidney disease (AOPKD) kindreds. Multipoint lod scores for ADPKD.
DI6S85, DI6S84. DI6SI25 and DI6S94 were analysed with the
HOMOG program. The maximum likelihood values of the proportion of
families linked, a. and of the recombination fractions, measured proxi-
mally from DI6S85. are shown for males (0„) and females (0r) separa¬






families linked) 0.81 (0.54 -0.97) 1.00
en 0.049 (0.025-0.059) 0.047
e,< 0.010 (0.005-0.012) 0.009
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Fig. 1. a Haplotype analysis of family PK53, in which there are either
two or three double recombinants with ADPKD, depending on the link-;
age phase, on the assumption of a PKDI locus. There is no evidence of
recombination between markers. Affected individuals are shown as
shaded boxes (male) or circles (female). The unaffected individuals
H-l.ll-4 and 11-5 are aged 39, 32 and 31 yean respectively. Possible
haplotypes are shown, with results using the following probes: D16S85,
(3'HVR). D16S84 (CMM65), DI6SI25 (26-6) and D16S94 (VK5B).
b Haplotype analysis of family PK32 in which a single recombination
(in 11-2) would be consistent with a PKDI locus although no exchange
of flanking markers has been demonstrated
Table 2. Conditional probabilities of linkage to PKDI are shown for














PKI 0.784 PK30 0.997
PK2 1.000 PK31 0.795
PK3 0.995 PK32 0.967
PK4 1.000 PK35 0.895
PK5 0.932 PK36 0.930
PK6 0.999 PK37 0.751
PK7 1.000 PK38 0.886
PK8 0.747 PK39 0.780
PKI 1 0.999 PK41 0.860
PK17 0.999 PK42 0.998
PK18 0.999 PK45 0.961
PKI9 0.871 PK49 0.958
PK24 0.881 PK50 0.608
PK25 0.460 PK52 0.013
PK26 0.895 PK53 0.007
PK27 0.574 PK55 0.602
PK28 0.982 PK56 0.886
PK29 0.289
0.81 with approximate 95% confidence limits of 0.54-0.97,
showing that at least 3% of families are unlinked. The recom¬
bination fractions separating ADPKD from the anchor locus
DI6S85 were 0.049 (males) and 0.010 (females) under link¬
age heterogeneity. Linkage heterogeneity is therefore present
in this sample of families.
Families thai appear unlinked to PKDI
Only 2 small families out of 35 analysed show statistical 1)
significant evidence of non-linkage to PKDI (Table 2), wit!
probabilities of 0.013 (PK52) and 0.007 (PK53) that they art
linked to PKD1, conditional on the maximum likelihood val
ues of a (0.81) and 6m (0.049). One family (Fig. la) (PK53
is informative with flanking markers D16S85 and D16S8<
distally and D16S125 proximally and would require eithe
two or three double recombinants out of five meioses to be con
sistent with a PKD 1 locus. No exchange of flanking marker
is seen. This family therefore does appear unlinked from hap
lotype analysis. The other family (PK52) (Fig. lb) is infor
mative for D16S85 and D16S84 distally but with neithe
proximal marker, so that only a single recombinant (wit!
D16S85 and D16S84) out of three meioses needs to be in
voked to be consistent with a PKDI locus. Further loci ar
currently being screened. The evidence for non-linkage i
this family is therefore ambiguous.
Discussion
Two families have been described in the literature that pro¬
vide clear evidence of non-linkage to the alpha globin (HBA)
region on chromosome 16 (Romeo et al. 1988; Kimberling et
al. 1988) and several others have been reported at meetings.
By all accounts, the frequency of unlinked families is low in
the experience of most laboratories, although only two for¬
mal heterogeneity analyses have been published in full
' (Reeders et al. 1987, Mandich et al. 1990).
Reeders et al. (1987) found no evidence of linkage hetero¬
geneity in 27 ADPKD families from the United Kingdom,
the Netherlands and Finland using D16S8S data alone.
Mandich et al. (1990) studied 29 Italian families with
ADPKD and also found no significant evidence of hetero¬
geneity using 2-point analysis with D16S8S or D16S80 al¬
though the peak value of a, the proportion of families linked,
was 0.92 (lod score 12.97). In the present study, the likeli¬
hood of two loci is 2£ 14.9 times greater than for a single lo¬
cus although only one small kindred (Fig. la) provides con¬
vincing evidence of non-linkage to PKD1.
Phenotypic differences between PKD1 and ADPKD fami¬
lies unlinked to PKD1 (PKD2) have been described. Bear et
al. (1989) reported the presence of a milder phenotype in
PKD2 families with delayed appearance of cysts and hyper¬
tension and a later age at which dialysis becomes necessary.
The phenotype in family PK53 is consistent with this, al¬
though it does not appear uniformly mild within the family.
Family PK52 shows die typical PKD1 phenotype. Both fam¬
ilies are of Scottish ancestry.
What ate the implications of these results for presympto-
matic diagnosis ofADPKD? Although the available evidence
suggests that there has been little demand for this in families
(Watson et al. 1990), die low level ofheterogeneity observed
is likely to have a relatively small effect on the accuracy of
genetic diagnosis. Caution should be exercised however if re¬
combination is observed in a family in the absence of flank¬
ing marker exchange.
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Abstract
Analysis of genetic linkage data in 33
adult onset polycystic kidney (ADPKD)
families was carried out using probes for
the D16S85, D16S84, and D16S94 loci. The
data set of 33 families shows no evidence
of genetic heterogeneity since one
unlinked familywas previously excluded.
Two point linkage analysis showedmaxi¬
mum likelihood values of the recombina¬
tion fraction of 0*07 for ADPKD and
D16S8S (lod score 18*78), 0*02 for ADPKD
and D16S84 (lod score 7*55), and 0-00 for
ADPKD and D16S94 (lod score 6*73).
Multipoint analysis showed a maximum
likelihood order of tO-D16S8S-0-06-
D16S84-0-Q2~-(PKDI, D16S94)-cen with a
multipoint lod score of 32-16. Analysis of
rare recombinants lying close to PKD1
gave results consistentwith this order.
(JMed Genet 199209438-41)
Adult onset polycystic kidney disease
(ADPKD) is an autosomal dominant condition
characterised by progressive formation and
enlargement of multiple cysts in the kidney
and other organs leading to deterioration in
renal function and die development of hyper¬
tension in middle life. End stage renal disease
is a common outcome although renal replace¬
ment programmes have improved the prog¬
nosis considerably.1 Premature deaths from
the complications of renal failure and rupture
of intracranial aneurysms are not uncommon.1
ADPKD is one of the commonest genetic
diseases in man affecting 1 per 1000 of die
general population.3 The pathophysiological
basis is not well understood although the ear¬
liest changes appear to include hyperplasia of
tubular epithelial cells and food microcyst
formation arising in any portion of the neph¬
ron from glomerulus to collecting tubules.4
Abnormalities in tubular basementmembrane,
sodium pump orientation, and sensitivity to
growth factors have recently been identified in
ADPKD kidneys and cultured tubular epithe¬
lial cells.3
Linkage was first shown between ADPKD
and D16S85 close to a globin in chromosomal
region 16pl3 by Reeders et al.* This localisa¬
tion has since been amply confirmed by several
other groups.7"* The orientation of the
ADPKD locus relative to D16S85, afterwards
localised to band 16pl3.3,1011 was shown in a
multipoint linkage analysis" which indicated
that the odds in favour of PKD1 lying proxi¬
mal to D16S85 were >10 000:1 compared
with a distal location. This group also showed
that the D16S63 and D16S4S loci were locate
proximal to both PKD1 and DJ6S85 by
combination of linkage and somatic cell hybri
analyses." Breuning et aP also showed that tl
disease locus is flanked by D16S80 proximall
and D16S85 distally.
A previous analysis of 27 ADPKD famili<
from four countries failed to show evidence <
genetic heterogeneity." However, two rcpor
subsequently appeared describing families th
failed to show linkage to the a globin region <
chromosome 16."14 Since accurate localisatic
of the gene first requires a genetically hom<
geneous sample, we extended our initial stuc
of 10 ADPKD families, included in the stu<
ofReeders et al,11 to a total of 34 families. Tl
results of this study are described elsewhere
and show that 81 to 83% ofthese families sho
linkage to this region ofchromosome 16. Ho\
ever, only one family (PK53) showed cle
evidence of non-linkage to PKD1" and w
therefore removed from the data set for tl
purpose of this multipoint analysis. We no
report the resultsofdie analysis of the remaii
ing 33 families using D16S8S, D16S84, at
D16S94.
Materials and methods
ASCERTAINMENT AND DIAGNOSIS OF FAMILY
MEMBERS
Families were ascertained through the Medi<
RenalUnit, Royal InfirmaryofEdinburgh ai
the Renal Unit, Western Infirmary, Glasgo
Diagnostic criteria included a family histo
of ADPKD (more than one affected memtx
and ultrasound findings of two or more cry
greater than 0-5 cm in diameter in one kidn
and at least one such cyst in the contralate
kidney.7 Pedigrees were drawn up after int<
views with patients and were checked agaii
the centralised Register for Births, Marriag
and Deaths for Scotland. Ethical approval v
obtained and, after obtaining informed cc
sent, 30 to 50ml EDTA anticoagulated bio
were drawn and frozen at — 70*C before D>
extraction. Thirty-four probands and 3
family members were initially ascertained a
their relatives sampled for biochemical a
DNA analysis and examined clinically as <
scribed previously,7 after which ultrasou
examinations were arranged and carried out
experienced sonologists, one in each centre
A previous study of linkage heterogeneii
identified one family (PK53) contribut:
disproportionately to the observed hetc
geneity and so was excluded from this stu<
This family showed a conditional probabi!
of 0 003 of being linked to the D16S
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D16S84, and D16S94 loci. None of the other
families showed good evidence of non-linkage
to this region, so this set of 33 families was
used in the study.
DNA EXTRACTION AND ANALYSIS
DNA was extracted by the method of Kunkel
et al.1* The following loci were used to type all
family members.
(1) D16S85 (3'HVR) is a hypervariable locus
described by Jarman et al" and located in
16pl3.3, which detects multiple alleles
with several restriction enzymes. DNA
samples were digested with the restriction
enzyme Pvull and allele frequencies were
each set at 0-1.
(2) D16S84 (pCMM65) was isolated byNaka-
mura et a/11 and detects two alleles of size
3-5 kb (Al) and 2-1 kb (A2) with frequen¬
cies of 0-40 and 0-60 with the enzyme
Pvull. It is localised to chromosomal re¬
gion 16p.
(3) D16S94 (pVKSB) was isolated by Hyland
etaf and detects alleles of 1-6 kb (Al) and
1-3 kb (A2) with the enzyme Mspl with
frequencies of0-55 and 0-45. It is localised
to chromosomal region 16pl3.3.
(4) D16S45 (CRI-090) was isolated by Donis-
Keller et aP° and detects two alleles (20 kb
and 13 kb) with frequencies of 0-47 and
0-53 with EcoRLThis probewas only used
to probe families containing key recombi¬
nants. It is localised to chromosomal re¬
gion 16pter-pl3.
Probes were used without purification of
inserts and labelledwith "P-dCTP by random
priming.21 Unincorporated counts were separ¬
ated by gel filtration. DNA from the patients
was digested to completion with the above
enzymes and separated by electrophoresis on
0-8% agarose gels in 1 * TBE buffer.
Transfers were carried out by the method of
Southern22 using nylon (Nytran) filters. Filters
were prehybridised for at least four hours in 5
x Denhardt's solution/4 x SSC/10% dextran
sulphate/0-1% sodium pyrophosphate/1%
sodium dodecylsulphate (SDS)/0-l mg mf~'
denatured salmon sperm DNA. Filters were
then hybridised in the same mixture contain¬
ing 1 to 2 x 10® cpm ml"1 of labelled probe
(2-5 ng ml-1). After overnight hybridisation at
68'C, filters were washed in 2 x SSC/1%
SDS down to a final stringency of 0-1 x SSC/
1% SDS at 68*C. Filters were used to expose
Kodak XAR-5 films in cassettes containing
double intensifier screens for one to 14 days at
— 70*C.
LINKAGE ANALYSIS
Linkage was analysed using the LINKAGE
program package version 5-03." The ADPKD
gene frequency was set at 0-0005 and male and
female mutation rates assumed to be equal at 5
x 10"' per locus per gamete. The female:male
recombination ratio was assumed to be con¬
stant and was found to maximise the likelihood
at a ratio of 0-2. This value was used for
LINKMAP runs.MLINK was unable to sup¬
port a fixed ratio of recombination in the two
sexes, so sex averaged values were obtained.
Two point linkage analyses were obtained
using the MLINK subroutine. Multipoint
analyses were run using LINKMAP with a
fixed order ofmarker loci as follows: D16S85-
0 06-D16S84-0 02-D16S94. The probabi¬
lities of ultrasonographic detection in gene
carriers were assumed to be 0-22, 0-66, 0-86,
and 0-95 during the first four decades of life
and were taken to be 1-00 after the age of 40.24
Results
TWO POINT LINKAGE ANALYSES
The results of two point linkage analyses are
shown in the table. The maximum likelihood
value of the recombination fraction (sex aver¬
aged) was found to be 0-07 at a lod score of
18-78 for PKD1-D16S85. The corresponding
values of the recombination fractions were
0.02 at a lod score of 7-55 for PKD1-D16S84
and 0-00 at a lod score of 6-73 for PKD1-
D16S94. All three loci show close linkage to
PKD1 and highly significant lod scores. No
recombination was found with D16S94 and
only a single definite recombinant -with
D16S84. „
MULTIPOINT LINKAGE ANALYSIS
The results of themultipoint analysis is shown
in die figure. In a four point analysis with
PKD1, D16S85, D16S84, and DJ6S94, the
maximum likelihood is found to occur at
die location D16S85-0-06-DI6S84-0-Q2-
(PKD1, D16S94)- cen (order 1) at a peak lod
scoreof32-16. Since no definite recombination
was observed betweenPAD/,and D16S94, the
order of these two lod cannot be determined.
This result is consistent with the presence ofa
single triply informative meiosis in anaffected
member of family PK52 which is recombinant
with both DI6S8S and D16S84, although the
family has not yet been found to be informa¬
tive for D16S94 or other proximal markers.
Exchange of flankingmarkers has therefore yet
to be shown. However, in the data set as a
whole the likelihood of the order D16S85-
0-04 -PKD1 - 0-02 -D16S84- 0-02 -D16S94 -
cen (order 2) is only 2-6 times lower than order
1, with PKDl proximal to D16S84. However,
order 1 is at least 2-7 x 10' times more likely
than with PKDl distal to D16S85.
A total of 20 recombinants out of 226 infor¬
mative meioses has been identified in the 33
APKD families using the D16S85, D16S84,
D16S94, and D16S45 lod. Only 12 of these
are multiply informative and therefore provide
information on the localisation of the PKDl
locus. Five out of eighteen D16S85 recombi¬
nants are also informative for D16S84, four of
which are non-recombinant with D16S84,
supporting the proposal that this locus is closer
to PKDl than D16S85.2' Five out of eighteen
D16S85 recombinants are informative for
D16S94, each of which is non-recombinant
with APKD, consistent with the hypothesis
that PKDl lies distal or close to D16S94.
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The results of ttvo piitnt linkage analyses of ADPKD and the D16SS5, DI6SS4, and
DI6S9-1 loci. Recombination fractions and the corresponding lod scores are shown. The
maximum likelihood values of the recombination fractions (Omax) and lod scores
(Zmaxi are indicated.
Locus ooo 0 01 005 0 10 0 20 0-30 040 Ommx Zmax
D16S8S 2 45 14 82 1862 18 37 14 53 44)2 3-27 04)7 1878
(J'HVR)
D16S84 6 14 7 42 7 34 668 4 75 263 076 04)2 7-55
(CMMftit
DI6S94 6 73 6 56 5 84 5-03 3 31 1 70 048 04)0 6-73
(VK5B)
Discussion
Previous multipoint analyses of the PKD1
locus have been described by Recders et al,lt
Germino et al," and Breuning et al*26 A very
substantial body ofevidence supports the loca¬
lisation of PKD1 proximal to D16S85, the
most distal marker known on chromosome 16,
and distal to the D16S4S, D16S63, and
D16S80 loci. Further refinementofdiemap of
this region has come from the combined use of
linkage and human-rodent hybrid cell lines
which have distinguished four subregions by
means of 23HA (GM2324), N-OH1, and
CY14 breakpoints.25* These regions separate
the most important polymorphic lod into the
following four groups, extending distally: (1)
D16S45, DI6S63, D16S80 (proximal to
23HA), (2) D16S94, D16S125 (proximal toN-
OHl, distal to 23HA), (3) D16S84, D16S259
(proximal to CY14, distal to N-OH1), (4)
D16S83, D16S21, D16S85 (distal to CYI4).
The genetic relationship ofPKD1 with loci
within groups 2 and 3 is less dear, however.
Most of these lod show few ifany recombina¬
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Results of multipoint analysis of ADPKD and D16S85
(HVR), D16S84 (CMM), and D16S94 (VK5J loci.
The multipoint lod scores are plotted against genetic
location (based on recombination fractions in males)
with reference to the D16S85 (3'HVR) locus at
position O. The location of the D16S84 and DI6S94
loci are also shown. Distances are given in centiMorgans
(cM).
supports the view that they lie doser to the
gene than those in groups 1 and 4, but on the
other hand makes ordering difficult. In the
absence ofADPKD patients showing chromo¬
somal rearrangements, the genetic definition of
closely finked flanking markers is an essential
prelude to successfully localising the gene by
physical means. Initially, no recombinants
were identified with D16S84," although at
least one has since been reported.27 Similarly,
at least one recombinant has been reported
with D/6S/25,24 which, together with the
above, is consistent with a localisation for
PKD1 between D16S84 and D16S125, an area
of less than 750 kb as determined by pulsed
field gel electrophoresis (PFGE) mapping.28
However, several potential pitfalls exist which
can lead to a misleading genetic assignment, so
that it is important to accumulate as much
genetic evidence as possible. Firstly, genetic
heterogeneity is now known to exist in
ADPKD so that genetic mapping should be
carried out as far as possible on a genetically
homogeneous population. We have attempted
to do this by first carrying out a heterogeneity
study and then by removalofunlinked families
from further analysis.15 Secondly, false posit- '
ive" and false negative28 diagnoses can-lead to
misinterpretation of results. Thirdlyj double
recombinants, although very rare in such small
genetic distances, can occur and may be
mimicked by gene conversion events.
Fourthly, mistyping can occur, so that it is
important that each apparent recombinant is
checked, preferably by an independent labora¬
tory. Finally, non-paternity can arise and lead
to erroneous interpretation of results, so that
this should ideally be checked by genetic
fingerprinting.
The results presented in this study confirm
the tight genetic linkage of D16S84 in region
3 which shows only a single definite recombi¬
nant with PDK1 (Gmax—0-02, Zmax*=
7-55), similarly with D16S94 in region 2,
which shows no definite recombination with
PDK1 (0max= O-OO, Zmax= 6-73). Multipoint
analysis showed the most likely order to be:
tel-D16S85-D16S84-(PKD1, D16S9S}-cen
which gave a multipoint lod score of 32-16.
A single recombinant with D16S84 was also
recombinant for D16S85, arguing in favour of
a location for PKD1 proximal to both these
loci. The recombinant subject is unequivocally
affected, so that a false positive diagnosis
seems highly unlikely, but the family has so far
been uninformative for proximal markers such
as D16S94. It will therefore be important to
show that exchange of flanking markers has
occurred in this instance, since the family is
not large enough to be unequivocally finked to
PKDl. Fine mapping these and other rare
recombinants in regions 2 and 3, using new
polymorphisms identified from these locations
will help to confirm the location of PKDl and
to narrow down the area of search by physical
mapping methods.
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SHORT COMMUNICATION
Evidence for linkage disequilibrium between
D16S94 and the adult onset polycystic kidney
disease (PKD1) gene
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Genetic mapping of the PKD1 gene in chro¬
mosomal region 16pl3.3 has depended on the
identification of closely linked markers and
rare recombinants that suggest the order of
loci in relation to meiotic crossover points.'2
This has led to the proposal that the PKD1
gene lies in an approximately 750 kb region
close to marker loci D16S84, D16SI25, and
D16S94, and proximal to the hypervariable
probe D16S85 that first detected linkage to
PKD1?* However, genetic (meiotic) mapping
can sometimes lead to inconsistent localisa¬
tions, as with the Huntington's disease gene,1
owing to factors such as rare double cross¬
overs, gene conversion events, gonadal mosaic¬
ism, genetic heterogeneity, misdiagnosis,
mistyping, and non-paternity. While many of
these factors can be minimised or excluded,
some are very difficult to exclude and, al¬
though rare, become significant compared
with the frequency, of rare recombination
events separating markers from disease genes.
In the absence of patients with chromosomal
rearrangements that can help to localise the
PKD1 gene physically, genetic methods of
mapping are critical.
A means of genetically mapping a disease
gene, other than by linkage analysis, is by the
identification ofnon-random allelic association
(linkage disequilibrium) between a marker and
disease locus. This can occur if a mutation
causing disease arises in close association with
a relatively uncommon marker allele or haplo-
type, which can then become over-represented
in the patient group relative to the general
population. The finding of linkage disequilib¬
rium has served to refine the mapping both of
the cystic fibrosis gene1 and of the Hunt¬
ington's disease gene.7 However, linkage dis¬
equilibrium is expected to occur only if the
mutation rate is relatively low or if the fre¬
quency of a particular chromosomal haplotype
is inflated in the population ofaffected subjects
as a result of previous selective advantage,
migration, or population stratification. It re¬
quires that many or most affected subjects
carry the same original mutation.
It has been suggested that the mutation rate
in ADPKD is high,8 based on the apparently
high frequency of unaffected parents of
ADPKD subjects and on the high population
prevalence. This study was carried out at a
time when methods of presymptomatic dia¬
gnosis were less sensitive than with ultrason¬
ography and when paternity testing was less
readily available. We therefore tested a genet¬
ically homogeneous set of 33 ADPKD families
for evidence of linkage disequilibrium between
the PKD1 locus and closely linked markers
D16S84, D16SI25, and D16S94.
A setof 34ADPKD families was ascertained w
through medical renal units in Edinburgh
and Glasgow and the diagnoses established
as described.*"" Family members were
typed for the markers DJ6S85 (3'HVR),
D16S84 (CMM65), D16S125 (26-6PROX),
and D16S94 (VK5). Multipoint heterogeneity
analysis was carried out to determine die pro¬
portion of families unlinked to the PKD1
region of chromosome 16.'° The sample was
found to show evidence of linkage hetero¬
geneity but 90 to 95% of the kindreds
were linked to PKD1. A single unequivocally
unlinked family was removed from the analy- -
sis, leaving 33 families for genetic mapping of
the PKD1 locus." In 28 families the haplo-
types could be determined unambiguously, in
one family the haplotype could not be estab¬
lished, and in the remaining four this was done
by minimising the number of crossovers. The
normal chromosomes used to establish control
allele frequencies were derived from the unaf¬
fected spouses of family members.
The results are shown in the table. No
evidence of allelic association was found
between PKD1 and either D16S84 or
D16S125, both of which show close genetic
linkage to PKDl.,Ilt In the case of D16S94,
there is evidence of linkage disequilibrium,
with the affected haplotypes in seven kindreds
showing the l-6kb allele (allele 1) and in 22
kindreds the l-3kb allele (allele 2) compared
with the control population, who showed 38
l-6kb alleles and 34 1-3 kb alleles. This result
is significant at the 2% level (Yates's corrected
Xz — 5-75). The allele frequencies in the control
population are in good agreement with those
published previously.2
The suggestion of linkage disequilibrium
between PKD1 and D16S94 has implications
for the genetic localisation of PKD1. Any
initial disequilibrium occurring when a muta¬
tion arises is dissipated at the rate of (l-r)n in
n generations, where r is the recombination
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Frequency of marker alleles in haplotypes of ADPKD IPKDI - chromosomes
compared with the general population. Yule's association coefficient provides a measure
of the degree of disequilibrium.* jr values were derived using Yates's correction.
DI6SS4 DI6SI2S 13/6594
Affected Control Affected Control Affected Control
Allele 1 13 28 9 13 7 38
Allele 2 15 38 15 49 22 34
x' 0-020 1 69 575
A 0-081 ±0-225 0 387 ±0 223 0 557±0 170
P NS NS <002
fraction separating marker and disease locus.
If r is very small, the rate of approach to
equilibrium is slow. Similarly, a recent muta¬
tion will take a finite time to reach equilibrium
with adjacent markers, even when r is signific¬
ant. In practice, a plateau of linkage disequili¬
brium can define an area of up to several
hundred kilobases ofDNA on each side of the
gene of interest, in the absenceof recombinatio-
nal hot spots. The identification of meiotic
crossover points by haplotype analysis has led
to the proposal that PKDI lies between
D16S84 and D16S125, a region shown by
pulsed field electrophoresis to contain less than
750 kb of DNA and found to contain a large
number ofgenes.4 Themore proximally located
marker D16S94 lies just outside this area. If the
presence of linkage disequilibrium can be con¬
firmed by other groups with ethnically homo¬
geneous patient populations, it would argue for
a detailed physicalmapping effort in the proxi¬
mal part of the D16S84-DJ6S125 interval,
although further marker studies are required
to establish the extentof the regionofdisequi¬
librium. The failure to find any disequilibrium
with D16S125, located about 50 to 100 kb
distally, could be because a common PKDI
mutation arose in association with the more
frequent D16S125 allele,making it more diffi¬
cult to detect disequilibrium, or because the
Taql polymorphism is itself subject to signific¬
ant mutational change.
The high population prevalence ofADPKD
(1 in 1000), 90 to 95% of which are the result
of PKD1 gene mutations,410 is consistent with
a high mutation rate but since the reproductive
fitness ofADKPD patients is also high, this is
not necessarily so. Additional factors, such as
reproductive compensation, previous selective
advantage, and genetic drift, may also contrib¬
ute to the high prevalence. Linkage disequilib¬
rium is not expected to occur if the mutation
rate is high since each newmutation is likely to
occur on a different chromosomal background.
The results described in these ADPKD famil¬
ies therefore add support to the idea that the
high prevalence is maintained by a high repro¬
ductive fitness or other factors referred to
above, in the presence of an intermediate or
low mutation rate. These issues await further
clarification when the gene is isolated.
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